US20050288290A1 - Fused heterocyclic kinase inhibitors - Google Patents
Fused heterocyclic kinase inhibitors Download PDFInfo
- Publication number
- US20050288290A1 US20050288290A1 US11/167,043 US16704305A US2005288290A1 US 20050288290 A1 US20050288290 A1 US 20050288290A1 US 16704305 A US16704305 A US 16704305A US 2005288290 A1 US2005288290 A1 US 2005288290A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- mmol
- triazin
- fluoro
- pyrrolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *BC1=[W]C=C(N([3*])C(=[Y])CC(=O)[V][1*])C=C1.*BC1=[W]C=C(N([3*])C([4*])=O)C=C1.CC.CC Chemical compound *BC1=[W]C=C(N([3*])C(=[Y])CC(=O)[V][1*])C=C1.*BC1=[W]C=C(N([3*])C([4*])=O)C=C1.CC.CC 0.000 description 28
- TUIZXCZAIIHRDH-UHFFFAOYSA-N CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1O Chemical compound CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1O TUIZXCZAIIHRDH-UHFFFAOYSA-N 0.000 description 3
- MTQDDECUYLJWIM-UHFFFAOYSA-N CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OC(=O)C(C)(C)C Chemical compound CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OC(=O)C(C)(C)C MTQDDECUYLJWIM-UHFFFAOYSA-N 0.000 description 3
- OARHOAIFBBGSLM-UHFFFAOYSA-N CC1=CC(C(C)C)=CC=C1F Chemical compound CC1=CC(C(C)C)=CC=C1F OARHOAIFBBGSLM-UHFFFAOYSA-N 0.000 description 3
- LTOKEBBIDLXBQN-UHFFFAOYSA-N CC(C)C1=C(F)C=CC=C1F Chemical compound CC(C)C1=C(F)C=CC=C1F LTOKEBBIDLXBQN-UHFFFAOYSA-N 0.000 description 2
- FGCURPSLFUFTIF-UHFFFAOYSA-N CC(C)C1=CC(F)=C(F)C=C1 Chemical compound CC(C)C1=CC(F)=C(F)C=C1 FGCURPSLFUFTIF-UHFFFAOYSA-N 0.000 description 2
- MXPSJOUWGDSBPZ-UHFFFAOYSA-N CC(C)C1=CC(F)=CC=C1F Chemical compound CC(C)C1=CC(F)=CC=C1F MXPSJOUWGDSBPZ-UHFFFAOYSA-N 0.000 description 2
- XZISOEPNTDOUEA-UHFFFAOYSA-N CC(C)C1=CC=C(F)C=C1 Chemical compound CC(C)C1=CC=C(F)C=C1 XZISOEPNTDOUEA-UHFFFAOYSA-N 0.000 description 2
- GTADDTOGTOQQMD-UHFFFAOYSA-N CC(C)C1=CC=C(OC(F)(F)F)C=C1 Chemical compound CC(C)C1=CC=C(OC(F)(F)F)C=C1 GTADDTOGTOQQMD-UHFFFAOYSA-N 0.000 description 2
- JHUBNQSPUZXGKI-UHFFFAOYSA-N CC(C)C1=CC=C2OCOC2=C1 Chemical compound CC(C)C1=CC=C2OCOC2=C1 JHUBNQSPUZXGKI-UHFFFAOYSA-N 0.000 description 2
- NRKSONABASVOGU-UHFFFAOYSA-N CC(C)C1=CC=CC([N+](=O)[O-])=C1 Chemical compound CC(C)C1=CC=CC([N+](=O)[O-])=C1 NRKSONABASVOGU-UHFFFAOYSA-N 0.000 description 2
- PMPBFICDXLLSRM-UHFFFAOYSA-N CC(C)C1=CC=CC2=C1C=CC=C2 Chemical compound CC(C)C1=CC=CC2=C1C=CC=C2 PMPBFICDXLLSRM-UHFFFAOYSA-N 0.000 description 2
- ICTCCOUARBGHFR-UHFFFAOYSA-N CC(C)C1=CC=CC=C1F Chemical compound CC(C)C1=CC=CC=C1F ICTCCOUARBGHFR-UHFFFAOYSA-N 0.000 description 2
- AFOPCURQYRRFRQ-UHFFFAOYSA-N CC(C)C1=CC=CO1 Chemical compound CC(C)C1=CC=CO1 AFOPCURQYRRFRQ-UHFFFAOYSA-N 0.000 description 2
- PFYPDUUXDADWKC-UHFFFAOYSA-N CC(C)C1=NC=CC=C1 Chemical compound CC(C)C1=NC=CC=C1 PFYPDUUXDADWKC-UHFFFAOYSA-N 0.000 description 2
- WFSAEFXYMMRMIZ-UHFFFAOYSA-N CC(C)NC1=C(Cl)C=CC=C1Cl Chemical compound CC(C)NC1=C(Cl)C=CC=C1Cl WFSAEFXYMMRMIZ-UHFFFAOYSA-N 0.000 description 2
- FCJBZRJUGDJGRW-UHFFFAOYSA-N CC1=C2C(=O)NC=NN2C=C1OC(=O)C(C)(C)C Chemical compound CC1=C2C(=O)NC=NN2C=C1OC(=O)C(C)(C)C FCJBZRJUGDJGRW-UHFFFAOYSA-N 0.000 description 2
- IYYMZEOYNHCECS-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 Chemical compound CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 IYYMZEOYNHCECS-UHFFFAOYSA-N 0.000 description 2
- BJJWDEPCHGGZCH-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1 Chemical compound CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1 BJJWDEPCHGGZCH-UHFFFAOYSA-N 0.000 description 2
- ULRXDQHZUGTDNB-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1CO Chemical compound CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1CO ULRXDQHZUGTDNB-UHFFFAOYSA-N 0.000 description 2
- VEUBILHUPQDITL-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 VEUBILHUPQDITL-UHFFFAOYSA-N 0.000 description 2
- KVIOYSFSZKTXFI-UHFFFAOYSA-N CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 Chemical compound CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 KVIOYSFSZKTXFI-UHFFFAOYSA-N 0.000 description 2
- VDTAHJAMMMXPAP-UHFFFAOYSA-N CC1=CC2=C(N=CC=C2OC2=CC=C([N+](=O)[O-])C=C2F)N1 Chemical compound CC1=CC2=C(N=CC=C2OC2=CC=C([N+](=O)[O-])C=C2F)N1 VDTAHJAMMMXPAP-UHFFFAOYSA-N 0.000 description 2
- BCPDGDMNHIRYJG-UHFFFAOYSA-N CC1=CC=C(F)C(C(=O)NC2=CC=C(OC3=NC=NN4C=C(C(=O)NCCN5CCOCC5)C(C)=C34)C(F)=C2)=C1 Chemical compound CC1=CC=C(F)C(C(=O)NC2=CC=C(OC3=NC=NN4C=C(C(=O)NCCN5CCOCC5)C(C)=C34)C(F)=C2)=C1 BCPDGDMNHIRYJG-UHFFFAOYSA-N 0.000 description 2
- MGLLLHSRZKECIK-UHFFFAOYSA-N CN(C)CC#CC1=CNC2=C1C(OC1=CC=C(N)C=C1F)=CC=N2 Chemical compound CN(C)CC#CC1=CNC2=C1C(OC1=CC=C(N)C=C1F)=CC=N2 MGLLLHSRZKECIK-UHFFFAOYSA-N 0.000 description 2
- BKWQPMUHWJESCV-UHFFFAOYSA-N CN(C)CC(=O)C1=CNC2=C1C(OC1=CC=C(NC(=O)NC(=O)CC3=CC=C(F)C=C3)C=C1F)=CC=N2 Chemical compound CN(C)CC(=O)C1=CNC2=C1C(OC1=CC=C(NC(=O)NC(=O)CC3=CC=C(F)C=C3)C=C1F)=CC=N2 BKWQPMUHWJESCV-UHFFFAOYSA-N 0.000 description 2
- DXKBUNHVRDQHHI-UHFFFAOYSA-N COC(=O)C1=CNC2=C1C(OC1=C(F)C=C(NC(=O)NC(=O)CC3=CC=C(F)C=C3)C=C1)=CC=N2 Chemical compound COC(=O)C1=CNC2=C1C(OC1=C(F)C=C(NC(=O)NC(=O)CC3=CC=C(F)C=C3)C=C1)=CC=N2 DXKBUNHVRDQHHI-UHFFFAOYSA-N 0.000 description 2
- HWINBBUYLKWIBO-UHFFFAOYSA-N COC1=CC(C(C)C)=CC=C1 Chemical compound COC1=CC(C(C)C)=CC=C1 HWINBBUYLKWIBO-UHFFFAOYSA-N 0.000 description 2
- NNZRVXTXKISCGS-UHFFFAOYSA-N COC1=CC=CC=C1C(C)C Chemical compound COC1=CC=CC=C1C(C)C NNZRVXTXKISCGS-UHFFFAOYSA-N 0.000 description 2
- GMCZGWRGTAEYRT-UHFFFAOYSA-N COC1=CN2N=CN=C(OC3=CC=C([N+](=O)[O-])C=C3F)C2=C1C Chemical compound COC1=CN2N=CN=C(OC3=CC=C([N+](=O)[O-])C=C3F)C2=C1C GMCZGWRGTAEYRT-UHFFFAOYSA-N 0.000 description 2
- ZSMOVCCNNYRHTP-UHFFFAOYSA-N C[Si](C)(C)CCOCN1C(C2=CC=CN=C2)=CC2=C1N=CC=C2OC1=CC=C(N)C=C1F Chemical compound C[Si](C)(C)CCOCN1C(C2=CC=CN=C2)=CC2=C1N=CC=C2OC1=CC=C(N)C=C1F ZSMOVCCNNYRHTP-UHFFFAOYSA-N 0.000 description 2
- XZIRRBIOVUGENX-UHFFFAOYSA-N C[Si](C)(C)CCOCN1C=CC2=C1N=CC=C2Cl Chemical compound C[Si](C)(C)CCOCN1C=CC2=C1N=CC=C2Cl XZIRRBIOVUGENX-UHFFFAOYSA-N 0.000 description 2
- XUOWNZOIFHYSKE-UHFFFAOYSA-N NC1=CC=C(OC2=CC=NC3=C2C(CCCO)=CN3)C(F)=C1 Chemical compound NC1=CC=C(OC2=CC=NC3=C2C(CCCO)=CN3)C(F)=C1 XUOWNZOIFHYSKE-UHFFFAOYSA-N 0.000 description 2
- WSSGUPZZBQGLBK-UHFFFAOYSA-N NC1=CN=C(OC2=CC=NC3=C2C=CN3)C(Cl)=C1 Chemical compound NC1=CN=C(OC2=CC=NC3=C2C=CN3)C(Cl)=C1 WSSGUPZZBQGLBK-UHFFFAOYSA-N 0.000 description 2
- GZXXLBVXBQQEBV-UHFFFAOYSA-N NC1CCN(CC2=C3C(OC4=CC=C(NC(=O)C5=C(F)C=CC=C5F)C=C4F)=NC=NN3C=C2)CC1 Chemical compound NC1CCN(CC2=C3C(OC4=CC=C(NC(=O)C5=C(F)C=CC=C5F)C=C4F)=NC=NN3C=C2)CC1 GZXXLBVXBQQEBV-UHFFFAOYSA-N 0.000 description 2
- WBGWAHIOTYSOTI-UHFFFAOYSA-N NCCNC1=CN(C2=CC=C(F)C=C2)C(=O)C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)=C1 Chemical compound NCCNC1=CN(C2=CC=C(F)C=C2)C(=O)C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)=C1 WBGWAHIOTYSOTI-UHFFFAOYSA-N 0.000 description 2
- ZXFMQSXJBPDWOL-UHFFFAOYSA-N O=C(NC1=C(F)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CC=CN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=C(F)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CC=CN(C2=CC=C(F)C=C2)C1=O ZXFMQSXJBPDWOL-UHFFFAOYSA-N 0.000 description 2
- DMMKQYBSKNOXRC-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CN=CC=C2)=CN3)C(F)=C1)C1=C(F)C=CC=C1F Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CN=CC=C2)=CN3)C(F)=C1)C1=C(F)C=CC=C1F DMMKQYBSKNOXRC-UHFFFAOYSA-N 0.000 description 2
- JWAGZJWORRMLPR-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C(CN2CCCC2)=CN3)C(F)=C1)C1CCN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C(CN2CCCC2)=CN3)C(F)=C1)C1CCN(C2=CC=C(F)C=C2)C1=O JWAGZJWORRMLPR-UHFFFAOYSA-N 0.000 description 2
- ICTICGVROZJBRU-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CC(Br)=CN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CC(Br)=CN(C2=CC=C(F)C=C2)C1=O ICTICGVROZJBRU-UHFFFAOYSA-N 0.000 description 2
- AZEJAORQGGQABR-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CC(N2CCOCC2)=CN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CC(N2CCOCC2)=CN(C2=CC=C(F)C=C2)C1=O AZEJAORQGGQABR-UHFFFAOYSA-N 0.000 description 2
- GBUCZIKLHKVGIN-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1CCN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1CCN(C2=CC=C(F)C=C2)C1=O GBUCZIKLHKVGIN-UHFFFAOYSA-N 0.000 description 2
- PFMAFXYUHZDKPY-UHFFFAOYSA-N O=C(O)C1(C(=O)NC2=CC=C(F)C=C2)CC1 Chemical compound O=C(O)C1(C(=O)NC2=CC=C(F)C=C2)CC1 PFMAFXYUHZDKPY-UHFFFAOYSA-N 0.000 description 2
- QIXODSBBMATLBG-UHFFFAOYSA-N O=C1CCC(=CC2=C3C(OC4=CC=C(NC(=O)C5=CN=CC=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound O=C1CCC(=CC2=C3C(OC4=CC=C(NC(=O)C5=CN=CC=C5)C=C4F)=NC=NN3C=C2)CC1 QIXODSBBMATLBG-UHFFFAOYSA-N 0.000 description 2
- MQBWIDXXJFSQOA-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound O=[N+]([O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 MQBWIDXXJFSQOA-UHFFFAOYSA-N 0.000 description 2
- MQWSGXHXGTZRJQ-UHFFFAOYSA-N OC1=NC=NN2C=C(C3=CC=NC=C3)C=C12 Chemical compound OC1=NC=NN2C=C(C3=CC=NC=C3)C=C12 MQWSGXHXGTZRJQ-UHFFFAOYSA-N 0.000 description 2
- FQOTZVPWCACRKJ-UHFFFAOYSA-N [H]N(C(=O)C1=CC(C2=CC=CC=C2)=CNC1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC(C2=CC=CC=C2)=CNC1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 FQOTZVPWCACRKJ-UHFFFAOYSA-N 0.000 description 2
- SXNOJIKYPLJNJK-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=C(F)C=C(OC2=CC=NC3=C2C=CN3)C=C1 Chemical compound [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=C(F)C=C(OC2=CC=NC3=C2C=CN3)C=C1 SXNOJIKYPLJNJK-UHFFFAOYSA-N 0.000 description 2
- HKDRWYBXVHDXDO-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(OC)C=C(OC2=CC=NC3=C2C=CN3)C=C1 Chemical compound [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(OC)C=C(OC2=CC=NC3=C2C=CN3)C=C1 HKDRWYBXVHDXDO-UHFFFAOYSA-N 0.000 description 2
- QVYGVRMOHAXJBD-UHFFFAOYSA-N BC(=O)N1C=C(C#CCO)C2=C1N=CC=C2OC1=CC=C([N+](=O)[O-])C=C1F Chemical compound BC(=O)N1C=C(C#CCO)C2=C1N=CC=C2OC1=CC=C([N+](=O)[O-])C=C1F QVYGVRMOHAXJBD-UHFFFAOYSA-N 0.000 description 1
- BQMKURIMSKNDLR-UHFFFAOYSA-N C#CCNC(C)C Chemical compound C#CCNC(C)C BQMKURIMSKNDLR-UHFFFAOYSA-N 0.000 description 1
- GFBVGRCEDUCVAC-UHFFFAOYSA-N C.CCO.CO.O=C(O)C1=CC=CC([Ar])=[N+]1[O-].O=C(O)C1=NC(Br)=CC=C1.O=C(O)C1=NC([Ar])=CC=C1.OBO.[Ar] Chemical compound C.CCO.CO.O=C(O)C1=CC=CC([Ar])=[N+]1[O-].O=C(O)C1=NC(Br)=CC=C1.O=C(O)C1=NC([Ar])=CC=C1.OBO.[Ar] GFBVGRCEDUCVAC-UHFFFAOYSA-N 0.000 description 1
- AUQJXSXVDJHCHG-UHFFFAOYSA-M C1=CC2=C(N=C1)NC=C2.CC.CC.CS(=O)(=O)Cl.ClC1=CC=NC2=C1C=CN2.O=COO[K].O=[N+]([O-])C1=CC=C(O)C=C1.O=[N+]([O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C=C1.[KH].[O-][N+]1=CC=CC2=C1NC=C2.[O-][N+]1=CC=CC2=C1NC=C2 Chemical compound C1=CC2=C(N=C1)NC=C2.CC.CC.CS(=O)(=O)Cl.ClC1=CC=NC2=C1C=CN2.O=COO[K].O=[N+]([O-])C1=CC=C(O)C=C1.O=[N+]([O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C=C1.[KH].[O-][N+]1=CC=CC2=C1NC=C2.[O-][N+]1=CC=CC2=C1NC=C2 AUQJXSXVDJHCHG-UHFFFAOYSA-M 0.000 description 1
- OWUBKHTYXCOYMM-UHFFFAOYSA-N C=CCNC(C)C Chemical compound C=CCNC(C)C OWUBKHTYXCOYMM-UHFFFAOYSA-N 0.000 description 1
- JYTHSLNJXAEHQT-UHFFFAOYSA-N CC(=O)C1=CC(C(C)C)=CC=C1 Chemical compound CC(=O)C1=CC(C(C)C)=CC=C1 JYTHSLNJXAEHQT-UHFFFAOYSA-N 0.000 description 1
- WTRBLDMEOQKMME-UHFFFAOYSA-N CC(=O)C1=CC=CC(C(=O)NC2=CC=C(OC3=NC=NN4C=C(OCCN5CCN(C)CC5)C(C)=C34)C(F)=C2)=C1 Chemical compound CC(=O)C1=CC=CC(C(=O)NC2=CC=C(OC3=NC=NN4C=C(OCCN5CCN(C)CC5)C(C)=C34)C(F)=C2)=C1 WTRBLDMEOQKMME-UHFFFAOYSA-N 0.000 description 1
- BLISLJMLKWOHPZ-UHFFFAOYSA-N CC(=O)NC1=C(NC(C)C)C=CC=C1 Chemical compound CC(=O)NC1=C(NC(C)C)C=CC=C1 BLISLJMLKWOHPZ-UHFFFAOYSA-N 0.000 description 1
- CFTCRFRSXVBECP-UHFFFAOYSA-N CC(=O)NC1=CC(C2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)=CC=C1 Chemical compound CC(=O)NC1=CC(C2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)=CC=C1 CFTCRFRSXVBECP-UHFFFAOYSA-N 0.000 description 1
- VIAYGVOINHZAAN-UHFFFAOYSA-N CC(=O)NC1=CC(C2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)=CC=C1 Chemical compound CC(=O)NC1=CC(C2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)=CC=C1 VIAYGVOINHZAAN-UHFFFAOYSA-N 0.000 description 1
- JTZCINZNRFOJCN-UHFFFAOYSA-N CC(=O)NC1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound CC(=O)NC1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 JTZCINZNRFOJCN-UHFFFAOYSA-N 0.000 description 1
- IQZCSWSXDHWKEV-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(I)C2=C1N=CC=C2OC1=CC=C([N+](=O)[O-])C=C1F Chemical compound CC(C)(C)OC(=O)N1C=C(I)C2=C1N=CC=C2OC1=CC=C([N+](=O)[O-])C=C1F IQZCSWSXDHWKEV-UHFFFAOYSA-N 0.000 description 1
- UGYLXFZCNVYTLL-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(N(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C(=O)OC(C)(C)C)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(N(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C(=O)OC(C)(C)C)CC1 UGYLXFZCNVYTLL-UHFFFAOYSA-N 0.000 description 1
- OPAPKRRDRFGTIR-UHFFFAOYSA-N CC(C)(C)OC(=O)NC1=CC=C(C2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C=C1 Chemical compound CC(C)(C)OC(=O)NC1=CC=C(C2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C=C1 OPAPKRRDRFGTIR-UHFFFAOYSA-N 0.000 description 1
- SQKQSSJHVPTPHP-UHFFFAOYSA-N CC(C)(C)OC(=O)NC1CCN(CC2=C3C(NC4=CC=C(N)C=C4)=NC=NN3C=C2)CC1 Chemical compound CC(C)(C)OC(=O)NC1CCN(CC2=C3C(NC4=CC=C(N)C=C4)=NC=NN3C=C2)CC1 SQKQSSJHVPTPHP-UHFFFAOYSA-N 0.000 description 1
- OJFQVASWQMXOER-UHFFFAOYSA-N CC(C)(C)OC(=O)NC1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)CC1 Chemical compound CC(C)(C)OC(=O)NC1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)CC1 OJFQVASWQMXOER-UHFFFAOYSA-N 0.000 description 1
- QNVOBCGNAVELKF-UHFFFAOYSA-N CC(C)(C)OC(=O)NCC1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)CC1 Chemical compound CC(C)(C)OC(=O)NCC1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)CC1 QNVOBCGNAVELKF-UHFFFAOYSA-N 0.000 description 1
- QKYPHIDDLVGNAF-UHFFFAOYSA-N CC(C)(C)OC(=O)NCC1CN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C1 Chemical compound CC(C)(C)OC(=O)NCC1CN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C1 QKYPHIDDLVGNAF-UHFFFAOYSA-N 0.000 description 1
- CMTITPATTOLATN-UHFFFAOYSA-N CC(C)(C)OC(=O)NCCCN(CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1)C(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)NCCCN(CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1)C(=O)OC(C)(C)C CMTITPATTOLATN-UHFFFAOYSA-N 0.000 description 1
- IZDBJIKIGVOBLQ-UHFFFAOYSA-N CC(C)(C)OC(=O)NCCNC1=CN(C2=CC=C(F)C=C2)C(=O)C(C(=O)O)=C1 Chemical compound CC(C)(C)OC(=O)NCCNC1=CN(C2=CC=C(F)C=C2)C(=O)C(C(=O)O)=C1 IZDBJIKIGVOBLQ-UHFFFAOYSA-N 0.000 description 1
- CTLKDBQXSSGRIB-MRXNPFEDSA-N CC(C)(C)OC(=O)N[C@@H]1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C1 Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C1 CTLKDBQXSSGRIB-MRXNPFEDSA-N 0.000 description 1
- OQIWJIKMDVFTBI-KRWDZBQOSA-N CC(C)(C)OC(=O)N[C@H]1CCCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C1 Chemical compound CC(C)(C)OC(=O)N[C@H]1CCCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C1 OQIWJIKMDVFTBI-KRWDZBQOSA-N 0.000 description 1
- CTLKDBQXSSGRIB-INIZCTEOSA-N CC(C)(C)OC(=O)N[C@H]1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C1 Chemical compound CC(C)(C)OC(=O)N[C@H]1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C1 CTLKDBQXSSGRIB-INIZCTEOSA-N 0.000 description 1
- RLRRTGMKLHRXCF-UHFFFAOYSA-N CC(C)C1=C(Cl)C=CS1 Chemical compound CC(C)C1=C(Cl)C=CS1 RLRRTGMKLHRXCF-UHFFFAOYSA-N 0.000 description 1
- BOWNKMWTAHSJJM-UHFFFAOYSA-N CC(C)C1=C(Cl)C=NC=C1Cl Chemical compound CC(C)C1=C(Cl)C=NC=C1Cl BOWNKMWTAHSJJM-UHFFFAOYSA-N 0.000 description 1
- CNHYUSHOBWKQOZ-UHFFFAOYSA-N CC(C)C1=C2C(=O)NC=NN2C=C1 Chemical compound CC(C)C1=C2C(=O)NC=NN2C=C1 CNHYUSHOBWKQOZ-UHFFFAOYSA-N 0.000 description 1
- QDBLQKDCZMHEPJ-UHFFFAOYSA-N CC(C)C1=C2C(Cl)=NC=NN2C=C1 Chemical compound CC(C)C1=C2C(Cl)=NC=NN2C=C1 QDBLQKDCZMHEPJ-UHFFFAOYSA-N 0.000 description 1
- ARBVMBYDZFKNOG-UHFFFAOYSA-N CC(C)C1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1 Chemical compound CC(C)C1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1 ARBVMBYDZFKNOG-UHFFFAOYSA-N 0.000 description 1
- AWYUMKBPFWHQMJ-UHFFFAOYSA-N CC(C)C1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1 Chemical compound CC(C)C1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1 AWYUMKBPFWHQMJ-UHFFFAOYSA-N 0.000 description 1
- GVMCCTQOVJPHIV-UHFFFAOYSA-N CC(C)C1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1 Chemical compound CC(C)C1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1 GVMCCTQOVJPHIV-UHFFFAOYSA-N 0.000 description 1
- UUVANYRJRBMMKG-UHFFFAOYSA-N CC(C)C1=CC(C(F)(F)F)=CC=C1F Chemical compound CC(C)C1=CC(C(F)(F)F)=CC=C1F UUVANYRJRBMMKG-UHFFFAOYSA-N 0.000 description 1
- SPOUQQVCENNDQD-UHFFFAOYSA-N CC(C)C1=CC(Cl)=CC=C1F Chemical compound CC(C)C1=CC(Cl)=CC=C1F SPOUQQVCENNDQD-UHFFFAOYSA-N 0.000 description 1
- WJQPODUHBHNYEV-UHFFFAOYSA-N CC(C)C1=CC(Cl)=CN=C1Cl Chemical compound CC(C)C1=CC(Cl)=CN=C1Cl WJQPODUHBHNYEV-UHFFFAOYSA-N 0.000 description 1
- VCQGGRUPKXCGJN-UHFFFAOYSA-N CC(C)C1=CC(Cl)=NC=C1 Chemical compound CC(C)C1=CC(Cl)=NC=C1 VCQGGRUPKXCGJN-UHFFFAOYSA-N 0.000 description 1
- ZSENERLFZXSGHI-UHFFFAOYSA-N CC(C)C1=CC(F)=C(F)C=C1F Chemical compound CC(C)C1=CC(F)=C(F)C=C1F ZSENERLFZXSGHI-UHFFFAOYSA-N 0.000 description 1
- UGXGHLUTCJOYLX-UHFFFAOYSA-N CC(C)C1=CC2=C(C=C1)N=CC=N2 Chemical compound CC(C)C1=CC2=C(C=C1)N=CC=N2 UGXGHLUTCJOYLX-UHFFFAOYSA-N 0.000 description 1
- SIZCAMBYKFGFAR-UHFFFAOYSA-N CC(C)C1=CC2=C(C=C1)N=CS2 Chemical compound CC(C)C1=CC2=C(C=C1)N=CS2 SIZCAMBYKFGFAR-UHFFFAOYSA-N 0.000 description 1
- YFDJCWXBKWRDPW-UHFFFAOYSA-N CC(C)C1=CC=C(C#N)C=C1 Chemical compound CC(C)C1=CC=C(C#N)C=C1 YFDJCWXBKWRDPW-UHFFFAOYSA-N 0.000 description 1
- HWBUVBCLPDLJLH-UHFFFAOYSA-N CC(C)C1=CC=C(C(F)(F)F)C=C1F Chemical compound CC(C)C1=CC=C(C(F)(F)F)C=C1F HWBUVBCLPDLJLH-UHFFFAOYSA-N 0.000 description 1
- DYYODOGOLNNNIX-UHFFFAOYSA-N CC(C)C1=CC=C(C(F)(F)F)N=C1 Chemical compound CC(C)C1=CC=C(C(F)(F)F)N=C1 DYYODOGOLNNNIX-UHFFFAOYSA-N 0.000 description 1
- FHBSIIZALGOVLM-UHFFFAOYSA-N CC(C)C1=CC=C(Cl)C=C1 Chemical compound CC(C)C1=CC=C(Cl)C=C1 FHBSIIZALGOVLM-UHFFFAOYSA-N 0.000 description 1
- DNJROFGCOSDKIL-UHFFFAOYSA-N CC(C)C1=CC=C(Cl)N=C1 Chemical compound CC(C)C1=CC=C(Cl)N=C1 DNJROFGCOSDKIL-UHFFFAOYSA-N 0.000 description 1
- ATGLUSRJDDWYEL-UHFFFAOYSA-N CC(C)C1=CC=C(F)C=C1C(F)(F)F Chemical compound CC(C)C1=CC=C(F)C=C1C(F)(F)F ATGLUSRJDDWYEL-UHFFFAOYSA-N 0.000 description 1
- CZTVXRSMLZRUMJ-UHFFFAOYSA-N CC(C)C1=CC=C(F)C=C1F Chemical compound CC(C)C1=CC=C(F)C=C1F CZTVXRSMLZRUMJ-UHFFFAOYSA-N 0.000 description 1
- MJRUTYCVCLZWSR-UHFFFAOYSA-N CC(C)C1=CC=C(N(C)C)C=C1 Chemical compound CC(C)C1=CC=C(N(C)C)C=C1 MJRUTYCVCLZWSR-UHFFFAOYSA-N 0.000 description 1
- NAYXHKRRAWPEKG-UHFFFAOYSA-N CC(C)C1=CC=CC(F)=C1 Chemical compound CC(C)C1=CC=CC(F)=C1 NAYXHKRRAWPEKG-UHFFFAOYSA-N 0.000 description 1
- LEXVIFZWCHIYMD-UHFFFAOYSA-N CC(C)C1=CC=CC(F)=C1F Chemical compound CC(C)C1=CC=CC(F)=C1F LEXVIFZWCHIYMD-UHFFFAOYSA-N 0.000 description 1
- ZZWJZCURFRSZPD-UHFFFAOYSA-N CC(C)C1=CC=CC(N(C)C)=C1 Chemical compound CC(C)C1=CC=CC(N(C)C)=C1 ZZWJZCURFRSZPD-UHFFFAOYSA-N 0.000 description 1
- SGPFUCRQUZMQCP-UHFFFAOYSA-N CC(C)C1=CC=CC(S(C)(=O)=O)=C1 Chemical compound CC(C)C1=CC=CC(S(C)(=O)=O)=C1 SGPFUCRQUZMQCP-UHFFFAOYSA-N 0.000 description 1
- LRMXTWCDIPSDCW-UHFFFAOYSA-N CC(C)C1=CC=CC=C1C(F)(F)F Chemical compound CC(C)C1=CC=CC=C1C(F)(F)F LRMXTWCDIPSDCW-UHFFFAOYSA-N 0.000 description 1
- NHVJMRHABPVQTR-UHFFFAOYSA-N CC(C)C1=CC=CN=C1Cl Chemical compound CC(C)C1=CC=CN=C1Cl NHVJMRHABPVQTR-UHFFFAOYSA-N 0.000 description 1
- SBKHPHGRNVBNHM-UHFFFAOYSA-N CC(C)C1=CC=CN=C1F Chemical compound CC(C)C1=CC=CN=C1F SBKHPHGRNVBNHM-UHFFFAOYSA-N 0.000 description 1
- FMCDHSFOXOMCER-UHFFFAOYSA-N CC(C)C1=CC=CN=C1OC1=CC=CC=C1 Chemical compound CC(C)C1=CC=CN=C1OC1=CC=CC=C1 FMCDHSFOXOMCER-UHFFFAOYSA-N 0.000 description 1
- LOXBELRNKUFSRD-UHFFFAOYSA-N CC(C)C1=CC=CS1 Chemical compound CC(C)C1=CC=CS1 LOXBELRNKUFSRD-UHFFFAOYSA-N 0.000 description 1
- FRGXNJWEDDQLFH-UHFFFAOYSA-N CC(C)C1=CC=NC=C1 Chemical compound CC(C)C1=CC=NC=C1 FRGXNJWEDDQLFH-UHFFFAOYSA-N 0.000 description 1
- GKRZKWYQQJJGCZ-UHFFFAOYSA-N CC(C)C1=CC=NC=C1F Chemical compound CC(C)C1=CC=NC=C1F GKRZKWYQQJJGCZ-UHFFFAOYSA-N 0.000 description 1
- ZGVSLIJCYFJGDQ-UHFFFAOYSA-N CC(C)C1=CC=NO1 Chemical compound CC(C)C1=CC=NO1 ZGVSLIJCYFJGDQ-UHFFFAOYSA-N 0.000 description 1
- PUACTIIESPYWSI-UHFFFAOYSA-N CC(C)C1=CN=CC=C1 Chemical compound CC(C)C1=CN=CC=C1 PUACTIIESPYWSI-UHFFFAOYSA-N 0.000 description 1
- DAAARXMHBLJQPU-UHFFFAOYSA-N CC(C)C1=COC=C1 Chemical compound CC(C)C1=COC=C1 DAAARXMHBLJQPU-UHFFFAOYSA-N 0.000 description 1
- FRDCSJHLYAPNKI-UHFFFAOYSA-N CC(C)C1=CSC(C2=CN=CC=C2)=N1 Chemical compound CC(C)C1=CSC(C2=CN=CC=C2)=N1 FRDCSJHLYAPNKI-UHFFFAOYSA-N 0.000 description 1
- LJPDBPCGTFTUDE-UHFFFAOYSA-N CC(C)C1=CSC=C1 Chemical compound CC(C)C1=CSC=C1 LJPDBPCGTFTUDE-UHFFFAOYSA-N 0.000 description 1
- NXUYGLIOLISFFN-UHFFFAOYSA-N CC(C)C1=NC2=C(C=CC=C2)N=C1 Chemical compound CC(C)C1=NC2=C(C=CC=C2)N=C1 NXUYGLIOLISFFN-UHFFFAOYSA-N 0.000 description 1
- GIMBKDZNMKTZMG-UHFFFAOYSA-N CC(C)C1=NC=CN=C1 Chemical compound CC(C)C1=NC=CN=C1 GIMBKDZNMKTZMG-UHFFFAOYSA-N 0.000 description 1
- PNCYPSGYEWPJHO-UHFFFAOYSA-N CC(C)CCN1C=CC=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)C1=O Chemical compound CC(C)CCN1C=CC=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)C1=O PNCYPSGYEWPJHO-UHFFFAOYSA-N 0.000 description 1
- BRPOAOCIOKRVDW-UHFFFAOYSA-N CC(C)N(C)C1=CC=C(F)C=C1 Chemical compound CC(C)N(C)C1=CC=C(F)C=C1 BRPOAOCIOKRVDW-UHFFFAOYSA-N 0.000 description 1
- BXVAVXHPXVAUBU-UHFFFAOYSA-N CC(C)N1CCCCCC1 Chemical compound CC(C)N1CCCCCC1 BXVAVXHPXVAUBU-UHFFFAOYSA-N 0.000 description 1
- ZWXQPERWRDHCMZ-UHFFFAOYSA-N CC(C)NC(C)(C)C Chemical compound CC(C)NC(C)(C)C ZWXQPERWRDHCMZ-UHFFFAOYSA-N 0.000 description 1
- UAOMVDZJSHZZME-UHFFFAOYSA-N CC(C)NC(C)C Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
- HFZWIOMMCVHMSX-UHFFFAOYSA-N CC(C)NC1=C(C(N)=O)C=CC=C1 Chemical compound CC(C)NC1=C(C(N)=O)C=CC=C1 HFZWIOMMCVHMSX-UHFFFAOYSA-N 0.000 description 1
- KMVMJYOOKHWRDT-UHFFFAOYSA-N CC(C)NC1=C(CC#N)C=CC=C1 Chemical compound CC(C)NC1=C(CC#N)C=CC=C1 KMVMJYOOKHWRDT-UHFFFAOYSA-N 0.000 description 1
- JCRMYLUIMGTZSR-UHFFFAOYSA-N CC(C)NC1=C(Cl)C=CC=C1 Chemical compound CC(C)NC1=C(Cl)C=CC=C1 JCRMYLUIMGTZSR-UHFFFAOYSA-N 0.000 description 1
- UKXHJPFPCVYBFE-UHFFFAOYSA-N CC(C)NC1=C(F)C=CC=C1Cl Chemical compound CC(C)NC1=C(F)C=CC=C1Cl UKXHJPFPCVYBFE-UHFFFAOYSA-N 0.000 description 1
- BLCSQUZTWKPKSR-UHFFFAOYSA-N CC(C)NC1=C(O)C=CC=C1 Chemical compound CC(C)NC1=C(O)C=CC=C1 BLCSQUZTWKPKSR-UHFFFAOYSA-N 0.000 description 1
- SSHDQOKWUBCYJF-UHFFFAOYSA-N CC(C)NC1=CC(C#N)=CC=C1 Chemical compound CC(C)NC1=CC(C#N)=CC=C1 SSHDQOKWUBCYJF-UHFFFAOYSA-N 0.000 description 1
- NUBHOOLLQMDUAZ-UHFFFAOYSA-N CC(C)NC1=CC(C(C)(C)C)=CC=C1 Chemical compound CC(C)NC1=CC(C(C)(C)C)=CC=C1 NUBHOOLLQMDUAZ-UHFFFAOYSA-N 0.000 description 1
- XSHXLSIXKPBKFK-UHFFFAOYSA-N CC(C)NC1=CC(CC2=CC=CC=C2)=CC=C1 Chemical compound CC(C)NC1=CC(CC2=CC=CC=C2)=CC=C1 XSHXLSIXKPBKFK-UHFFFAOYSA-N 0.000 description 1
- IKHOHPACXARWCK-UHFFFAOYSA-N CC(C)NC1=CC(Cl)=CC=C1Cl Chemical compound CC(C)NC1=CC(Cl)=CC=C1Cl IKHOHPACXARWCK-UHFFFAOYSA-N 0.000 description 1
- WLDRSPFHOGPUKE-UHFFFAOYSA-N CC(C)NC1=CC(Cl)=CC=C1F Chemical compound CC(C)NC1=CC(Cl)=CC=C1F WLDRSPFHOGPUKE-UHFFFAOYSA-N 0.000 description 1
- ADVGIEJIUCIANF-UHFFFAOYSA-N CC(C)NC1=CC(F)=C(F)C=C1 Chemical compound CC(C)NC1=CC(F)=C(F)C=C1 ADVGIEJIUCIANF-UHFFFAOYSA-N 0.000 description 1
- UFDPHGGPXUIWSP-UHFFFAOYSA-N CC(C)NC1=CC(F)=CC=C1F Chemical compound CC(C)NC1=CC(F)=CC=C1F UFDPHGGPXUIWSP-UHFFFAOYSA-N 0.000 description 1
- ZCDQGCFYSDREOQ-UHFFFAOYSA-N CC(C)NC1=CC(OC2=CC=CC=C2)=CC=C1 Chemical compound CC(C)NC1=CC(OC2=CC=CC=C2)=CC=C1 ZCDQGCFYSDREOQ-UHFFFAOYSA-N 0.000 description 1
- SKODCHPTCLQVTN-UHFFFAOYSA-N CC(C)NC1=CC2=C(C=C1)CCC2 Chemical compound CC(C)NC1=CC2=C(C=C1)CCC2 SKODCHPTCLQVTN-UHFFFAOYSA-N 0.000 description 1
- SWHNSGVWGMLBBT-UHFFFAOYSA-N CC(C)NC1=CC2=C(C=C1)NC=C2 Chemical compound CC(C)NC1=CC2=C(C=C1)NC=C2 SWHNSGVWGMLBBT-UHFFFAOYSA-N 0.000 description 1
- ROTKVBNHXLXEIF-UHFFFAOYSA-N CC(C)NC1=CC2=C(C=C1)NN=C2 Chemical compound CC(C)NC1=CC2=C(C=C1)NN=C2 ROTKVBNHXLXEIF-UHFFFAOYSA-N 0.000 description 1
- DFJUAQRBUUGSNE-UHFFFAOYSA-N CC(C)NC1=CC=C(C#N)C=C1 Chemical compound CC(C)NC1=CC=C(C#N)C=C1 DFJUAQRBUUGSNE-UHFFFAOYSA-N 0.000 description 1
- CULMZLFXBMWJDG-UHFFFAOYSA-N CC(C)NC1=CC=C(C2=CC=CC=C2)C=C1 Chemical compound CC(C)NC1=CC=C(C2=CC=CC=C2)C=C1 CULMZLFXBMWJDG-UHFFFAOYSA-N 0.000 description 1
- VMISTBHYUBGZJP-UHFFFAOYSA-N CC(C)NC1=CC=C(F)C=C1F Chemical compound CC(C)NC1=CC=C(F)C=C1F VMISTBHYUBGZJP-UHFFFAOYSA-N 0.000 description 1
- FRCFWPVMFJMNDP-UHFFFAOYSA-N CC(C)NC1=CC=CC=C1 Chemical compound CC(C)NC1=CC=CC=C1 FRCFWPVMFJMNDP-UHFFFAOYSA-N 0.000 description 1
- IGFAUTSEOYDBII-UHFFFAOYSA-N CC(C)NC1=CC=CC=C1C(C)C Chemical compound CC(C)NC1=CC=CC=C1C(C)C IGFAUTSEOYDBII-UHFFFAOYSA-N 0.000 description 1
- ADARRCKUGOHWKH-UHFFFAOYSA-N CC(C)NC1=CC=CC=C1C1=CC=CC=C1 Chemical compound CC(C)NC1=CC=CC=C1C1=CC=CC=C1 ADARRCKUGOHWKH-UHFFFAOYSA-N 0.000 description 1
- BIPRNRDNBVGHNV-UHFFFAOYSA-N CC(C)NC1=CC=NC=C1 Chemical compound CC(C)NC1=CC=NC=C1 BIPRNRDNBVGHNV-UHFFFAOYSA-N 0.000 description 1
- KJSHRGNATIWUSZ-UHFFFAOYSA-N CC(C)NC1=CN=CC=C1 Chemical compound CC(C)NC1=CN=CC=C1 KJSHRGNATIWUSZ-UHFFFAOYSA-N 0.000 description 1
- JQPJCPJUEYREHV-UHFFFAOYSA-N CC(C)NC1=NC=CC=C1 Chemical compound CC(C)NC1=NC=CC=C1 JQPJCPJUEYREHV-UHFFFAOYSA-N 0.000 description 1
- RZALQYQCABSXLA-UHFFFAOYSA-N CC(C)NC1=NNC=C1 Chemical compound CC(C)NC1=NNC=C1 RZALQYQCABSXLA-UHFFFAOYSA-N 0.000 description 1
- QPAYKLQAWLDKOO-UHFFFAOYSA-N CC(C)NC1C2=C(C=CC=C2)CC1O Chemical compound CC(C)NC1C2=C(C=CC=C2)CC1O QPAYKLQAWLDKOO-UHFFFAOYSA-N 0.000 description 1
- XWGXFOVSOYMSGT-UHFFFAOYSA-N CC(C)NC1CC1 Chemical compound CC(C)NC1CC1 XWGXFOVSOYMSGT-UHFFFAOYSA-N 0.000 description 1
- HGEXOWFANSIFAZ-UHFFFAOYSA-N CC(C)NC1CCCC1 Chemical compound CC(C)NC1CCCC1 HGEXOWFANSIFAZ-UHFFFAOYSA-N 0.000 description 1
- UYYCVBASZNFFRX-UHFFFAOYSA-N CC(C)NC1CCCCC1 Chemical compound CC(C)NC1CCCCC1 UYYCVBASZNFFRX-UHFFFAOYSA-N 0.000 description 1
- BAMIITPCPOUFPY-UHFFFAOYSA-N CC(C)NC1CCCCCC1 Chemical compound CC(C)NC1CCCCCC1 BAMIITPCPOUFPY-UHFFFAOYSA-N 0.000 description 1
- ABKJVDAMVQXXSZ-UHFFFAOYSA-N CC(C)NC1CCOCC1 Chemical compound CC(C)NC1CCOCC1 ABKJVDAMVQXXSZ-UHFFFAOYSA-N 0.000 description 1
- BVVNMQQFLWWRFT-UHFFFAOYSA-N CC(C)NCC(C)(C)N Chemical compound CC(C)NCC(C)(C)N BVVNMQQFLWWRFT-UHFFFAOYSA-N 0.000 description 1
- IDZSJVHMHRLKIU-UHFFFAOYSA-N CC(C)NCC1=CC=C(F)C=C1 Chemical compound CC(C)NCC1=CC=C(F)C=C1 IDZSJVHMHRLKIU-UHFFFAOYSA-N 0.000 description 1
- LYBKPDDZTNUNNM-UHFFFAOYSA-N CC(C)NCC1=CC=CC=C1 Chemical compound CC(C)NCC1=CC=CC=C1 LYBKPDDZTNUNNM-UHFFFAOYSA-N 0.000 description 1
- CRYXHQBSIQUCFG-UHFFFAOYSA-N CC(C)NCC1=CC=CN=C1 Chemical compound CC(C)NCC1=CC=CN=C1 CRYXHQBSIQUCFG-UHFFFAOYSA-N 0.000 description 1
- GAGIUQGGHJZYTE-UHFFFAOYSA-N CC(C)NCC1=CC=CO1 Chemical compound CC(C)NCC1=CC=CO1 GAGIUQGGHJZYTE-UHFFFAOYSA-N 0.000 description 1
- NPGDRWOUJFBPMC-UHFFFAOYSA-N CC(C)NCCC(C)(C)C Chemical compound CC(C)NCCC(C)(C)C NPGDRWOUJFBPMC-UHFFFAOYSA-N 0.000 description 1
- HNPAEWJKFXEUDW-UHFFFAOYSA-N CC(C)NCCC1=CC=CC=C1 Chemical compound CC(C)NCCC1=CC=CC=C1 HNPAEWJKFXEUDW-UHFFFAOYSA-N 0.000 description 1
- AGDHSWAZTKYTNX-UHFFFAOYSA-N CC(C)NCCCC1=CC=CC=C1 Chemical compound CC(C)NCCCC1=CC=CC=C1 AGDHSWAZTKYTNX-UHFFFAOYSA-N 0.000 description 1
- SXQMJKAMQXDOFL-SNVBAGLBSA-N CC(C)N[C@@H](C(N)=O)C1=CC=CC=C1 Chemical compound CC(C)N[C@@H](C(N)=O)C1=CC=CC=C1 SXQMJKAMQXDOFL-SNVBAGLBSA-N 0.000 description 1
- SXQMJKAMQXDOFL-JTQLQIEISA-N CC(C)N[C@H](C(N)=O)C1=CC=CC=C1 Chemical compound CC(C)N[C@H](C(N)=O)C1=CC=CC=C1 SXQMJKAMQXDOFL-JTQLQIEISA-N 0.000 description 1
- NXBJSUOOKXVSFX-IUCAKERBSA-N CC(C)N[C@H]1CCCC[C@@H]1O Chemical compound CC(C)N[C@H]1CCCC[C@@H]1O NXBJSUOOKXVSFX-IUCAKERBSA-N 0.000 description 1
- NXBJSUOOKXVSFX-DTWKUNHWSA-N CC(C)N[C@H]1CCCC[C@H]1O Chemical compound CC(C)N[C@H]1CCCC[C@H]1O NXBJSUOOKXVSFX-DTWKUNHWSA-N 0.000 description 1
- RNFDZDMIFOFNMC-UHFFFAOYSA-N CC(O)CNC(C)C Chemical compound CC(O)CNC(C)C RNFDZDMIFOFNMC-UHFFFAOYSA-N 0.000 description 1
- BJWPTEXSPDCOJU-UHFFFAOYSA-N CC.CC.CCC1=C2C(OC3=CC=C(N)C=C3)=NC=NN2C=C1.CCC1=C2C(SC)=NC=NN2C=C1.CSC1=NC=NN2C=CC(C)=C12.NC1=CC=C(O)C=C1 Chemical compound CC.CC.CCC1=C2C(OC3=CC=C(N)C=C3)=NC=NN2C=C1.CCC1=C2C(SC)=NC=NN2C=C1.CSC1=NC=NN2C=CC(C)=C12.NC1=CC=C(O)C=C1 BJWPTEXSPDCOJU-UHFFFAOYSA-N 0.000 description 1
- DOUOXIACEJHQCR-UHFFFAOYSA-N CC.CC.C[SiH](C)CCOCN1C([Ar])=CC2=C1N=CC=C2Cl.C[Si](C)(C)CCOCN1C(B(O)O)=CC2=C1N=CC=C2Cl.C[Si](C)(C)CCOCN1C=CC2=C1N=CC=C2Cl.ClC1=CC=NC2=C1C=C([Ar])N2.O=[N+]([O-])C1=CC=C(O)C=C1.O=[N+]([O-])C1=CC=C(OC2=CC=NC3=C2C=C([Ar])N3)C=C1 Chemical compound CC.CC.C[SiH](C)CCOCN1C([Ar])=CC2=C1N=CC=C2Cl.C[Si](C)(C)CCOCN1C(B(O)O)=CC2=C1N=CC=C2Cl.C[Si](C)(C)CCOCN1C=CC2=C1N=CC=C2Cl.ClC1=CC=NC2=C1C=C([Ar])N2.O=[N+]([O-])C1=CC=C(O)C=C1.O=[N+]([O-])C1=CC=C(OC2=CC=NC3=C2C=C([Ar])N3)C=C1 DOUOXIACEJHQCR-UHFFFAOYSA-N 0.000 description 1
- ZOGPASJCJMPOCC-UHFFFAOYSA-K CC.CCC(=O)C1=CNC2=C1C(OC1=CC=C(N)C=C1F)=CC=N2.Cl[Al](Cl)Cl.NC(N)=S.NC1=CC=C(OC2=CC=NC3=C2C(C2=CSC(N)=N2)=CN3)C(F)=C1.NC1=NC(C2=CNC3=C2C(OC2=CC=C([N+](=O)[O-])C=C2F)=CC=N3)=CS1.O=C(CBr)C1=CNC2=C1C(OC1=CC=C([N+](=O)[O-])C=C1F)=CC=N2.O=C(Cl)CBr.O=[N+]([O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C=C1 Chemical compound CC.CCC(=O)C1=CNC2=C1C(OC1=CC=C(N)C=C1F)=CC=N2.Cl[Al](Cl)Cl.NC(N)=S.NC1=CC=C(OC2=CC=NC3=C2C(C2=CSC(N)=N2)=CN3)C(F)=C1.NC1=NC(C2=CNC3=C2C(OC2=CC=C([N+](=O)[O-])C=C2F)=CC=N3)=CS1.O=C(CBr)C1=CNC2=C1C(OC1=CC=C([N+](=O)[O-])C=C1F)=CC=N2.O=C(Cl)CBr.O=[N+]([O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C=C1 ZOGPASJCJMPOCC-UHFFFAOYSA-K 0.000 description 1
- OBSHEDYSIWLDIK-JXAWBTAJSA-N CC1(O)CCC(=CC2=C3C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound CC1(O)CCC(=CC2=C3C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 OBSHEDYSIWLDIK-JXAWBTAJSA-N 0.000 description 1
- NZDWYSQVBKRCLV-UHFFFAOYSA-N CC1=C(C(C)C)OC=C1 Chemical compound CC1=C(C(C)C)OC=C1 NZDWYSQVBKRCLV-UHFFFAOYSA-N 0.000 description 1
- CDFGAXXPIIJXSS-UHFFFAOYSA-N CC1=C(Cl)C=CC=C1NC(C)C Chemical compound CC1=C(Cl)C=CC=C1NC(C)C CDFGAXXPIIJXSS-UHFFFAOYSA-N 0.000 description 1
- CCSZKSZMNLWLRW-UHFFFAOYSA-N CC1=C(F)C=CC(NC(C)C)=C1 Chemical compound CC1=C(F)C=CC(NC(C)C)=C1 CCSZKSZMNLWLRW-UHFFFAOYSA-N 0.000 description 1
- JKIJTEKYCLUFOB-UHFFFAOYSA-N CC1=C(NC(C)C)C(Cl)=CC=C1 Chemical compound CC1=C(NC(C)C)C(Cl)=CC=C1 JKIJTEKYCLUFOB-UHFFFAOYSA-N 0.000 description 1
- XVQHVNWXTDOLQR-UHFFFAOYSA-N CC1=C(NC(C)C)C=CC(F)=C1 Chemical compound CC1=C(NC(C)C)C=CC(F)=C1 XVQHVNWXTDOLQR-UHFFFAOYSA-N 0.000 description 1
- ZWPFCAYJUSBNTQ-UHFFFAOYSA-N CC1=C(NC(C)C)C=CC=C1F Chemical compound CC1=C(NC(C)C)C=CC=C1F ZWPFCAYJUSBNTQ-UHFFFAOYSA-N 0.000 description 1
- YANYBIWYQVVFPQ-UHFFFAOYSA-N CC1=C2C(=O)NC=NN2C=C1C(C)(C)O Chemical compound CC1=C2C(=O)NC=NN2C=C1C(C)(C)O YANYBIWYQVVFPQ-UHFFFAOYSA-N 0.000 description 1
- PCWSBYIKVFVFGS-UHFFFAOYSA-N CC1=C2C(=O)NC=NN2C=C1O Chemical compound CC1=C2C(=O)NC=NN2C=C1O PCWSBYIKVFVFGS-UHFFFAOYSA-N 0.000 description 1
- UNTXLACJAGMQMM-UHFFFAOYSA-N CC1=C2C(Cl)=NC=NN2C=C1OC(=O)C(C)(C)C Chemical compound CC1=C2C(Cl)=NC=NN2C=C1OC(=O)C(C)(C)C UNTXLACJAGMQMM-UHFFFAOYSA-N 0.000 description 1
- WQCCSDDRXXSATJ-UHFFFAOYSA-N CC1=C2C(O)=NC=NN2C=C1C(=O)NN Chemical compound CC1=C2C(O)=NC=NN2C=C1C(=O)NN WQCCSDDRXXSATJ-UHFFFAOYSA-N 0.000 description 1
- SUEOMVYNPBJIDY-UHFFFAOYSA-N CC1=C2C(O)=NC=NN2C=C1C(=O)O Chemical compound CC1=C2C(O)=NC=NN2C=C1C(=O)O SUEOMVYNPBJIDY-UHFFFAOYSA-N 0.000 description 1
- PZXVIXWGHOVZTQ-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1 Chemical compound CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1 PZXVIXWGHOVZTQ-UHFFFAOYSA-N 0.000 description 1
- FETVXGFKZWUGAO-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1C(=O)NCCN1CCOCC1 Chemical compound CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1C(=O)NCCN1CCOCC1 FETVXGFKZWUGAO-UHFFFAOYSA-N 0.000 description 1
- QCNVDBKJAPIIMK-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1OCCCN(C)C Chemical compound CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1OCCCN(C)C QCNVDBKJAPIIMK-UHFFFAOYSA-N 0.000 description 1
- QBKQXTVSAWVWDC-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1OCCCN1CCOCC1 Chemical compound CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1OCCCN1CCOCC1 QBKQXTVSAWVWDC-UHFFFAOYSA-N 0.000 description 1
- ZZAQQEDSSKIBRR-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1OCCN(C)C Chemical compound CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1OCCN(C)C ZZAQQEDSSKIBRR-UHFFFAOYSA-N 0.000 description 1
- YRPGOIRENZFYOP-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1OCCN1CCOCC1 Chemical compound CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1OCCN1CCOCC1 YRPGOIRENZFYOP-UHFFFAOYSA-N 0.000 description 1
- UPWXYRPDRDNGAX-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)C4=C(Cl)N=CC(Cl)=C4)C=C3F)=NC=NN2C=C1OCCCN(C)C Chemical compound CC1=C2C(OC3=CC=C(NC(=O)C4=C(Cl)N=CC(Cl)=C4)C=C3F)=NC=NN2C=C1OCCCN(C)C UPWXYRPDRDNGAX-UHFFFAOYSA-N 0.000 description 1
- FGBUUKMIHXTQQT-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)C4=C(F)C=CC=C4F)C=C3F)=NC=NN2C=C1OCCCN(C)C Chemical compound CC1=C2C(OC3=CC=C(NC(=O)C4=C(F)C=CC=C4F)C=C3F)=NC=NN2C=C1OCCCN(C)C FGBUUKMIHXTQQT-UHFFFAOYSA-N 0.000 description 1
- JXWZDSFNFVQKTI-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)C4=CN=CC=C4)C=C3F)=NC=NN2C=C1C(=O)NCCN1CCOCC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=O)C4=CN=CC=C4)C=C3F)=NC=NN2C=C1C(=O)NCCN1CCOCC1 JXWZDSFNFVQKTI-UHFFFAOYSA-N 0.000 description 1
- LYUZVGOQWISIPF-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)C4=CN=CC=C4)C=C3F)=NC=NN2C=C1OCCCN(C)C Chemical compound CC1=C2C(OC3=CC=C(NC(=O)C4=CN=CC=C4)C=C3F)=NC=NN2C=C1OCCCN(C)C LYUZVGOQWISIPF-UHFFFAOYSA-N 0.000 description 1
- VONPMQHGBZMIQD-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)C4=CN=CC=C4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=O)C4=CN=CC=C4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 VONPMQHGBZMIQD-UHFFFAOYSA-N 0.000 description 1
- YMMDHODJLWKWOC-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1C=O Chemical compound CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1C=O YMMDHODJLWKWOC-UHFFFAOYSA-N 0.000 description 1
- HICPUMFJJOPNPK-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1CN1CCN(C)CC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1CN1CCN(C)CC1 HICPUMFJJOPNPK-UHFFFAOYSA-N 0.000 description 1
- BQWKANPACPSXHN-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1CNCCN1CCOCC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1CNCCN1CCOCC1 BQWKANPACPSXHN-UHFFFAOYSA-N 0.000 description 1
- NHDPKNXRQJKSBS-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCCN(C)C Chemical compound CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCCN(C)C NHDPKNXRQJKSBS-UHFFFAOYSA-N 0.000 description 1
- HWOXQSUVADVKLF-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN(C)C Chemical compound CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN(C)C HWOXQSUVADVKLF-UHFFFAOYSA-N 0.000 description 1
- IAVWXGZIULVTLN-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 IAVWXGZIULVTLN-UHFFFAOYSA-N 0.000 description 1
- QTEFLIXPCHNEHB-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN1CCOCC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN1CCOCC1 QTEFLIXPCHNEHB-UHFFFAOYSA-N 0.000 description 1
- VOUYKYYIBDLJGT-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)NC(=O)C4CC4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=O)NC(=O)C4CC4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 VOUYKYYIBDLJGT-UHFFFAOYSA-N 0.000 description 1
- LTJJQWUFSHDXIN-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCCN(C)C Chemical compound CC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCCN(C)C LTJJQWUFSHDXIN-UHFFFAOYSA-N 0.000 description 1
- XBLYKDYWBVOKLN-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN(C)C Chemical compound CC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN(C)C XBLYKDYWBVOKLN-UHFFFAOYSA-N 0.000 description 1
- JGKKVHUMEAYNGF-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 JGKKVHUMEAYNGF-UHFFFAOYSA-N 0.000 description 1
- JSATXKGJAJEVND-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4CC4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4CC4)C=C3F)=NC=NN2C=C1OCCN1CCN(C)CC1 JSATXKGJAJEVND-UHFFFAOYSA-N 0.000 description 1
- PZAWELQMAFWEES-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)OCC4=CC=CC=C4)C=C3F)=C(C#N)C=NN2C=C1C(C)(C)O Chemical compound CC1=C2C(OC3=CC=C(NC(=O)OCC4=CC=CC=C4)C=C3F)=C(C#N)C=NN2C=C1C(C)(C)O PZAWELQMAFWEES-UHFFFAOYSA-N 0.000 description 1
- QIEISNIMLCASRE-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=O)OCC4=CC=CC=C4)C=C3F)=C(C#N)C=NN2C=C1O Chemical compound CC1=C2C(OC3=CC=C(NC(=O)OCC4=CC=CC=C4)C=C3F)=C(C#N)C=NN2C=C1O QIEISNIMLCASRE-UHFFFAOYSA-N 0.000 description 1
- GHUWDEWNARKSPN-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1 Chemical compound CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1 GHUWDEWNARKSPN-UHFFFAOYSA-N 0.000 description 1
- NKBFUBBGPCDJDE-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OC(=O)C(C)(C)C Chemical compound CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OC(=O)C(C)(C)C NKBFUBBGPCDJDE-UHFFFAOYSA-N 0.000 description 1
- ODZVWBVOEMRBMD-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCCN1CCOCC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCCN1CCOCC1 ODZVWBVOEMRBMD-UHFFFAOYSA-N 0.000 description 1
- CNYSROSPQMHZQO-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN1CCOCC1 Chemical compound CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1OCCN1CCOCC1 CNYSROSPQMHZQO-UHFFFAOYSA-N 0.000 description 1
- NQZDTLQUKVQDAY-UHFFFAOYSA-N CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=CC=C4)C=C3F)=NC=NN2C=C1OC(=O)C(C)(C)C Chemical compound CC1=C2C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=CC=C4)C=C3F)=NC=NN2C=C1OC(=O)C(C)(C)C NQZDTLQUKVQDAY-UHFFFAOYSA-N 0.000 description 1
- IXGFYWLZNXLUJI-UHFFFAOYSA-N CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1 Chemical compound CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1 IXGFYWLZNXLUJI-UHFFFAOYSA-N 0.000 description 1
- HOKZBMUOIZJKOQ-UHFFFAOYSA-N CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1C(=O)NCCN1CCOCC1 Chemical compound CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1C(=O)NCCN1CCOCC1 HOKZBMUOIZJKOQ-UHFFFAOYSA-N 0.000 description 1
- HIWSMFAPEHZLTL-UHFFFAOYSA-N CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OCCCN(C)C Chemical compound CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OCCCN(C)C HIWSMFAPEHZLTL-UHFFFAOYSA-N 0.000 description 1
- SITLVHUZSAQUML-UHFFFAOYSA-N CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OCCCN1CCOCC1 Chemical compound CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OCCCN1CCOCC1 SITLVHUZSAQUML-UHFFFAOYSA-N 0.000 description 1
- JBZFOWPXCTXRIJ-UHFFFAOYSA-N CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OCCN(C)C Chemical compound CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OCCN(C)C JBZFOWPXCTXRIJ-UHFFFAOYSA-N 0.000 description 1
- KWDZTQLUUCVMJO-UHFFFAOYSA-N CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OCCN1CCOCC1 Chemical compound CC1=C2C(OC3=CC=C([N+](=O)[O-])C=C3F)=NC=NN2C=C1OCCN1CCOCC1 KWDZTQLUUCVMJO-UHFFFAOYSA-N 0.000 description 1
- ZBXSUKWLSTVTSE-UHFFFAOYSA-N CC1=CC(C(C)C)=C(C(F)(F)F)O1 Chemical compound CC1=CC(C(C)C)=C(C(F)(F)F)O1 ZBXSUKWLSTVTSE-UHFFFAOYSA-N 0.000 description 1
- DGPJRCVBQHQQOR-UHFFFAOYSA-N CC1=CC(C(C)C)=C(C)O1 Chemical compound CC1=CC(C(C)C)=C(C)O1 DGPJRCVBQHQQOR-UHFFFAOYSA-N 0.000 description 1
- AWIUNHGSPIGOHC-UHFFFAOYSA-N CC1=CC(C(C)C)=CC(Cl)=N1 Chemical compound CC1=CC(C(C)C)=CC(Cl)=N1 AWIUNHGSPIGOHC-UHFFFAOYSA-N 0.000 description 1
- FKSUYCMWHIJXCW-UHFFFAOYSA-N CC1=CC(C(C)C)=NO1 Chemical compound CC1=CC(C(C)C)=NO1 FKSUYCMWHIJXCW-UHFFFAOYSA-N 0.000 description 1
- OFCAZVVESRXGRC-UHFFFAOYSA-N CC1=CC2=C(N=CC=C2Cl)N1 Chemical compound CC1=CC2=C(N=CC=C2Cl)N1 OFCAZVVESRXGRC-UHFFFAOYSA-N 0.000 description 1
- AKXXCOIRFNSXHL-UHFFFAOYSA-N CC1=CC2=C(N=CC=C2Cl)N1COCC[Si](C)(C)C Chemical compound CC1=CC2=C(N=CC=C2Cl)N1COCC[Si](C)(C)C AKXXCOIRFNSXHL-UHFFFAOYSA-N 0.000 description 1
- QOIMTMSVWJUVPZ-UHFFFAOYSA-N CC1=CC2=C(N=CC=C2O)N1 Chemical compound CC1=CC2=C(N=CC=C2O)N1 QOIMTMSVWJUVPZ-UHFFFAOYSA-N 0.000 description 1
- SSRVMRNZQVPCFG-UHFFFAOYSA-N CC1=CC2=C(N=CC=C2OC2=CC=C(N)C=C2F)N1 Chemical compound CC1=CC2=C(N=CC=C2OC2=CC=C(N)C=C2F)N1 SSRVMRNZQVPCFG-UHFFFAOYSA-N 0.000 description 1
- YBZNCJRXJKSDTH-UHFFFAOYSA-N CC1=CC2=C(N=CC=C2OC2=CC=C(NC(=O)C3=CC=CN(C4=CC=C(F)C=C4)C3=O)C=C2F)N1 Chemical compound CC1=CC2=C(N=CC=C2OC2=CC=C(NC(=O)C3=CC=CN(C4=CC=C(F)C=C4)C3=O)C=C2F)N1 YBZNCJRXJKSDTH-UHFFFAOYSA-N 0.000 description 1
- ZMQGUCFLMCEQRW-UHFFFAOYSA-N CC1=CC2=C(N=CC=C2OC2=CC=C(NC(=O)CC(=O)NC3=CC=C(F)C=C3)C=C2F)N1 Chemical compound CC1=CC2=C(N=CC=C2OC2=CC=C(NC(=O)CC(=O)NC3=CC=C(F)C=C3)C=C2F)N1 ZMQGUCFLMCEQRW-UHFFFAOYSA-N 0.000 description 1
- USRQJPCMELJZQN-UHFFFAOYSA-N CC1=CC=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)C(=O)N1C1=CC=C(F)C=C1 Chemical compound CC1=CC=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)C(=O)N1C1=CC=C(F)C=C1 USRQJPCMELJZQN-UHFFFAOYSA-N 0.000 description 1
- BTPCWSQBSXUYHV-UHFFFAOYSA-N CC1=CC=C(C(=O)O)C(=O)N1C1=CC=C(F)C=C1 Chemical compound CC1=CC=C(C(=O)O)C(=O)N1C1=CC=C(F)C=C1 BTPCWSQBSXUYHV-UHFFFAOYSA-N 0.000 description 1
- HFPZCAJZSCWRBC-UHFFFAOYSA-N CC1=CC=C(C(C)C)C=C1 Chemical compound CC1=CC=C(C(C)C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 1
- FWNHQACWPUSEBW-UHFFFAOYSA-N CC1=CC=C(F)C(C(=O)NC2=CC=C(OC3=NC=NN4C=C(OCCN5CCN(C)CC5)C(C)=C34)C(F)=C2)=C1 Chemical compound CC1=CC=C(F)C(C(=O)NC2=CC=C(OC3=NC=NN4C=C(OCCN5CCN(C)CC5)C(C)=C34)C(F)=C2)=C1 FWNHQACWPUSEBW-UHFFFAOYSA-N 0.000 description 1
- GXNJVTWXIDPNSY-UHFFFAOYSA-N CC1=CC=C(F)C(C(=O)NC2=CC=C(OC3=NC=NN4C=C(OCCN5CCOCC5)C(C)=C34)C(F)=C2)=C1 Chemical compound CC1=CC=C(F)C(C(=O)NC2=CC=C(OC3=NC=NN4C=C(OCCN5CCOCC5)C(C)=C34)C(F)=C2)=C1 GXNJVTWXIDPNSY-UHFFFAOYSA-N 0.000 description 1
- HVHNGBFVTVHMJQ-UHFFFAOYSA-N CC1=CC=C(F)C(C(C)C)=C1 Chemical compound CC1=CC=C(F)C(C(C)C)=C1 HVHNGBFVTVHMJQ-UHFFFAOYSA-N 0.000 description 1
- BMNJIKZYDCWEJM-UHFFFAOYSA-N CC1=CC=C(F)C=C1NC(C)C Chemical compound CC1=CC=C(F)C=C1NC(C)C BMNJIKZYDCWEJM-UHFFFAOYSA-N 0.000 description 1
- WWRCMNKATXZARA-UHFFFAOYSA-N CC1=CC=CC=C1C(C)C Chemical compound CC1=CC=CC=C1C(C)C WWRCMNKATXZARA-UHFFFAOYSA-N 0.000 description 1
- HHPZXTRZNCOSCN-UHFFFAOYSA-N CC1=CC=CN=C1NC(C)C Chemical compound CC1=CC=CN=C1NC(C)C HHPZXTRZNCOSCN-UHFFFAOYSA-N 0.000 description 1
- ZHFRTTBPOPDEKX-UHFFFAOYSA-N CC1=CN=CC(C(C)C)=C1 Chemical compound CC1=CN=CC(C(C)C)=C1 ZHFRTTBPOPDEKX-UHFFFAOYSA-N 0.000 description 1
- ZSMPXLJQCKPGFF-UHFFFAOYSA-N CC1=CSC(NC(C)C)=N1 Chemical compound CC1=CSC(NC(C)C)=N1 ZSMPXLJQCKPGFF-UHFFFAOYSA-N 0.000 description 1
- MKJJXEFLODLRFB-UHFFFAOYSA-N CC1=CSC2=C1C(OC1=CC=C(NC(=S)NC(=O)CC3=CC=C(F)C=C3)C=C1F)=NC=N2 Chemical compound CC1=CSC2=C1C(OC1=CC=C(NC(=S)NC(=O)CC3=CC=C(F)C=C3)C=C1F)=NC=N2 MKJJXEFLODLRFB-UHFFFAOYSA-N 0.000 description 1
- VYPPIUIWIABGBQ-UHFFFAOYSA-N CC1=CSC2=C1N=CN=C2OC1=CC=C(NC(=S)NC(=O)CC2=CC=C(F)C=C2)C=C1F Chemical compound CC1=CSC2=C1N=CN=C2OC1=CC=C(NC(=S)NC(=O)CC2=CC=C(F)C=C2)C=C1F VYPPIUIWIABGBQ-UHFFFAOYSA-N 0.000 description 1
- FXRHRTPRRNCQEE-UHFFFAOYSA-N CC1=NN=C(C2=CN3N=CN=C(Cl)C3=C2C)O1 Chemical compound CC1=NN=C(C2=CN3N=CN=C(Cl)C3=C2C)O1 FXRHRTPRRNCQEE-UHFFFAOYSA-N 0.000 description 1
- VXDVNBUGNJZYQX-UHFFFAOYSA-N CC1=NN=C(C2=CN3N=CN=C(OC4=CC=C(N)C=C4F)C3=C2C)O1 Chemical compound CC1=NN=C(C2=CN3N=CN=C(OC4=CC=C(N)C=C4F)C3=C2C)O1 VXDVNBUGNJZYQX-UHFFFAOYSA-N 0.000 description 1
- YDLXRNHBUYQPBS-UHFFFAOYSA-N CC1=NN=C(C2=CN3N=CN=C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)C3=C2C)O1 Chemical compound CC1=NN=C(C2=CN3N=CN=C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)C3=C2C)O1 YDLXRNHBUYQPBS-UHFFFAOYSA-N 0.000 description 1
- HAEMGZIQCLXZTN-UHFFFAOYSA-N CC1=NN=C(C2=CN3N=CN=C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)C3=C2C)O1 Chemical compound CC1=NN=C(C2=CN3N=CN=C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)C3=C2C)O1 HAEMGZIQCLXZTN-UHFFFAOYSA-N 0.000 description 1
- PETQCNNNDDILBQ-UHFFFAOYSA-N CC1=NN=C(C2=CN3N=CN=C(OC4=CC=C([N+](=O)[O-])C=C4F)C3=C2C)O1 Chemical compound CC1=NN=C(C2=CN3N=CN=C(OC4=CC=C([N+](=O)[O-])C=C4F)C3=C2C)O1 PETQCNNNDDILBQ-UHFFFAOYSA-N 0.000 description 1
- JPDPRXXLFYTTRV-UHFFFAOYSA-N CC1=NOC(C)=C1C(C)C Chemical compound CC1=NOC(C)=C1C(C)C JPDPRXXLFYTTRV-UHFFFAOYSA-N 0.000 description 1
- DGHXKNKPMFTCMY-UHFFFAOYSA-N CC1=NOC(C)=C1C1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1 Chemical compound CC1=NOC(C)=C1C1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1 DGHXKNKPMFTCMY-UHFFFAOYSA-N 0.000 description 1
- DFOGVYDYQGDEGL-UHFFFAOYSA-N CCC1=NC2=C(N=CN=C2OC2=CC=C(NC(=S)NC(=O)CC3=CC=C(F)C=C3)C=C2F)N1C(C1CC1)C1CC1 Chemical compound CCC1=NC2=C(N=CN=C2OC2=CC=C(NC(=S)NC(=O)CC3=CC=C(F)C=C3)C=C2F)N1C(C1CC1)C1CC1 DFOGVYDYQGDEGL-UHFFFAOYSA-N 0.000 description 1
- QZVOGTCZLKSISB-UHFFFAOYSA-N CCNC(=O)OC1=CN2N=CN=C(OC3=CC=C(N)C=C3F)C2=C1C Chemical compound CCNC(=O)OC1=CN2N=CN=C(OC3=CC=C(N)C=C3F)C2=C1C QZVOGTCZLKSISB-UHFFFAOYSA-N 0.000 description 1
- XBTKCGZBDFMDDC-UHFFFAOYSA-N CCNC(=O)OC1=CN2N=CN=C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C Chemical compound CCNC(=O)OC1=CN2N=CN=C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C XBTKCGZBDFMDDC-UHFFFAOYSA-N 0.000 description 1
- AOMHHGOQJYPVJL-UHFFFAOYSA-N CCNC(=O)OC1=CN2N=CN=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C Chemical compound CCNC(=O)OC1=CN2N=CN=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C AOMHHGOQJYPVJL-UHFFFAOYSA-N 0.000 description 1
- HJDHODKTWNZFQM-UHFFFAOYSA-N CCNC(=O)OC1=CN2N=CN=C(OC3=CC=C([N+](=O)[O-])C=C3F)C2=C1C Chemical compound CCNC(=O)OC1=CN2N=CN=C(OC3=CC=C([N+](=O)[O-])C=C3F)C2=C1C HJDHODKTWNZFQM-UHFFFAOYSA-N 0.000 description 1
- KMJYOBFHWAPRAV-UHFFFAOYSA-N CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C(N)C=C3F)C2=C1C Chemical compound CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C(N)C=C3F)C2=C1C KMJYOBFHWAPRAV-UHFFFAOYSA-N 0.000 description 1
- RLUHSSGFUKOUNW-UHFFFAOYSA-N CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=CC=C4)C=C3F)C2=C1C Chemical compound CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=CC=C4)C=C3F)C2=C1C RLUHSSGFUKOUNW-UHFFFAOYSA-N 0.000 description 1
- DSWLLRCJLUPAEG-UHFFFAOYSA-N CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=O)OCC4=CC=CC=C4)C=C3F)C2=C1C Chemical compound CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=O)OCC4=CC=CC=C4)C=C3F)C2=C1C DSWLLRCJLUPAEG-UHFFFAOYSA-N 0.000 description 1
- SUJREQTWOBRNGF-UHFFFAOYSA-N CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C Chemical compound CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C SUJREQTWOBRNGF-UHFFFAOYSA-N 0.000 description 1
- LTHRQSMRZNSVML-UHFFFAOYSA-N CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=CC=C4)C=C3F)C2=C1C Chemical compound CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=CC=C4)C=C3F)C2=C1C LTHRQSMRZNSVML-UHFFFAOYSA-N 0.000 description 1
- OTOUTSVRHMBOGY-UHFFFAOYSA-N CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C([N+](=O)[O-])C=C3F)C2=C1C Chemical compound CCOC(=O)C1=CN2N=CC(C#N)=C(OC3=CC=C([N+](=O)[O-])C=C3F)C2=C1C OTOUTSVRHMBOGY-UHFFFAOYSA-N 0.000 description 1
- YMGXPGPMXSIYKQ-UHFFFAOYSA-N CCOC(=O)C1=CN2N=CN=C(OC3=CC=C(N)C=C3F)C2=C1C Chemical compound CCOC(=O)C1=CN2N=CN=C(OC3=CC=C(N)C=C3F)C2=C1C YMGXPGPMXSIYKQ-UHFFFAOYSA-N 0.000 description 1
- QPFWEFIYBWAJJU-UHFFFAOYSA-N CCOC(=O)C1=CN2N=CN=C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)C2=C1C Chemical compound CCOC(=O)C1=CN2N=CN=C(OC3=CC=C(NC(=O)CC(=O)NC4=CC=C(F)C=C4)C=C3F)C2=C1C QPFWEFIYBWAJJU-UHFFFAOYSA-N 0.000 description 1
- KMNCHDADLOEZIZ-UHFFFAOYSA-N CCOC(=O)C1=CN2N=CN=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3)C2=C1C Chemical compound CCOC(=O)C1=CN2N=CN=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3)C2=C1C KMNCHDADLOEZIZ-UHFFFAOYSA-N 0.000 description 1
- JKGJPRZGGQQRKK-UHFFFAOYSA-N CCOC(=O)C1=CN2N=CN=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C Chemical compound CCOC(=O)C1=CN2N=CN=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C JKGJPRZGGQQRKK-UHFFFAOYSA-N 0.000 description 1
- PXCCWZZBSNCDDD-UHFFFAOYSA-N CCOC(=O)C1=CN2N=CN=C(OC3=CC=C([N+](=O)[O-])C=C3F)C2=C1C Chemical compound CCOC(=O)C1=CN2N=CN=C(OC3=CC=C([N+](=O)[O-])C=C3F)C2=C1C PXCCWZZBSNCDDD-UHFFFAOYSA-N 0.000 description 1
- QYBQPBAYKVUDSU-UHFFFAOYSA-N CCOC(=O)C1=CNN2C=CC=C2C1=O Chemical compound CCOC(=O)C1=CNN2C=CC=C2C1=O QYBQPBAYKVUDSU-UHFFFAOYSA-N 0.000 description 1
- PVIHWOOGKNPTHS-UHFFFAOYSA-N CCOC(=O)CC(=O)NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1 Chemical compound CCOC(=O)CC(=O)NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1 PVIHWOOGKNPTHS-UHFFFAOYSA-N 0.000 description 1
- YBNPCQWEETVCIY-UHFFFAOYSA-N CC[N+](CC)(CC)CC1=C2C(Cl)=NC=NN2C=C1.[Br-] Chemical compound CC[N+](CC)(CC)CC1=C2C(Cl)=NC=NN2C=C1.[Br-] YBNPCQWEETVCIY-UHFFFAOYSA-N 0.000 description 1
- DJDSGQUTALPJCB-UHFFFAOYSA-O CC[N+](CC)(CC)CC1=C2C(NC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3)=NN=NN2C=C1.[Br-] Chemical compound CC[N+](CC)(CC)CC1=C2C(NC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3)=NN=NN2C=C1.[Br-] DJDSGQUTALPJCB-UHFFFAOYSA-O 0.000 description 1
- DUNZPNOAGPQMRY-UHFFFAOYSA-N CN(C)C1=CN(C2=CC=C(F)C=C2)C(=O)C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)=C1 Chemical compound CN(C)C1=CN(C2=CC=C(F)C=C2)C(=O)C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)=C1 DUNZPNOAGPQMRY-UHFFFAOYSA-N 0.000 description 1
- RALPAQCSUULHGB-UHFFFAOYSA-N CN(C)C1=CN(C2=CC=C(F)C=C2)C(=O)C(C(=O)O)=C1 Chemical compound CN(C)C1=CN(C2=CC=C(F)C=C2)C(=O)C(C(=O)O)=C1 RALPAQCSUULHGB-UHFFFAOYSA-N 0.000 description 1
- CEFJNNMKMKMCEN-UHFFFAOYSA-N CN(C)CC#CC1=CN(C(=O)OC(C)(C)C)C2=C1C(OC1=CC=C([N+](=O)[O-])C=C1F)=CC=N2 Chemical compound CN(C)CC#CC1=CN(C(=O)OC(C)(C)C)C2=C1C(OC1=CC=C([N+](=O)[O-])C=C1F)=CC=N2 CEFJNNMKMKMCEN-UHFFFAOYSA-N 0.000 description 1
- SSCHZCGXDUUUCZ-UHFFFAOYSA-N CN(C)CC#CC1=CNC2=C1C(OC1=CC=C(NC(=O)C3=C(F)C=CC=C3F)C=C1F)=CC=N2 Chemical compound CN(C)CC#CC1=CNC2=C1C(OC1=CC=C(NC(=O)C3=C(F)C=CC=C3F)C=C1F)=CC=N2 SSCHZCGXDUUUCZ-UHFFFAOYSA-N 0.000 description 1
- WQTUPWROIONYAH-UHFFFAOYSA-N CN(C)CC#CC1=CNC2=C1C(OC1=CC=C(NC(=O)C3=CC=CN(C4=CC=C(F)C=C4)C3=O)C=C1F)=CC=N2 Chemical compound CN(C)CC#CC1=CNC2=C1C(OC1=CC=C(NC(=O)C3=CC=CN(C4=CC=C(F)C=C4)C3=O)C=C1F)=CC=N2 WQTUPWROIONYAH-UHFFFAOYSA-N 0.000 description 1
- KTCIXOFXQFPXGD-UHFFFAOYSA-N CN(C)CC#CC1=CNC2=C1C(OC1=CC=C(NC(=O)NC(=O)CC3=CC=C(F)C=C3)C=C1F)=CC=N2 Chemical compound CN(C)CC#CC1=CNC2=C1C(OC1=CC=C(NC(=O)NC(=O)CC3=CC=C(F)C=C3)C=C1F)=CC=N2 KTCIXOFXQFPXGD-UHFFFAOYSA-N 0.000 description 1
- TXRQHZQSMIEQTI-UHFFFAOYSA-N CN(C)CC(=O)C1=CNC2=C1C(OC1=CC=C(N)C=C1F)=CC=N2 Chemical compound CN(C)CC(=O)C1=CNC2=C1C(OC1=CC=C(N)C=C1F)=CC=N2 TXRQHZQSMIEQTI-UHFFFAOYSA-N 0.000 description 1
- ZQOPIJSRSPQVQZ-UHFFFAOYSA-N CN(C)CC(=O)C1=CNC2=C1C(OC1=CC=C([N+](=O)[O-])C=C1F)=CC=N2 Chemical compound CN(C)CC(=O)C1=CNC2=C1C(OC1=CC=C([N+](=O)[O-])C=C1F)=CC=N2 ZQOPIJSRSPQVQZ-UHFFFAOYSA-N 0.000 description 1
- OWIKHJXLTGGELJ-UHFFFAOYSA-N CN(C)CCCC1=CNC2=C1C(OC1=CC=C(NC(=O)C3=CC=CN(C4=CC=C(F)C=C4)C3=O)C=C1F)=CC=N2 Chemical compound CN(C)CCCC1=CNC2=C1C(OC1=CC=C(NC(=O)C3=CC=CN(C4=CC=C(F)C=C4)C3=O)C=C1F)=CC=N2 OWIKHJXLTGGELJ-UHFFFAOYSA-N 0.000 description 1
- IDRMFZIJYPZDKN-UHFFFAOYSA-N CN(C)CCCOC1=CC=CC=C1N1C=CC=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)C1=O Chemical compound CN(C)CCCOC1=CC=CC=C1N1C=CC=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)C1=O IDRMFZIJYPZDKN-UHFFFAOYSA-N 0.000 description 1
- WEFYKHNUVVQBQF-UHFFFAOYSA-N CN(C)CCCOC1=CC=CC=C1N1C=CC=C(C(=O)O)C1=O Chemical compound CN(C)CCCOC1=CC=CC=C1N1C=CC=C(C(=O)O)C1=O WEFYKHNUVVQBQF-UHFFFAOYSA-N 0.000 description 1
- YJEHCGOJNJUOII-UHFFFAOYSA-N CN(C)c(cc1)ccc1F Chemical compound CN(C)c(cc1)ccc1F YJEHCGOJNJUOII-UHFFFAOYSA-N 0.000 description 1
- VPDRLDCOHGSLLK-UHFFFAOYSA-N CN(CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1)C1CCNCC1 Chemical compound CN(CC1=C2C(OC3=CC=C(N)C=C3F)=NC=NN2C=C1)C1CCNCC1 VPDRLDCOHGSLLK-UHFFFAOYSA-N 0.000 description 1
- UWSNTBFOBHEJGK-UHFFFAOYSA-N CN(CC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1)C1CCNCC1 Chemical compound CN(CC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1)C1CCNCC1 UWSNTBFOBHEJGK-UHFFFAOYSA-N 0.000 description 1
- XCVRAKNNYXAQOF-UHFFFAOYSA-N CN1C=C(C2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C=N1 Chemical compound CN1C=C(C2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C=N1 XCVRAKNNYXAQOF-UHFFFAOYSA-N 0.000 description 1
- JPOQTSBRIDEBAX-UHFFFAOYSA-N CN1CCN(CC(=O)C2=CNC3=C2C(OC2=CC=C(NC(=O)C4=C(F)C=CC=C4F)C=C2F)=CC=N3)CC1 Chemical compound CN1CCN(CC(=O)C2=CNC3=C2C(OC2=CC=C(NC(=O)C4=C(F)C=CC=C4F)C=C2F)=CC=N3)CC1 JPOQTSBRIDEBAX-UHFFFAOYSA-N 0.000 description 1
- YCKJHGRXFRZQOT-UHFFFAOYSA-N CN1CCN(CC(=O)C2=CNC3=C2C(OC2=CC=C(NC(=O)C4=CC=CN(C5=CC=C(F)C=C5)C4=O)C=C2F)=CC=N3)CC1 Chemical compound CN1CCN(CC(=O)C2=CNC3=C2C(OC2=CC=C(NC(=O)C4=CC=CN(C5=CC=C(F)C=C5)C4=O)C=C2F)=CC=N3)CC1 YCKJHGRXFRZQOT-UHFFFAOYSA-N 0.000 description 1
- MPSRWRRUASWMRM-UHFFFAOYSA-N CN1CCN(CC(=O)C2=CNC3=C2C(OC2=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C2F)=CC=N3)CC1 Chemical compound CN1CCN(CC(=O)C2=CNC3=C2C(OC2=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C2F)=CC=N3)CC1 MPSRWRRUASWMRM-UHFFFAOYSA-N 0.000 description 1
- XFDUHIYQPPBUDW-UHFFFAOYSA-N CN1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)CC1 Chemical compound CN1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)CC1 XFDUHIYQPPBUDW-UHFFFAOYSA-N 0.000 description 1
- XMTAJBTUPLHEDT-UHFFFAOYSA-N CN1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound CN1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 XMTAJBTUPLHEDT-UHFFFAOYSA-N 0.000 description 1
- MYHOBQSCJOHKDR-UHFFFAOYSA-N CN1N=CC2=C1N=C(Cl)N=C2OC1=CC=C(NC(=S)NC(=O)CC2=CC=C(F)C=C2)C=C1F Chemical compound CN1N=CC2=C1N=C(Cl)N=C2OC1=CC=C(NC(=S)NC(=O)CC2=CC=C(F)C=C2)C=C1F MYHOBQSCJOHKDR-UHFFFAOYSA-N 0.000 description 1
- RYCMYJPTITZOAW-JXAWBTAJSA-N CNC1CCC(=CC2=C3C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound CNC1CCC(=CC2=C3C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 RYCMYJPTITZOAW-JXAWBTAJSA-N 0.000 description 1
- JWJCCVJVBPNLQF-UHFFFAOYSA-N COC(=O)C1=CC(Br)=CN(C2=CC=C(F)C=C2)C1=O Chemical compound COC(=O)C1=CC(Br)=CN(C2=CC=C(F)C=C2)C1=O JWJCCVJVBPNLQF-UHFFFAOYSA-N 0.000 description 1
- RDHVDAHFXXOMMA-UHFFFAOYSA-N COC(=O)C1=CC(N(C)C)=CN(C2=CC=C(F)C=C2)C1=O Chemical compound COC(=O)C1=CC(N(C)C)=CN(C2=CC=C(F)C=C2)C1=O RDHVDAHFXXOMMA-UHFFFAOYSA-N 0.000 description 1
- OZBPEDRDEJFXFG-UHFFFAOYSA-N COC(=O)C1=CC(N)=CN(C2=CC=C(F)C=C2)C1=O Chemical compound COC(=O)C1=CC(N)=CN(C2=CC=C(F)C=C2)C1=O OZBPEDRDEJFXFG-UHFFFAOYSA-N 0.000 description 1
- LLBBERVMJDVHHV-UHFFFAOYSA-N COC(=O)C1=CC(NCCNC(=O)OC(C)(C)C)=CN(C2=CC=C(F)C=C2)C1=O Chemical compound COC(=O)C1=CC(NCCNC(=O)OC(C)(C)C)=CN(C2=CC=C(F)C=C2)C1=O LLBBERVMJDVHHV-UHFFFAOYSA-N 0.000 description 1
- FLNRFOJIUVQQDY-UHFFFAOYSA-N COC(=O)C1=CC([N+](=O)[O-])=CN(C2=CC=C(F)C=C2)C1=O Chemical compound COC(=O)C1=CC([N+](=O)[O-])=CN(C2=CC=C(F)C=C2)C1=O FLNRFOJIUVQQDY-UHFFFAOYSA-N 0.000 description 1
- DLMMETCUQGSGOK-UHFFFAOYSA-N COC(=O)C1=CC([N+](=O)[O-])=CNC1=O Chemical compound COC(=O)C1=CC([N+](=O)[O-])=CNC1=O DLMMETCUQGSGOK-UHFFFAOYSA-N 0.000 description 1
- WLGIETJZWGQIDX-UHFFFAOYSA-N COC(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O Chemical compound COC(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O WLGIETJZWGQIDX-UHFFFAOYSA-N 0.000 description 1
- XMNUAIINLBMAFB-UHFFFAOYSA-N COC(=O)C1=CC=CN(C2=CN=CC=C2)C1=O Chemical compound COC(=O)C1=CC=CN(C2=CN=CC=C2)C1=O XMNUAIINLBMAFB-UHFFFAOYSA-N 0.000 description 1
- QCNPUPBRGNOIJO-UHFFFAOYSA-N COC(=O)C1=CC=CN(C2=NC=CC=C2)C1=O Chemical compound COC(=O)C1=CC=CN(C2=NC=CC=C2)C1=O QCNPUPBRGNOIJO-UHFFFAOYSA-N 0.000 description 1
- MGNGQOFNRDRJIY-UHFFFAOYSA-N COC(=O)C1=CC=CN(CC2=CC=C(F)C=C2)C1=O Chemical compound COC(=O)C1=CC=CN(CC2=CC=C(F)C=C2)C1=O MGNGQOFNRDRJIY-UHFFFAOYSA-N 0.000 description 1
- NVMNDQMWOAZOKZ-UHFFFAOYSA-N COC(=O)C1=CNC2=C1C(OC1=C(F)C=C(N)C=C1)=CC=N2 Chemical compound COC(=O)C1=CNC2=C1C(OC1=C(F)C=C(N)C=C1)=CC=N2 NVMNDQMWOAZOKZ-UHFFFAOYSA-N 0.000 description 1
- PGYLUKFVUMUBGN-UHFFFAOYSA-N COC(CO)C1=CNC2=C1C(OC1=C(F)C=C(NC(=O)NC(=O)CC3=CC=C(F)C=C3)C=C1)=CC=N2 Chemical compound COC(CO)C1=CNC2=C1C(OC1=C(F)C=C(NC(=O)NC(=O)CC3=CC=C(F)C=C3)C=C1)=CC=N2 PGYLUKFVUMUBGN-UHFFFAOYSA-N 0.000 description 1
- KKYAKCRRVYSZFR-UHFFFAOYSA-N COC1=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C(Br)=CN4COCC[Si](C)(C)C)C(F)=C2)C(F)=CC=C1 Chemical compound COC1=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C(Br)=CN4COCC[Si](C)(C)C)C(F)=C2)C(F)=CC=C1 KKYAKCRRVYSZFR-UHFFFAOYSA-N 0.000 description 1
- FRNXZKLQQPUSHX-UHFFFAOYSA-N COC1=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C(C#N)=CN4)C(F)=C2)C(F)=CC=C1 Chemical compound COC1=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C(C#N)=CN4)C(F)=C2)C(F)=CC=C1 FRNXZKLQQPUSHX-UHFFFAOYSA-N 0.000 description 1
- ZLVOQIYYIBFFKZ-UHFFFAOYSA-N COC1=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C(C3=CC=C(N)C=N3)=CN4)C(F)=C2)C(F)=CC=C1 Chemical compound COC1=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C(C3=CC=C(N)C=N3)=CN4)C(F)=C2)C(F)=CC=C1 ZLVOQIYYIBFFKZ-UHFFFAOYSA-N 0.000 description 1
- PVLNMNNEVYMSDU-UHFFFAOYSA-N COC1=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C(C3=CC=NC=C3)=CN4)C(F)=C2)C(F)=CC=C1 Chemical compound COC1=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C(C3=CC=NC=C3)=CN4)C(F)=C2)C(F)=CC=C1 PVLNMNNEVYMSDU-UHFFFAOYSA-N 0.000 description 1
- BLGHGCJFVBDKNV-UHFFFAOYSA-N COC1=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)C(F)=CC=C1 Chemical compound COC1=C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)C(F)=CC=C1 BLGHGCJFVBDKNV-UHFFFAOYSA-N 0.000 description 1
- FPYAPWXJWNCTQJ-UHFFFAOYSA-N COC1=C(NC(C)C)C(C)=CC=C1 Chemical compound COC1=C(NC(C)C)C(C)=CC=C1 FPYAPWXJWNCTQJ-UHFFFAOYSA-N 0.000 description 1
- ZSRHOISGDCJOAT-UHFFFAOYSA-N COC1=CC=C(C(C)C)C(OC)=C1 Chemical compound COC1=CC=C(C(C)C)C(OC)=C1 ZSRHOISGDCJOAT-UHFFFAOYSA-N 0.000 description 1
- CBYUMGSUMMGZBG-UHFFFAOYSA-N COC1=CC=CC(NC(=O)CC(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)=C1 Chemical compound COC1=CC=CC(NC(=O)CC(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)=C1 CBYUMGSUMMGZBG-UHFFFAOYSA-N 0.000 description 1
- ZAADRZBKVOCSCQ-UHFFFAOYSA-N COC1=CN2N=CC(C#N)=C(OC3=CC=C(N)C=C3F)C2=C1C Chemical compound COC1=CN2N=CC(C#N)=C(OC3=CC=C(N)C=C3F)C2=C1C ZAADRZBKVOCSCQ-UHFFFAOYSA-N 0.000 description 1
- ULLQVGHEVGIEHN-UHFFFAOYSA-N COC1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=O)OCC4=CC=CC=C4)C=C3F)C2=C1C Chemical compound COC1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=O)OCC4=CC=CC=C4)C=C3F)C2=C1C ULLQVGHEVGIEHN-UHFFFAOYSA-N 0.000 description 1
- SOTZGQLSAPATFW-UHFFFAOYSA-N COC1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=S)CC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C Chemical compound COC1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=S)CC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C SOTZGQLSAPATFW-UHFFFAOYSA-N 0.000 description 1
- VLQAWXPRCMTHOA-UHFFFAOYSA-N COC1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=S)CC(=O)CC4=CC=CC=C4)C=C3F)C2=C1C Chemical compound COC1=CN2N=CC(C#N)=C(OC3=CC=C(NC(=S)CC(=O)CC4=CC=CC=C4)C=C3F)C2=C1C VLQAWXPRCMTHOA-UHFFFAOYSA-N 0.000 description 1
- JQALAZBQBDDPSH-UHFFFAOYSA-N COC1=CN2N=CN=C(OC3=CC=C(N)C=C3F)C2=C1C Chemical compound COC1=CN2N=CN=C(OC3=CC=C(N)C=C3F)C2=C1C JQALAZBQBDDPSH-UHFFFAOYSA-N 0.000 description 1
- BTVDEPMCNZWNMW-UHFFFAOYSA-N COC1=CN2N=CN=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C Chemical compound COC1=CN2N=CN=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)C2=C1C BTVDEPMCNZWNMW-UHFFFAOYSA-N 0.000 description 1
- PQBNCHYGBIOBKF-UHFFFAOYSA-N COC1=CN2N=CN=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=CC=C4)C=C3F)C2=C1C Chemical compound COC1=CN2N=CN=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=CC=C4)C=C3F)C2=C1C PQBNCHYGBIOBKF-UHFFFAOYSA-N 0.000 description 1
- BFHYGYDIHZJIQB-UHFFFAOYSA-N COCC1=CNC2=C1C(OC1=C(F)C=C(NC(=O)NC(=O)CC3=CC=C(F)C=C3)C=C1)=CC=N2 Chemical compound COCC1=CNC2=C1C(OC1=C(F)C=C(NC(=O)NC(=O)CC3=CC=C(F)C=C3)C=C1)=CC=N2 BFHYGYDIHZJIQB-UHFFFAOYSA-N 0.000 description 1
- IGKRCEMLHDKLEE-UHFFFAOYSA-N CSC1=CC=C(C(C)C)C=C1 Chemical compound CSC1=CC=C(C(C)C)C=C1 IGKRCEMLHDKLEE-UHFFFAOYSA-N 0.000 description 1
- CLEQDVFCXSKUIJ-UHFFFAOYSA-N CSC1=NC=CC=C1C(C)C Chemical compound CSC1=NC=CC=C1C(C)C CLEQDVFCXSKUIJ-UHFFFAOYSA-N 0.000 description 1
- QYEJRILORDMTIT-UHFFFAOYSA-N CSC1=NC=NN2C=CC(C)=C12 Chemical compound CSC1=NC=NN2C=CC(C)=C12 QYEJRILORDMTIT-UHFFFAOYSA-N 0.000 description 1
- HBKMWKJLKVTYTE-UHFFFAOYSA-N CSC1=NC=NN2C=CC(CN(C(=O)OC(C)(C)C)C3CCN(C(=O)OC(C)(C)C)CC3)=C12 Chemical compound CSC1=NC=NN2C=CC(CN(C(=O)OC(C)(C)C)C3CCN(C(=O)OC(C)(C)C)CC3)=C12 HBKMWKJLKVTYTE-UHFFFAOYSA-N 0.000 description 1
- XDXMZIUHNMJVDO-UHFFFAOYSA-N CSC1=NC=NN2C=CC(CN(CCCNC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)=C12 Chemical compound CSC1=NC=NN2C=CC(CN(CCCNC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)=C12 XDXMZIUHNMJVDO-UHFFFAOYSA-N 0.000 description 1
- XYCOQDJRRHTWSD-UHFFFAOYSA-N CSC1=NC=NN2C=CC(CN3CC(CNC(=O)OC(C)(C)C)C3)=C12 Chemical compound CSC1=NC=NN2C=CC(CN3CC(CNC(=O)OC(C)(C)C)C3)=C12 XYCOQDJRRHTWSD-UHFFFAOYSA-N 0.000 description 1
- HXYGYIKGADCWEO-UHFFFAOYSA-N CSC1=NC=NN2C=CC(CN3CCC(O)CC3)=C12 Chemical compound CSC1=NC=NN2C=CC(CN3CCC(O)CC3)=C12 HXYGYIKGADCWEO-UHFFFAOYSA-N 0.000 description 1
- YETPSXJFZGIGQS-GHMZBOCLSA-N CSC1=NC=NN2C=CC(CN3CC[C@@H](N=[N+]=[N-])[C@H](O)C3)=C12 Chemical compound CSC1=NC=NN2C=CC(CN3CC[C@@H](N=[N+]=[N-])[C@H](O)C3)=C12 YETPSXJFZGIGQS-GHMZBOCLSA-N 0.000 description 1
- ODTXYLPWTXEXLV-UHFFFAOYSA-N CSC1=NC=NN2C=CC(CNC3CCN(C(=O)OC(C)(C)C)CC3)=C12 Chemical compound CSC1=NC=NN2C=CC(CNC3CCN(C(=O)OC(C)(C)C)CC3)=C12 ODTXYLPWTXEXLV-UHFFFAOYSA-N 0.000 description 1
- UHBMVRJTXLHDDI-UHFFFAOYSA-N CSC1=NC=NN2C=CC(CNCCCNC(=O)OC(C)(C)C)=C12 Chemical compound CSC1=NC=NN2C=CC(CNCCCNC(=O)OC(C)(C)C)=C12 UHBMVRJTXLHDDI-UHFFFAOYSA-N 0.000 description 1
- ASPZZZQISULCMI-UHFFFAOYSA-N C[Si](C)(C)CCOCN1C(B(O)O)=CC2=C1N=CC=C2Cl Chemical compound C[Si](C)(C)CCOCN1C(B(O)O)=CC2=C1N=CC=C2Cl ASPZZZQISULCMI-UHFFFAOYSA-N 0.000 description 1
- SHZPLOJGLSUCMZ-UHFFFAOYSA-N C[Si](C)(C)CCOCN1C(C2=CC=CN=C2)=CC2=C1N=CC=C2Cl Chemical compound C[Si](C)(C)CCOCN1C(C2=CC=CN=C2)=CC2=C1N=CC=C2Cl SHZPLOJGLSUCMZ-UHFFFAOYSA-N 0.000 description 1
- LCZUHOHXDOXXFW-UHFFFAOYSA-N C[Si](C)(C)CCOCN1C=C(Br)C2=C1N=CC=C2OC1=CC=C(N)C=C1F Chemical compound C[Si](C)(C)CCOCN1C=C(Br)C2=C1N=CC=C2OC1=CC=C(N)C=C1F LCZUHOHXDOXXFW-UHFFFAOYSA-N 0.000 description 1
- NIVMVJWSOCFUCV-UHFFFAOYSA-N C[Si](C)(C)CCOCN1C=C(Br)C2=C1N=CC=C2OC1=CC=C([N+](=O)[O-])C=C1F Chemical compound C[Si](C)(C)CCOCN1C=C(Br)C2=C1N=CC=C2OC1=CC=C([N+](=O)[O-])C=C1F NIVMVJWSOCFUCV-UHFFFAOYSA-N 0.000 description 1
- JZLCEURDKRJNGS-UHFFFAOYSA-N C[Si](C)(C)CCOCN1C=C(C2=CC=NC=C2)C2=C1N=CC=C2OC1=C(F)C=C([N+](=O)[O-])C=C1 Chemical compound C[Si](C)(C)CCOCN1C=C(C2=CC=NC=C2)C2=C1N=CC=C2OC1=C(F)C=C([N+](=O)[O-])C=C1 JZLCEURDKRJNGS-UHFFFAOYSA-N 0.000 description 1
- APYCNBLZBBJPTF-UHFFFAOYSA-N C[Si](C)(C)CCOCN1C=CC2=C1N=CC=C2OC1=CC=C([N+](=O)[O-])C=C1F Chemical compound C[Si](C)(C)CCOCN1C=CC2=C1N=CC=C2OC1=CC=C([N+](=O)[O-])C=C1F APYCNBLZBBJPTF-UHFFFAOYSA-N 0.000 description 1
- GVVPRIOOYUQCET-UHFFFAOYSA-N ClC1=NC=NN2C=C(C3=CC(N4CCOCC4)=NC=C3)C=C12 Chemical compound ClC1=NC=NN2C=C(C3=CC(N4CCOCC4)=NC=C3)C=C12 GVVPRIOOYUQCET-UHFFFAOYSA-N 0.000 description 1
- YFVVOBZVXBZCEC-UHFFFAOYSA-N ClC1=NC=NN2C=C(C3=CC=CN=C3)C=C12 Chemical compound ClC1=NC=NN2C=C(C3=CC=CN=C3)C=C12 YFVVOBZVXBZCEC-UHFFFAOYSA-N 0.000 description 1
- HTZROYOEKWLCOC-UHFFFAOYSA-N ClC1=NC=NN2C=C(C3=CC=NC=C3)C=C12 Chemical compound ClC1=NC=NN2C=C(C3=CC=NC=C3)C=C12 HTZROYOEKWLCOC-UHFFFAOYSA-N 0.000 description 1
- AYCNJTDTQXSPEW-UHFFFAOYSA-N ClC1=NC=NN2C=CC(CBr)=C12 Chemical compound ClC1=NC=NN2C=CC(CBr)=C12 AYCNJTDTQXSPEW-UHFFFAOYSA-N 0.000 description 1
- QUFRWQJHIBMRGA-UHFFFAOYSA-N ClC1=NC=NN2C=CC(Cl)=C12 Chemical compound ClC1=NC=NN2C=CC(Cl)=C12 QUFRWQJHIBMRGA-UHFFFAOYSA-N 0.000 description 1
- ONTLBVKRDUFQFP-UHFFFAOYSA-N ClC1=NC=NN2C=CC=C12 Chemical compound ClC1=NC=NN2C=CC=C12 ONTLBVKRDUFQFP-UHFFFAOYSA-N 0.000 description 1
- SDYJZXBMADZFAV-UHFFFAOYSA-N N#CSC(=O)CC1=CC=C(F)C=C1 Chemical compound N#CSC(=O)CC1=CC=C(F)C=C1 SDYJZXBMADZFAV-UHFFFAOYSA-N 0.000 description 1
- XSUCZPWDHFXHBW-UHFFFAOYSA-N N#CSC(=O)CC1=CC=CC=C1 Chemical compound N#CSC(=O)CC1=CC=CC=C1 XSUCZPWDHFXHBW-UHFFFAOYSA-N 0.000 description 1
- KVJJYZZNQXCKEJ-UHFFFAOYSA-N N=C(NC(=O)CC1=CC=C(F)C=C1)NC1=CC=C(OC2=NC=NN3=CC=CC23)C(F)=C1 Chemical compound N=C(NC(=O)CC1=CC=C(F)C=C1)NC1=CC=C(OC2=NC=NN3=CC=CC23)C(F)=C1 KVJJYZZNQXCKEJ-UHFFFAOYSA-N 0.000 description 1
- AASVXJBVSHJSCR-UHFFFAOYSA-N NC1=C(F)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound NC1=C(F)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 AASVXJBVSHJSCR-UHFFFAOYSA-N 0.000 description 1
- VRYWRDHVVUNQNY-UHFFFAOYSA-N NC1=CC(F)=C(OC2=CC=NC3=C2C(C(O)CO)=CN3)C=C1.NC1=CC(F)=C(OC2=CC=NC3=C2C(CCO)=CN3)C=C1 Chemical compound NC1=CC(F)=C(OC2=CC=NC3=C2C(C(O)CO)=CN3)C=C1.NC1=CC(F)=C(OC2=CC=NC3=C2C(CCO)=CN3)C=C1 VRYWRDHVVUNQNY-UHFFFAOYSA-N 0.000 description 1
- DRRJSILBYXEJBK-UHFFFAOYSA-N NC1=CC(F)=C(OC2=CC=NC3=C2C(C2=CC=NC=C2)=CN3)C=C1 Chemical compound NC1=CC(F)=C(OC2=CC=NC3=C2C(C2=CC=NC=C2)=CN3)C=C1 DRRJSILBYXEJBK-UHFFFAOYSA-N 0.000 description 1
- VCQXEFUJWDGTSK-UHFFFAOYSA-N NC1=CC(F)=C(OC2=CC=NN3C=CC=C23)C=C1 Chemical compound NC1=CC(F)=C(OC2=CC=NN3C=CC=C23)C=C1 VCQXEFUJWDGTSK-UHFFFAOYSA-N 0.000 description 1
- KITPQRJSFLDYBB-UHFFFAOYSA-N NC1=CC=C(C2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C=C1 Chemical compound NC1=CC=C(C2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C=C1 KITPQRJSFLDYBB-UHFFFAOYSA-N 0.000 description 1
- UUCLPZPONAZXLU-UHFFFAOYSA-N NC1=CC=C(NC(=O)NC(=O)CC2=CC=C(F)C=C2)C=C1 Chemical compound NC1=CC=C(NC(=O)NC(=O)CC2=CC=C(F)C=C2)C=C1 UUCLPZPONAZXLU-UHFFFAOYSA-N 0.000 description 1
- OTAFFCQLEGELIA-UHFFFAOYSA-N NC1=CC=C(OC2=CC=NC3=C2C(C(=O)C(Cl)(Cl)Cl)=CN3)C(F)=C1 Chemical compound NC1=CC=C(OC2=CC=NC3=C2C(C(=O)C(Cl)(Cl)Cl)=CN3)C(F)=C1 OTAFFCQLEGELIA-UHFFFAOYSA-N 0.000 description 1
- OECDERUZSUTJPL-UHFFFAOYSA-N NC1=CC=C(OC2=CC=NC3=C2C(C2=CSC(N)=N2)=CN3)C(F)=C1 Chemical compound NC1=CC=C(OC2=CC=NC3=C2C(C2=CSC(N)=N2)=CN3)C(F)=C1 OECDERUZSUTJPL-UHFFFAOYSA-N 0.000 description 1
- WQGAKRTYCGIOMQ-UHFFFAOYSA-N NC1=CC=C(OC2=CC=NC3=C2C(CC2=CC(F)=CC=C2)=CN3)C(F)=C1 Chemical compound NC1=CC=C(OC2=CC=NC3=C2C(CC2=CC(F)=CC=C2)=CN3)C(F)=C1 WQGAKRTYCGIOMQ-UHFFFAOYSA-N 0.000 description 1
- QGRYXRRVGNHTCG-UHFFFAOYSA-N NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1 Chemical compound NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1 QGRYXRRVGNHTCG-UHFFFAOYSA-N 0.000 description 1
- HQYDVMOYLQJCFB-UHFFFAOYSA-N NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 HQYDVMOYLQJCFB-UHFFFAOYSA-N 0.000 description 1
- GEEHINCILQXHJR-UHFFFAOYSA-N NC1=CC=C(OC2=CC=NC3=C2C=CN3)C=C1F Chemical compound NC1=CC=C(OC2=CC=NC3=C2C=CN3)C=C1F GEEHINCILQXHJR-UHFFFAOYSA-N 0.000 description 1
- BAPSJDZDFOLJFE-UHFFFAOYSA-N NC1=CC=C(OC2=NC=NN3C=C(C4=CC(N5CCOCC5)=NC=C4)C=C23)C(F)=C1 Chemical compound NC1=CC=C(OC2=NC=NN3C=C(C4=CC(N5CCOCC5)=NC=C4)C=C23)C(F)=C1 BAPSJDZDFOLJFE-UHFFFAOYSA-N 0.000 description 1
- PFDOJBHOSFNOCT-UHFFFAOYSA-N NC1=CC=C(OC2=NC=NN3C=C(C4=CC=CN=C4)C=C23)C(F)=C1 Chemical compound NC1=CC=C(OC2=NC=NN3C=C(C4=CC=CN=C4)C=C23)C(F)=C1 PFDOJBHOSFNOCT-UHFFFAOYSA-N 0.000 description 1
- MBOVBSQHBXBUDU-UHFFFAOYSA-N NC1=CC=C(OC2=NC=NN3C=C(C4=CC=NC=C4)C=C23)C(F)=C1 Chemical compound NC1=CC=C(OC2=NC=NN3C=C(C4=CC=NC=C4)C=C23)C(F)=C1 MBOVBSQHBXBUDU-UHFFFAOYSA-N 0.000 description 1
- JEIXMNSIWTWCAQ-UHFFFAOYSA-N NC1=CC=C(OC2=NC=NN3C=CC(C=C4CCC(=O)CC4)=C23)C(F)=C1 Chemical compound NC1=CC=C(OC2=NC=NN3C=CC(C=C4CCC(=O)CC4)=C23)C(F)=C1 JEIXMNSIWTWCAQ-UHFFFAOYSA-N 0.000 description 1
- PBGPNYJMAYMEOX-UHFFFAOYSA-N NC1=CC=C(OC2=NC=NN3C=CC(CN4CCC(O)CC4)=C23)C(F)=C1 Chemical compound NC1=CC=C(OC2=NC=NN3C=CC(CN4CCC(O)CC4)=C23)C(F)=C1 PBGPNYJMAYMEOX-UHFFFAOYSA-N 0.000 description 1
- LJNUZZWRRUWESQ-UHFFFAOYSA-N NC1=CC=C(OC2=NC=NN3C=CC(CN4CCNCC4)=C23)C(F)=C1 Chemical compound NC1=CC=C(OC2=NC=NN3C=CC(CN4CCNCC4)=C23)C(F)=C1 LJNUZZWRRUWESQ-UHFFFAOYSA-N 0.000 description 1
- HENKLNCMJSLJTB-UHFFFAOYSA-N NC1=CC=C(OC2=NC=NN3C=CC(CN4CCOCC4)=C23)C(F)=C1 Chemical compound NC1=CC=C(OC2=NC=NN3C=CC(CN4CCOCC4)=C23)C(F)=C1 HENKLNCMJSLJTB-UHFFFAOYSA-N 0.000 description 1
- ASGURLWIOUGWKS-UHFFFAOYSA-N NC1=CC=C(OC2=NC=NN3C=CC(Cl)=C23)C(F)=C1 Chemical compound NC1=CC=C(OC2=NC=NN3C=CC(Cl)=C23)C(F)=C1 ASGURLWIOUGWKS-UHFFFAOYSA-N 0.000 description 1
- OXUJVBRIAMNJQQ-UHFFFAOYSA-N NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1 Chemical compound NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1 OXUJVBRIAMNJQQ-UHFFFAOYSA-N 0.000 description 1
- SSSKYKHNNPYQNS-UHFFFAOYSA-N NC1=CN(C2=CC=C(F)C=C2)C(=O)C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)=C1 Chemical compound NC1=CN(C2=CC=C(F)C=C2)C(=O)C(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)=C1 SSSKYKHNNPYQNS-UHFFFAOYSA-N 0.000 description 1
- CHZSVHWDWXNMBC-UHFFFAOYSA-N NC1=NC(C2=CNC3=C2C(OC2=CC=C(NC(=O)C4=C(F)C=CC=C4F)C=C2F)=CC=N3)=CS1 Chemical compound NC1=NC(C2=CNC3=C2C(OC2=CC=C(NC(=O)C4=C(F)C=CC=C4F)C=C2F)=CC=N3)=CS1 CHZSVHWDWXNMBC-UHFFFAOYSA-N 0.000 description 1
- OUWMNXPBIIOOIR-UHFFFAOYSA-N NC1=NC(C2=CNC3=C2C(OC2=CC=C(NC(=O)C4=CC=CN(C5=CC=C(F)C=C5)C4=O)C=C2F)=CC=N3)=CS1 Chemical compound NC1=NC(C2=CNC3=C2C(OC2=CC=C(NC(=O)C4=CC=CN(C5=CC=C(F)C=C5)C4=O)C=C2F)=CC=N3)=CS1 OUWMNXPBIIOOIR-UHFFFAOYSA-N 0.000 description 1
- QTUXEMICRORAEI-UHFFFAOYSA-N NC1=NC(C2=CNC3=C2C(OC2=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C2F)=CC=N3)=CS1 Chemical compound NC1=NC(C2=CNC3=C2C(OC2=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C2F)=CC=N3)=CS1 QTUXEMICRORAEI-UHFFFAOYSA-N 0.000 description 1
- FCCCPHYIYLLZMI-VBKFSLOCSA-N NC1CCC(=CC2=C3C(OC4=CC=C(NC(=O)C5=CN=CC=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound NC1CCC(=CC2=C3C(OC4=CC=C(NC(=O)C5=CN=CC=C5)C=C4F)=NC=NN3C=C2)CC1 FCCCPHYIYLLZMI-VBKFSLOCSA-N 0.000 description 1
- CSBILPIYDYWGGY-LGMDPLHJSA-N NC1CCC(=CC2=C3C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound NC1CCC(=CC2=C3C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 CSBILPIYDYWGGY-LGMDPLHJSA-N 0.000 description 1
- RZBUEYNQBUDJSK-LGMDPLHJSA-N NC1CCC(=CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound NC1CCC(=CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 RZBUEYNQBUDJSK-LGMDPLHJSA-N 0.000 description 1
- MFLBSEPZZBDZSS-UHFFFAOYSA-N NC1CCN(CC2=C3C(NC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4)=NC=NN3C=C2)CC1 Chemical compound NC1CCN(CC2=C3C(NC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4)=NC=NN3C=C2)CC1 MFLBSEPZZBDZSS-UHFFFAOYSA-N 0.000 description 1
- LNYZNHQHYRJYCE-UHFFFAOYSA-N NC1CCN(CC2=C3C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound NC1CCN(CC2=C3C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 LNYZNHQHYRJYCE-UHFFFAOYSA-N 0.000 description 1
- YQQFRBUHZZNTGY-UHFFFAOYSA-N NC1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound NC1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 YQQFRBUHZZNTGY-UHFFFAOYSA-N 0.000 description 1
- VRXCVXPQSXIQRY-UHFFFAOYSA-N NCC1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound NCC1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 VRXCVXPQSXIQRY-UHFFFAOYSA-N 0.000 description 1
- FIGRHFKKEQZCFS-UHFFFAOYSA-N NCC1CN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C1 Chemical compound NCC1CN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C1 FIGRHFKKEQZCFS-UHFFFAOYSA-N 0.000 description 1
- MPFHXHMMZKGSSL-UHFFFAOYSA-N NCCCNCC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1 Chemical compound NCCCNCC1=C2C(OC3=CC=C(NC(=O)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=NC=NN2C=C1 MPFHXHMMZKGSSL-UHFFFAOYSA-N 0.000 description 1
- VUKFDUWOWCBEJY-DHIUTWEWSA-N N[C@@H]1CCN(CC2=C3C(NC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4)=NC=NN3C=C2)C[C@H]1O Chemical compound N[C@@H]1CCN(CC2=C3C(NC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4)=NC=NN3C=C2)C[C@H]1O VUKFDUWOWCBEJY-DHIUTWEWSA-N 0.000 description 1
- PVXNNCDQTCGDOV-LJQANCHMSA-N N[C@@H]1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C1 Chemical compound N[C@@H]1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C1 PVXNNCDQTCGDOV-LJQANCHMSA-N 0.000 description 1
- DRUPVGBBYMYKJN-FGZHOGPDSA-N N[C@@H]1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C[C@H]1O Chemical compound N[C@@H]1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C[C@H]1O DRUPVGBBYMYKJN-FGZHOGPDSA-N 0.000 description 1
- CQONUECZXVJNRZ-FQEVSTJZSA-N N[C@H]1CCCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C1 Chemical compound N[C@H]1CCCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C1 CQONUECZXVJNRZ-FQEVSTJZSA-N 0.000 description 1
- PVXNNCDQTCGDOV-IBGZPJMESA-N N[C@H]1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C1 Chemical compound N[C@H]1CCN(CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)C1 PVXNNCDQTCGDOV-IBGZPJMESA-N 0.000 description 1
- OTTVOPATCCCFGL-UHFFFAOYSA-N O=C(CBr)C1=CNC2=C1C(OC1=CC=C([N+](=O)[O-])C=C1F)=CC=N2 Chemical compound O=C(CBr)C1=CNC2=C1C(OC1=CC=C([N+](=O)[O-])C=C1F)=CC=N2 OTTVOPATCCCFGL-UHFFFAOYSA-N 0.000 description 1
- RMQKLNLIYHNYQP-UHFFFAOYSA-N O=C(CC(=O)NC1=CC(F)=C(O)C=C1)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC(F)=C(O)C=C1)NC1=CC=C(F)C=C1 RMQKLNLIYHNYQP-UHFFFAOYSA-N 0.000 description 1
- CGUJFGQOIYPNNZ-UHFFFAOYSA-N O=C(CC(=O)NC1=CC(F)=C(OC2=CC=NN3C=CC=C23)C=C1)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC(F)=C(OC2=CC=NN3C=CC=C23)C=C1)NC1=CC=C(F)C=C1 CGUJFGQOIYPNNZ-UHFFFAOYSA-N 0.000 description 1
- PZVMAPWJHUUYTN-UHFFFAOYSA-N O=C(CC(=O)NC1=CC(F)=C(OC2=NC=NC3=C2C=CS3)C=C1)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC(F)=C(OC2=NC=NC3=C2C=CS3)C=C1)NC1=CC=C(F)C=C1 PZVMAPWJHUUYTN-UHFFFAOYSA-N 0.000 description 1
- DVQYYSZZZVRTPU-UHFFFAOYSA-N O=C(CC(=O)NC1=CC(F)=C(OC2=NC=NC3=C2SC=C3)C=C1)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC(F)=C(OC2=NC=NC3=C2SC=C3)C=C1)NC1=CC=C(F)C=C1 DVQYYSZZZVRTPU-UHFFFAOYSA-N 0.000 description 1
- NQVBLCPVPXBRCO-UHFFFAOYSA-N O=C(CC(=O)NC1=CC(F)=C(OC2=NC=NN3C=C(C4=CC=CN=C4)C=C23)C=C1)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC(F)=C(OC2=NC=NN3C=C(C4=CC=CN=C4)C=C23)C=C1)NC1=CC=C(F)C=C1 NQVBLCPVPXBRCO-UHFFFAOYSA-N 0.000 description 1
- ZQRVPSUSMNNXQX-UHFFFAOYSA-N O=C(CC(=O)NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1)NC1=CC=C(F)C=C1 ZQRVPSUSMNNXQX-UHFFFAOYSA-N 0.000 description 1
- PLLLNZXGUXHIHY-UHFFFAOYSA-N O=C(CC(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)NC1=CC=C(F)C=C1 PLLLNZXGUXHIHY-UHFFFAOYSA-N 0.000 description 1
- YHUFDIUWSJIISM-UHFFFAOYSA-N O=C(CC(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C=C1F)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C=C1F)NC1=CC=C(F)C=C1 YHUFDIUWSJIISM-UHFFFAOYSA-N 0.000 description 1
- FKVMOLUOROGEKG-UHFFFAOYSA-N O=C(CC(=O)NC1=CC=C(OC2=NC=NN3C=C(C4=CC(N5CCOCC5)=NC=C4)C=C23)C(F)=C1)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC=C(OC2=NC=NN3C=C(C4=CC(N5CCOCC5)=NC=C4)C=C23)C(F)=C1)NC1=CC=C(F)C=C1 FKVMOLUOROGEKG-UHFFFAOYSA-N 0.000 description 1
- VTHHYEGJQZBMJJ-UHFFFAOYSA-N O=C(CC(=O)NC1=CC=C(OC2=NC=NN3C=C(C4=CC=NC=C4)C=C23)C(F)=C1)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC=C(OC2=NC=NN3C=C(C4=CC=NC=C4)C=C23)C(F)=C1)NC1=CC=C(F)C=C1 VTHHYEGJQZBMJJ-UHFFFAOYSA-N 0.000 description 1
- FSUAFGXZUXLQFW-LGMDPLHJSA-N O=C(CC(=O)NC1=CC=C(OC2=NC=NN3C=CC(C=C4CCC(O)CC4)=C23)C(F)=C1)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC=C(OC2=NC=NN3C=CC(C=C4CCC(O)CC4)=C23)C(F)=C1)NC1=CC=C(F)C=C1 FSUAFGXZUXLQFW-LGMDPLHJSA-N 0.000 description 1
- DLURRQMWIKEHMO-UHFFFAOYSA-N O=C(CC(=O)NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1)NC1=CC=C(F)C=C1 Chemical compound O=C(CC(=O)NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1)NC1=CC=C(F)C=C1 DLURRQMWIKEHMO-UHFFFAOYSA-N 0.000 description 1
- OEWZCDDXHJUMDQ-UHFFFAOYSA-N O=C(CC(=O)NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1)NC1=CC=CC=C1 Chemical compound O=C(CC(=O)NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1)NC1=CC=CC=C1 OEWZCDDXHJUMDQ-UHFFFAOYSA-N 0.000 description 1
- ZREBLYREOLCONH-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC(F)=C(OC2=CC=NC3=C2C(C(O)CO)=CN3)C=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC(F)=C(OC2=CC=NC3=C2C(C(O)CO)=CN3)C=C1 ZREBLYREOLCONH-UHFFFAOYSA-N 0.000 description 1
- YHRODYLKVZIFSW-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC(F)=C(OC2=CC=NC3=C2C(C2=CN=CC=C2)=CN3)C=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC(F)=C(OC2=CC=NC3=C2C(C2=CN=CC=C2)=CN3)C=C1 YHRODYLKVZIFSW-UHFFFAOYSA-N 0.000 description 1
- DYFJYOVDYFGZDE-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC(F)=C(OC2=CC=NC3=C2C(CO)=CN3)C=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC(F)=C(OC2=CC=NC3=C2C(CO)=CN3)C=C1 DYFJYOVDYFGZDE-UHFFFAOYSA-N 0.000 description 1
- BBERYMMEKQLJRH-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC(F)=C(OC2=CC=NN3C=CC=C23)C=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC(F)=C(OC2=CC=NN3C=CC=C23)C=C1 BBERYMMEKQLJRH-UHFFFAOYSA-N 0.000 description 1
- PYVIOGQVKUDFPQ-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C(C(=O)C(Cl)(Cl)Cl)=CN3)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C(C(=O)C(Cl)(Cl)Cl)=CN3)C(F)=C1 PYVIOGQVKUDFPQ-UHFFFAOYSA-N 0.000 description 1
- HMAOSXKYTAOLFO-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C(C(=O)CN2CCC(O)C2)=CN3)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C(C(=O)CN2CCC(O)C2)=CN3)C(F)=C1 HMAOSXKYTAOLFO-UHFFFAOYSA-N 0.000 description 1
- WGRLPFLJQGNPHU-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C(C(=O)NCC2=CN=CC=C2)=CN3)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C(C(=O)NCC2=CN=CC=C2)=CN3)C(F)=C1 WGRLPFLJQGNPHU-UHFFFAOYSA-N 0.000 description 1
- NWYHBEQKPKUWBM-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C(CC2=CC(F)=CC=C2)=CN3)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C(CC2=CC(F)=CC=C2)=CN3)C(F)=C1 NWYHBEQKPKUWBM-UHFFFAOYSA-N 0.000 description 1
- BLFYQKYEPRTHMF-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C(CCO)=CN3)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C(CCO)=CN3)C(F)=C1 BLFYQKYEPRTHMF-UHFFFAOYSA-N 0.000 description 1
- VVILWTFRDKYFFA-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1 VVILWTFRDKYFFA-UHFFFAOYSA-N 0.000 description 1
- BMPOCDJEXAXXEZ-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 BMPOCDJEXAXXEZ-UHFFFAOYSA-N 0.000 description 1
- WMUKZNBBNMRNEE-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=C(C4=CC(N5CCOCC5)=NC=C4)C=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=C(C4=CC(N5CCOCC5)=NC=C4)C=C23)C(F)=C1 WMUKZNBBNMRNEE-UHFFFAOYSA-N 0.000 description 1
- BXRYAKGMFZVKOH-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=C(C4=CC=CN=C4)C=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=C(C4=CC=CN=C4)C=C23)C(F)=C1 BXRYAKGMFZVKOH-UHFFFAOYSA-N 0.000 description 1
- CYAJSKHOAGKKKE-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=C(C4=CC=NC=C4)C=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=C(C4=CC=NC=C4)C=C23)C(F)=C1 CYAJSKHOAGKKKE-UHFFFAOYSA-N 0.000 description 1
- UWSKHTRAJZLSMW-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(C4=CC=CC([N+](=O)[O-])=C4)=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(C4=CC=CC([N+](=O)[O-])=C4)=C23)C(F)=C1 UWSKHTRAJZLSMW-UHFFFAOYSA-N 0.000 description 1
- PWLNNRDAQPANDX-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(C4=CC=CC=C4)=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(C4=CC=CC=C4)=C23)C(F)=C1 PWLNNRDAQPANDX-UHFFFAOYSA-N 0.000 description 1
- WIOXKSTUQHLKLL-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(C4=CN=CN=C4)=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(C4=CN=CN=C4)=C23)C(F)=C1 WIOXKSTUQHLKLL-UHFFFAOYSA-N 0.000 description 1
- SPXSJGLBRZKMGW-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(C4=CSC=C4)=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(C4=CSC=C4)=C23)C(F)=C1 SPXSJGLBRZKMGW-UHFFFAOYSA-N 0.000 description 1
- PEXLOCWUDPQMOT-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(CN4CCC(O)CC4)=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(CN4CCC(O)CC4)=C23)C(F)=C1 PEXLOCWUDPQMOT-UHFFFAOYSA-N 0.000 description 1
- VSHBKTLTOHLWDO-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(CN4CCNCC4)=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(CN4CCNCC4)=C23)C(F)=C1 VSHBKTLTOHLWDO-UHFFFAOYSA-N 0.000 description 1
- DAUNYOFBILOYNT-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(CN4CCOCC4)=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(CN4CCOCC4)=C23)C(F)=C1 DAUNYOFBILOYNT-UHFFFAOYSA-N 0.000 description 1
- YMVDFYNERAZVFU-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(CNC4CCNCC4)=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C(OC2=NC=NN3C=CC(CNC4CCNCC4)=C23)C(F)=C1 YMVDFYNERAZVFU-UHFFFAOYSA-N 0.000 description 1
- DUWNTZRHCAXQOF-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C([N+](=O)[O-])C=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=O)NC1=CC=C([N+](=O)[O-])C=C1 DUWNTZRHCAXQOF-UHFFFAOYSA-N 0.000 description 1
- HBZKKAHNVUCDNB-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(O)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(O)C(F)=C1 HBZKKAHNVUCDNB-UHFFFAOYSA-N 0.000 description 1
- UVJXXQPVLZJLOE-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(O)C=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(O)C=C1 UVJXXQPVLZJLOE-UHFFFAOYSA-N 0.000 description 1
- TWKQXPFHNKXAGK-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(OC2=CC=NN3C=CC=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(OC2=CC=NN3C=CC=C23)C(F)=C1 TWKQXPFHNKXAGK-UHFFFAOYSA-N 0.000 description 1
- JUDAPEUSHUNMSY-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(OC2=NC=NC3=C2C=CN3)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(OC2=NC=NC3=C2C=CN3)C(F)=C1 JUDAPEUSHUNMSY-UHFFFAOYSA-N 0.000 description 1
- XDEZOYQDZHVZRA-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(OC2=NC=NC3=C2C=CS3)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(OC2=NC=NC3=C2C=CS3)C(F)=C1 XDEZOYQDZHVZRA-UHFFFAOYSA-N 0.000 description 1
- FGCQXAZBVMRHGK-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)NC(=S)NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1 FGCQXAZBVMRHGK-UHFFFAOYSA-N 0.000 description 1
- ZXWMZOMYYNUHHK-UHFFFAOYSA-N O=C(CC1=CC=CC=C1)NC(=S)NC1=CC=C(O)C(F)=C1 Chemical compound O=C(CC1=CC=CC=C1)NC(=S)NC1=CC=C(O)C(F)=C1 ZXWMZOMYYNUHHK-UHFFFAOYSA-N 0.000 description 1
- KZYMKCIIFYKFSM-UHFFFAOYSA-N O=C(CC1CC1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound O=C(CC1CC1)NC(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 KZYMKCIIFYKFSM-UHFFFAOYSA-N 0.000 description 1
- XJXFTRPTWMMAGN-UHFFFAOYSA-N O=C(CN1CCC(O)C1)C1=CNC2=C1C(OC1=CC=C(NC(=O)C3=C(F)C=CC=C3F)C=C1F)=CC=N2 Chemical compound O=C(CN1CCC(O)C1)C1=CNC2=C1C(OC1=CC=C(NC(=O)C3=C(F)C=CC=C3F)C=C1F)=CC=N2 XJXFTRPTWMMAGN-UHFFFAOYSA-N 0.000 description 1
- GWXAPFZHVKDSCP-UHFFFAOYSA-N O=C(NC(=O)C1CC1)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound O=C(NC(=O)C1CC1)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 GWXAPFZHVKDSCP-UHFFFAOYSA-N 0.000 description 1
- AYWTXKOTPJDUSX-UHFFFAOYSA-N O=C(NC1=CC(F)=C(OC2=NC=NN3C=C(C4=CC=CN=C4)C=C23)C=C1)C1=C(F)C=CC=C1F Chemical compound O=C(NC1=CC(F)=C(OC2=NC=NN3C=C(C4=CC=CN=C4)C=C23)C=C1)C1=C(F)C=CC=C1F AYWTXKOTPJDUSX-UHFFFAOYSA-N 0.000 description 1
- GGHDNHUNMNZQNK-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)CC1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)CC1 GGHDNHUNMNZQNK-UHFFFAOYSA-N 0.000 description 1
- VTHOZEOEXPHUTE-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CC=NC=C2)=CN3)C(F)=C1)C1=C(F)C=CC=C1F Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CC=NC=C2)=CN3)C(F)=C1)C1=C(F)C=CC=C1F VTHOZEOEXPHUTE-UHFFFAOYSA-N 0.000 description 1
- OSIFHHUMBHGOJS-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CC=NC=C2)=CN3)C(F)=C1)C1=CC=CC=C1F Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CC=NC=C2)=CN3)C(F)=C1)C1=CC=CC=C1F OSIFHHUMBHGOJS-UHFFFAOYSA-N 0.000 description 1
- IFKCNWUDZSQRLL-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CN=CC=C2)=CN3)C(F)=C1)C1=CC=CN(C2=CC=CC=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CN=CC=C2)=CN3)C(F)=C1)C1=CC=CN(C2=CC=CC=C2)C1=O IFKCNWUDZSQRLL-UHFFFAOYSA-N 0.000 description 1
- WZHZPNHQIHETLI-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CN=CC=C2)=CN3)C(F)=C1)C1=CN=CC=C1 Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CN=CC=C2)=CN3)C(F)=C1)C1=CN=CC=C1 WZHZPNHQIHETLI-UHFFFAOYSA-N 0.000 description 1
- TUXFOKJSVMKKJR-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CN=CC=C2)=CN3)C(F)=C1)C1=[N+]([O-])C(C2=CC=C(F)C=C2)=CC=C1 Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C(C2=CN=CC=C2)=CN3)C(F)=C1)C1=[N+]([O-])C(C2=CC=C(F)C=C2)=CC=C1 TUXFOKJSVMKKJR-UHFFFAOYSA-N 0.000 description 1
- SENNSLDMYLALGG-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C(CC2=CC(F)=CC=C2)=CN3)C(F)=C1)C1CCN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C(CC2=CC(F)=CC=C2)=CN3)C(F)=C1)C1CCN(C2=CC=C(F)C=C2)C1=O SENNSLDMYLALGG-UHFFFAOYSA-N 0.000 description 1
- OBCGLLSLELGMAE-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C(CCCO)=CN3)C(F)=C1)C1=CC=CN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C(CCCO)=CN3)C(F)=C1)C1=CC=CN(C2=CC=C(F)C=C2)C1=O OBCGLLSLELGMAE-UHFFFAOYSA-N 0.000 description 1
- MXPZQBVIFNKNRC-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C(CN2CCC(O)CC2)=CN3)C(F)=C1)C1CCN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C(CN2CCC(O)CC2)=CN3)C(F)=C1)C1CCN(C2=CC=C(F)C=C2)C1=O MXPZQBVIFNKNRC-UHFFFAOYSA-N 0.000 description 1
- BHCIJBFMAMZAFC-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C(CN2CCCCC2)=CN3)C(F)=C1)C1CCN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C(CN2CCCCC2)=CN3)C(F)=C1)C1CCN(C2=CC=C(F)C=C2)C1=O BHCIJBFMAMZAFC-UHFFFAOYSA-N 0.000 description 1
- JWJABKKBOIQNHG-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1)C1=C(F)C=CC=C1F Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1)C1=C(F)C=CC=C1F JWJABKKBOIQNHG-UHFFFAOYSA-N 0.000 description 1
- DVQGZQRBROPGPV-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1)C1=CC=CN(C2=CC=CC=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1)C1=CC=CN(C2=CC=CC=C2)C1=O DVQGZQRBROPGPV-UHFFFAOYSA-N 0.000 description 1
- CKCHNUWKZJLBMS-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1)C1=CN=CC=C1 Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1)C1=CN=CC=C1 CKCHNUWKZJLBMS-UHFFFAOYSA-N 0.000 description 1
- PIUCHSMNOFRZIF-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=C(F)C=CC=C1F Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=C(F)C=CC=C1F PIUCHSMNOFRZIF-UHFFFAOYSA-N 0.000 description 1
- MBBMIIKHTSKIBE-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CC([N+](=O)[O-])=CN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CC([N+](=O)[O-])=CN(C2=CC=C(F)C=C2)C1=O MBBMIIKHTSKIBE-UHFFFAOYSA-N 0.000 description 1
- DIDIVIXODOFLFJ-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CC=CN(CC2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CC=CN(CC2=CC=C(F)C=C2)C1=O DIDIVIXODOFLFJ-UHFFFAOYSA-N 0.000 description 1
- KTQVNWLWBRRVIB-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CN=CC=C1 Chemical compound O=C(NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1)C1=CN=CC=C1 KTQVNWLWBRRVIB-UHFFFAOYSA-N 0.000 description 1
- AETQPTAECQEAAL-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=NC=NN3C=C(C4=CC=NC=C4)C=C23)C(F)=C1)C1=C(F)C=CC=C1F Chemical compound O=C(NC1=CC=C(OC2=NC=NN3C=C(C4=CC=NC=C4)C=C23)C(F)=C1)C1=C(F)C=CC=C1F AETQPTAECQEAAL-UHFFFAOYSA-N 0.000 description 1
- RDEWKGXPTUISEX-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=NC=NN3C=CC(Cl)=C23)C(F)=C1)C1=CN=CC=C1 Chemical compound O=C(NC1=CC=C(OC2=NC=NN3C=CC(Cl)=C23)C(F)=C1)C1=CN=CC=C1 RDEWKGXPTUISEX-UHFFFAOYSA-N 0.000 description 1
- SKJMMJPFZLPFSP-UHFFFAOYSA-N O=C(NC1=CN=C(OC2=CC=NC3=C2C=CN3)C(Cl)=C1)C1=CC=CN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(NC1=CN=C(OC2=CC=NC3=C2C=CN3)C(Cl)=C1)C1=CC=CN(C2=CC=C(F)C=C2)C1=O SKJMMJPFZLPFSP-UHFFFAOYSA-N 0.000 description 1
- OLPKJBIDKSTZOL-UHFFFAOYSA-N O=C(NCC1=CC=C(F)C=C1)C1(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)CC1 Chemical compound O=C(NCC1=CC=C(F)C=C1)C1(C(=O)NC2=CC=C(OC3=CC=NC4=C3C=CN4)C(F)=C2)CC1 OLPKJBIDKSTZOL-UHFFFAOYSA-N 0.000 description 1
- NNJNTFWMJIQVIR-UHFFFAOYSA-N O=C(O)C1(C(=O)NCC2=CC=C(F)C=C2)CC1 Chemical compound O=C(O)C1(C(=O)NCC2=CC=C(F)C=C2)CC1 NNJNTFWMJIQVIR-UHFFFAOYSA-N 0.000 description 1
- XAFVIFVNMJQQGP-UHFFFAOYSA-N O=C(O)C1=CC(Br)=CN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(O)C1=CC(Br)=CN(C2=CC=C(F)C=C2)C1=O XAFVIFVNMJQQGP-UHFFFAOYSA-N 0.000 description 1
- SIHMMTANWQXEHE-UHFFFAOYSA-N O=C(O)C1=CC(C2=CC=CC=C2)=CNC1=O Chemical compound O=C(O)C1=CC(C2=CC=CC=C2)=CNC1=O SIHMMTANWQXEHE-UHFFFAOYSA-N 0.000 description 1
- PBGNDMZYCXKPJU-UHFFFAOYSA-N O=C(O)C1=CC([N+](=O)[O-])=CN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(O)C1=CC([N+](=O)[O-])=CN(C2=CC=C(F)C=C2)C1=O PBGNDMZYCXKPJU-UHFFFAOYSA-N 0.000 description 1
- WEEVXEKXCIBZMB-UHFFFAOYSA-N O=C(O)C1=CC=CC(C2=CC=C(F)C=C2)=N1 Chemical compound O=C(O)C1=CC=CC(C2=CC=C(F)C=C2)=N1 WEEVXEKXCIBZMB-UHFFFAOYSA-N 0.000 description 1
- HSVCYMYXCVETLA-UHFFFAOYSA-N O=C(O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-] Chemical compound O=C(O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-] HSVCYMYXCVETLA-UHFFFAOYSA-N 0.000 description 1
- WPJGHIVGAOVUAT-UHFFFAOYSA-N O=C(O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O WPJGHIVGAOVUAT-UHFFFAOYSA-N 0.000 description 1
- CVROAYZMRHZRBO-UHFFFAOYSA-N O=C(O)C1=CC=CN(C2=CN=CC=C2)C1=O Chemical compound O=C(O)C1=CC=CN(C2=CN=CC=C2)C1=O CVROAYZMRHZRBO-UHFFFAOYSA-N 0.000 description 1
- MTYGMEUMDAFSOY-UHFFFAOYSA-N O=C(O)C1=CC=CN(C2=NC=CC=C2)C1=O Chemical compound O=C(O)C1=CC=CN(C2=NC=CC=C2)C1=O MTYGMEUMDAFSOY-UHFFFAOYSA-N 0.000 description 1
- KFUPGHOUJJNVJQ-UHFFFAOYSA-N O=C(O)C1=CC=CN(CC2=CC=C(F)C=C2)C1=O Chemical compound O=C(O)C1=CC=CN(CC2=CC=C(F)C=C2)C1=O KFUPGHOUJJNVJQ-UHFFFAOYSA-N 0.000 description 1
- CXOPUGLYEYDAMC-UHFFFAOYSA-N O=C(O)C1=NC(C2=CC=CC=C2)=CC=C1 Chemical compound O=C(O)C1=NC(C2=CC=CC=C2)=CC=C1 CXOPUGLYEYDAMC-UHFFFAOYSA-N 0.000 description 1
- HMFVEVMNCGZAOC-UHFFFAOYSA-N O=C(O)C1=[N+]([O-])C(C2=CC=CC=C2)=CC=C1 Chemical compound O=C(O)C1=[N+]([O-])C(C2=CC=CC=C2)=CC=C1 HMFVEVMNCGZAOC-UHFFFAOYSA-N 0.000 description 1
- GKKWONDBUXUCHF-UHFFFAOYSA-N O=C(O)C1CCN(C2=CC=C(F)C=C2)C1=O Chemical compound O=C(O)C1CCN(C2=CC=C(F)C=C2)C1=O GKKWONDBUXUCHF-UHFFFAOYSA-N 0.000 description 1
- ISLQUPSDLYAGBQ-UHFFFAOYSA-N O=C(O)CC(=O)NC1=CC=C(F)C=C1 Chemical compound O=C(O)CC(=O)NC1=CC=C(F)C=C1 ISLQUPSDLYAGBQ-UHFFFAOYSA-N 0.000 description 1
- RPQCWAKDJSAYBO-UHFFFAOYSA-N O=C(O)CC(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound O=C(O)CC(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 RPQCWAKDJSAYBO-UHFFFAOYSA-N 0.000 description 1
- MBSOMHVBZNNIBX-UHFFFAOYSA-N O=C(O)CC(=O)NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1 Chemical compound O=C(O)CC(=O)NC1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1 MBSOMHVBZNNIBX-UHFFFAOYSA-N 0.000 description 1
- QGWOZLJTLRKDOF-UHFFFAOYSA-N O=C1C=CNN2C=CC=C12 Chemical compound O=C1C=CNN2C=CC=C12 QGWOZLJTLRKDOF-UHFFFAOYSA-N 0.000 description 1
- ZDVLKQGDWVBJDX-UHFFFAOYSA-N O=C1CCC(=CC2=C3C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound O=C1CCC(=CC2=C3C(OC4=CC=C(NC(=O)CC(=O)NC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 ZDVLKQGDWVBJDX-UHFFFAOYSA-N 0.000 description 1
- WFLXWSBQCABYKX-UHFFFAOYSA-N O=C1CCC(=CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 Chemical compound O=C1CCC(=CC2=C3C(OC4=CC=C(NC(=O)NC(=O)CC5=CC=C(F)C=C5)C=C4F)=NC=NN3C=C2)CC1 WFLXWSBQCABYKX-UHFFFAOYSA-N 0.000 description 1
- MQUOCQDYAGASGH-UHFFFAOYSA-N O=C1NC=CC=C1C(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound O=C1NC=CC=C1C(=O)NC1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 MQUOCQDYAGASGH-UHFFFAOYSA-N 0.000 description 1
- HRJQMAIKMCZVAD-UHFFFAOYSA-N O=C1NC=NN2C=CC(Cl)=C12 Chemical compound O=C1NC=NN2C=CC(Cl)=C12 HRJQMAIKMCZVAD-UHFFFAOYSA-N 0.000 description 1
- FVBRMNFEXWSLNI-UHFFFAOYSA-N O=C=NC(=O)C1CC1 Chemical compound O=C=NC(=O)C1CC1 FVBRMNFEXWSLNI-UHFFFAOYSA-N 0.000 description 1
- UDZXXLPKRIAPKR-UHFFFAOYSA-N O=C=NC(=O)CC1=CC=C(F)C=C1 Chemical compound O=C=NC(=O)CC1=CC=C(F)C=C1 UDZXXLPKRIAPKR-UHFFFAOYSA-N 0.000 description 1
- SMTUNIMBRXGDKX-UHFFFAOYSA-N O=C=NC(=O)CC1=CC=CC=C1 Chemical compound O=C=NC(=O)CC1=CC=CC=C1 SMTUNIMBRXGDKX-UHFFFAOYSA-N 0.000 description 1
- MRWMBMNOCVWPGP-UHFFFAOYSA-N O=C=NC(=O)CC1CC1 Chemical compound O=C=NC(=O)CC1CC1 MRWMBMNOCVWPGP-UHFFFAOYSA-N 0.000 description 1
- YNTVOSDINFQRMP-UHFFFAOYSA-N O=COCC(=O)C1=CNC2=C1C(OC1=C(F)C=C([N+](=O)[O-])C=C1)=CC=N2 Chemical compound O=COCC(=O)C1=CNC2=C1C(OC1=C(F)C=C([N+](=O)[O-])C=C1)=CC=N2 YNTVOSDINFQRMP-UHFFFAOYSA-N 0.000 description 1
- ICRPOUJITUGSRX-UHFFFAOYSA-N O=[N+]([O-])C1=C(F)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound O=[N+]([O-])C1=C(F)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 ICRPOUJITUGSRX-UHFFFAOYSA-N 0.000 description 1
- NPXPALBLABYOJL-UHFFFAOYSA-N O=[N+]([O-])C1=CC(F)=C(OC2=CC=NN3C=CC=C23)C=C1 Chemical compound O=[N+]([O-])C1=CC(F)=C(OC2=CC=NN3C=CC=C23)C=C1 NPXPALBLABYOJL-UHFFFAOYSA-N 0.000 description 1
- WCPUFWPEMFVWPH-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(OC2=CC=NC3=C2C(I)=CN3)C(F)=C1 Chemical compound O=[N+]([O-])C1=CC=C(OC2=CC=NC3=C2C(I)=CN3)C(F)=C1 WCPUFWPEMFVWPH-UHFFFAOYSA-N 0.000 description 1
- OHSAVRZZNASZOY-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(OC2=NC=NN3C=C(C4=CC(N5CCOCC5)=NC=C4)C=C23)C(F)=C1 Chemical compound O=[N+]([O-])C1=CC=C(OC2=NC=NN3C=C(C4=CC(N5CCOCC5)=NC=C4)C=C23)C(F)=C1 OHSAVRZZNASZOY-UHFFFAOYSA-N 0.000 description 1
- VHXDANXHONGFDT-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(OC2=NC=NN3C=C(C4=CC=CN=C4)C=C23)C(F)=C1 Chemical compound O=[N+]([O-])C1=CC=C(OC2=NC=NN3C=C(C4=CC=CN=C4)C=C23)C(F)=C1 VHXDANXHONGFDT-UHFFFAOYSA-N 0.000 description 1
- CUQPDCOBZYXNLA-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(OC2=NC=NN3C=C(C4=CC=NC=C4)C=C23)C(F)=C1 Chemical compound O=[N+]([O-])C1=CC=C(OC2=NC=NN3C=C(C4=CC=NC=C4)C=C23)C(F)=C1 CUQPDCOBZYXNLA-UHFFFAOYSA-N 0.000 description 1
- UYBCJKDCDMZTGT-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(OC2=NC=NN3C=CC(Cl)=C23)C(F)=C1 Chemical compound O=[N+]([O-])C1=CC=C(OC2=NC=NN3C=CC(Cl)=C23)C(F)=C1 UYBCJKDCDMZTGT-UHFFFAOYSA-N 0.000 description 1
- ONYCZVHMTYHYDA-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1 Chemical compound O=[N+]([O-])C1=CC=C(OC2=NC=NN3C=CC=C23)C(F)=C1 ONYCZVHMTYHYDA-UHFFFAOYSA-N 0.000 description 1
- MPUHMXSKCLHKHO-UHFFFAOYSA-N O=[N+]([O-])C1=CN=C(OC2=CC=NC3=C2C=CN3)C(Cl)=C1 Chemical compound O=[N+]([O-])C1=CN=C(OC2=CC=NC3=C2C=CN3)C(Cl)=C1 MPUHMXSKCLHKHO-UHFFFAOYSA-N 0.000 description 1
- DYUHEIMQQFRXMH-UHFFFAOYSA-N OC1=NC=NN2C=C(C3=CC(N4CCOCC4)=NC=C3)C=C12 Chemical compound OC1=NC=NN2C=C(C3=CC(N4CCOCC4)=NC=C3)C=C12 DYUHEIMQQFRXMH-UHFFFAOYSA-N 0.000 description 1
- KVYRQDXTZWZZRO-UHFFFAOYSA-N OC1=NC=NN2C=C(C3=CC=CN=C3)C=C12 Chemical compound OC1=NC=NN2C=C(C3=CC=CN=C3)C=C12 KVYRQDXTZWZZRO-UHFFFAOYSA-N 0.000 description 1
- FJKUZDBVSWFNHP-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC=C1NC(C)C Chemical compound [C-]#[N+]C1=CC=CC=C1NC(C)C FJKUZDBVSWFNHP-UHFFFAOYSA-N 0.000 description 1
- QWMPNTGUZGHXGY-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=C(Br)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=C(Br)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 QWMPNTGUZGHXGY-UHFFFAOYSA-N 0.000 description 1
- ZNFPKOUPRRBMGL-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=C(C(F)(F)F)C=C(OC2=CC=NC3=C2C=CN3)C=C1 Chemical compound [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=C(C(F)(F)F)C=C(OC2=CC=NC3=C2C=CN3)C=C1 ZNFPKOUPRRBMGL-UHFFFAOYSA-N 0.000 description 1
- SGFDQFPTQGTVNC-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=C(C)C=C(OC2=CC=NC3=C2C=CN3)C=C1 Chemical compound [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=C(C)C=C(OC2=CC=NC3=C2C=CN3)C=C1 SGFDQFPTQGTVNC-UHFFFAOYSA-N 0.000 description 1
- DYIMBIPZCDWAGE-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=C(Cl)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=C(Cl)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 DYIMBIPZCDWAGE-UHFFFAOYSA-N 0.000 description 1
- OQYNXMFCSZLCES-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=CC=C(OC2=CC=NC3=C2C=C(C2=CC=CN=C2)N3)C(F)=C1 OQYNXMFCSZLCES-UHFFFAOYSA-N 0.000 description 1
- FNYUYCAFUHPIEP-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C(Cl)=C1 Chemical compound [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C(Cl)=C1 FNYUYCAFUHPIEP-UHFFFAOYSA-N 0.000 description 1
- UQVQABXFQLZIAR-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CC(C2=CC=C(F)C=C2)=[N+]1[O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 UQVQABXFQLZIAR-UHFFFAOYSA-N 0.000 description 1
- PGLMTHFDBWHAIP-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CC(C2=CC=CC=C2)=N1)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CC(C2=CC=CC=C2)=N1)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 PGLMTHFDBWHAIP-UHFFFAOYSA-N 0.000 description 1
- QDVLUPLLJVFWGU-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CC(C2=CC=CC=C2)=[N+]1[O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CC(C2=CC=CC=C2)=[N+]1[O-])C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 QDVLUPLLJVFWGU-UHFFFAOYSA-N 0.000 description 1
- IIOGSFFJNZSMHN-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(Br)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(Br)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 IIOGSFFJNZSMHN-UHFFFAOYSA-N 0.000 description 1
- NPBNYCVMHBTYLX-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(C#N)C=C(OC2=CC=NC3=C2C=CN3)C=C1 Chemical compound [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(C#N)C=C(OC2=CC=NC3=C2C=CN3)C=C1 NPBNYCVMHBTYLX-UHFFFAOYSA-N 0.000 description 1
- KRBMRKBUVQOQGL-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(C(F)(F)F)C=C(OC2=CC=NC3=C2C=CN3)C=C1 Chemical compound [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(C(F)(F)F)C=C(OC2=CC=NC3=C2C=CN3)C=C1 KRBMRKBUVQOQGL-UHFFFAOYSA-N 0.000 description 1
- OSGTXRVOYWSWLH-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(C)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(C)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 OSGTXRVOYWSWLH-UHFFFAOYSA-N 0.000 description 1
- FNZAMCZRFYIWKW-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(Cl)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(Cl)C=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 FNZAMCZRFYIWKW-UHFFFAOYSA-N 0.000 description 1
- BPXCKTSZNCEUPN-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(Cl)C=C(OC2=CC=NC3=C2C=CN3)C=C1 Chemical compound [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(Cl)C=C(OC2=CC=NC3=C2C=CN3)C=C1 BPXCKTSZNCEUPN-UHFFFAOYSA-N 0.000 description 1
- AFUCETULUNLGRW-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(Cl)C=C(OC2=CC=NC3=C2C=CN3)C=C1F Chemical compound [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(Cl)C=C(OC2=CC=NC3=C2C=CN3)C=C1F AFUCETULUNLGRW-UHFFFAOYSA-N 0.000 description 1
- SNJOZOUNRPFGCK-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(F)C=C(OC2=CC=NC3=C2C=CN3)C=C1F Chemical compound [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=C(F)C=C(OC2=CC=NC3=C2C=CN3)C=C1F SNJOZOUNRPFGCK-UHFFFAOYSA-N 0.000 description 1
- OBSFXHDOLBYWRJ-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CN(C2=CC=C(F)C=C2)C1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 OBSFXHDOLBYWRJ-UHFFFAOYSA-N 0.000 description 1
- XUKXSDZCMRYFRY-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CC=CC=C2)C1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CN(C2=CC=CC=C2)C1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 XUKXSDZCMRYFRY-UHFFFAOYSA-N 0.000 description 1
- QNUMETKRNAQBDZ-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=CN=CC=C2)C1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CN(C2=CN=CC=C2)C1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 QNUMETKRNAQBDZ-UHFFFAOYSA-N 0.000 description 1
- CKDFZTKKHWVVPB-UHFFFAOYSA-N [H]N(C(=O)C1=CC=CN(C2=NC=CC=C2)C1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CC=CN(C2=NC=CC=C2)C1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 CKDFZTKKHWVVPB-UHFFFAOYSA-N 0.000 description 1
- UBOWIPOOKZKEGC-UHFFFAOYSA-N [H]N(C(=O)C1=CNC=C(CC2=CC=CC=C2)C1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 Chemical compound [H]N(C(=O)C1=CNC=C(CC2=CC=CC=C2)C1=O)C1=CC=C(OC2=CC=NC3=C2C=CN3)C(F)=C1 UBOWIPOOKZKEGC-UHFFFAOYSA-N 0.000 description 1
- WHFUAXRQORIIPX-HUUCEWRRSA-N [N-]=[N+]=N[C@@H]1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C[C@H]1O Chemical compound [N-]=[N+]=N[C@@H]1CCN(CC2=C3C(OC4=CC=C(N)C=C4F)=NC=NN3C=C2)C[C@H]1O WHFUAXRQORIIPX-HUUCEWRRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- This invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors such as c-Met, thereby making them useful as anti-cancer agents.
- the pharmaceutical compositions that comprise these compounds are also useful in the treatment of diseases, other than cancer, which are associated with signal transduction pathways operating through growth factor and anti-angiogenesis receptors such as c-Met.
- Hepatocyte growth factor also known as scatter factor (SF)
- SF scatter factor
- HGF initiates these physiological processes through high affinity binding to its cognate receptor, the Met protein tyrosine kinase receptor, an identified protooncogene (Park et al., Proc. Natl. Acad. Sci. USA 84:6379-83, 1987 and Bottaro et al., Science 251:802-4, 1991).
- Met protein tyrosine kinase receptor
- the mature form of Met consists of a highly glycosylated external ⁇ -subunit as well as a ⁇ -subunit with a large extracellular domain, a transmembrane segment and a cytoplasmic tyrosine kinase domain.
- Ligand engagement induces Met dimerization that results in an autophosphorylated activated receptor.
- Activation of Met promotes signal transduction cascades as defined by transphosphorylation of key cytoplasmic tyrosine residues responsible for recruiting multiple effector proteins (Furge et al., Oncogene 19:5582-9, 2000). These include the p85 subunit of the PI3-kinase, phospholipase C ⁇ (Gaul et al., Oncogene 19:1509-18, 2000), Grb2 and Shc adaptor proteins, the protein phosphatase SHP2 and Gab1. The latter adapter has emerged as the major downstream docking molecule that becomes tyrosine phosphorylated in response to ligand occupancy (Schaeper et al., J. Cell Biol.
- Met also referred to as hepatocyte growth factor receptor (HGFR)
- HGFR hepatocyte growth factor receptor
- HGF hepatocyte growth factor receptor
- HCC hepatocellular carcinomas
- Met has also been identified in ovarian cancer, childhood HCC, gastric carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, colorectal metastasis (Christensen et al., Cancer Res., 63:7345-55, 2003; Lee et al., Oncogene, 19:4947-53, 2000 and Direnzo et al., Clin. Cancer Res., 1:147-54, 1995).
- further evidence supporting the role of the Met in cancer is based on the overexpression of HGF and Met receptor in various tumors including thyroid, ovarian and pancreatic carcinomas. It has also been demonstrated to be amplified in liver metastases of colorectal carcinomas (Rong et al.
- TPR-Met an activated form similar to BCR/Abl in CML
- PNAS 88:4892-6 1991
- expression of either the receptor or ligand is a predictor of decreased survival, further linking Met to tumor progression (Camp et al., Cancer 86:2259-65 1999 and Masuya et al., Br. J. Cancer, 90:1555-62, 2004).
- most human tumors and tumor cell lines of mesenchymal origin inappropriately express HGFR and/or HGF.
- Biological agents such as ribozymes, antibodies and antisense RNA targeting either HGF or Met have been shown to inhibit tumorogenesis (Stabile et al., Gene Therapy, 11:325-35, 2004, Jiang et al., Clin. Cancer Res, 9:4274-81, 2003 and Genentech U.S. Pat. No. 6,214,344, 2001).
- selective, small molecule kinase modulators targeting Met are expected to have therapeutic potential for the treatment of cancers in which Met receptor activation plays a critical role in the development and progression of primary tumors and secondary metastases.
- HGF is also known to regulate angiogenesis, a process critical in tumor growth and dissemination. Therefore, there is a potential for this class of modulators to impact angiogenesis-dependent diseases as well that may include among others, diabetic retinopathy, macular degeneration, obesity and inflammatory disease such as rheumatoid arthritis.
- the present invention is directed to compounds having the following Formulas I and II: including pharmaceutically acceptable salts, enantiomers, diastereomers, and solvates thereof, wherein:
- R 1 is an optionally substituted C 1-6 alkyl, alkenyl, alkynyl, optionally substituted C 3-7 cycloalkyl, C 3-7 eterocycloalkyl, optionally substituted phenyl, optionally substituted biphenyl, or a C 5 to C 11 optionally substituted monocyclic or bicyclic heteroaryl.
- R 1 is phenyl, optionally substituted with at least one of Cl, F, OCH 3 , C 1-4 alkyl, alkenyl, alkynyl, CN, hydroxy, amido, phenoxy, CH 2 CN, benzyl, NHCO 2 CH 3 ; biphenyl, pyridyl, azepanyl, pyrazolyl, thiazolyl, indolyl, indazolyl, indenyl, cyclopropyl, isopropyl, phenylethyl, aminoalkyl, benzyl, amidoalkyl, morpholine, and furanylmethyl.
- R 2 is H, alkoxy, halo, methyl, haloalky or CN.
- R 4 is an optionally substituted phenyl, an optionally substituted pyridyl, an optionally substituted pyrrolidinyl, an optionally substituted pyridyl-N-oxy, or an optionally substituted pyridinone, wherein said substituent is selected, for example, from hydroxyl, halo, C 1 to C 4 alkyl, C 3 to C 7 cycloalkyl, CN, alkylthio, alkoxy, phenyl, amino, heterocycloalkyl, aminoalkylamino and alkylaminoalkoxy.
- the substituent is F, Br, Cl, methyl, pentyl, methoxy, phenyl, morpholinyl, NH 2 , or NHCHNH 2 .
- A is one of the following:
- R 19 is H or CN and R 16 , R 17 , and R 18 are independently H, C 1 to C 4 alkyl, C 1 to C 4 alkoxy, or —C(O) 2 R 29 wherein R 29 is C 1 to C 4 alkyl.
- R 22 and R 61 are H.
- R 68 , R 69 and R 70 are H;
- R 20 is C 1 to C 4 alkyl; alkenyl; alkynyl; C 5 to C 6 heterocycloaryl; —CO(CH 2 ) 1 R 41 , wherein R 41 is C 1 to C 4 alkyl; haloalkyl; amino; alkylamino; C 5 to C 7 heterocycloalkyl; C 5 to C 7 heteroaryl; or C(O) 2 R 29 wherein R 29 is ethyl; CN; alkoxy; phenylmethyl; alkylaminoalkynyl; alkylaminoalkyl, hydroxyalkyl; or methoxyalkyl.
- Y is O or S.
- B is O.
- Z is CR 13 R 14 or NR 15 wherein R 13 , R 14 , and R 15 are each H or R 13 and R 14 together with the carbon to which they are attached form a cyclopropyl.
- the present invention is also directed to pharmaceutical compositions comprising therapeutically effective amounts of a compound of Formula I or II, or a salt or solvate thereof, together with a pharmaceutically acceptable carrier.
- the present invention also provides methods for the treatment of cancer comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of Formula I or II or a salt or solvate thereof, optionally including administering to the patient at least one additional anticancer agent.
- the present invention provides for compounds of Formulas I and II defined above, pharmaceutical compositions employing such compounds, methods of making and methods of using such compounds.
- alkyl herein alone or as part of another group refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 12 carbon atoms unless otherwise defined. Preferred alkyl groups have from 1 to 6 carbon atoms. An alkyl group is an optionally substituted straight, branched or cyclic saturated hydrocarbon group. Alkyl groups may be substituted at any available point of attachment. An alkyl group substituted with another alkyl group is also referred to as a “branched alkyl group”.
- Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the like.
- substituents include but are not limited to one or more of the following groups: alkyl, aryl, halo (such as F, Cl, Br, I), haloalkyl (such as CCl 3 or CF 3 ), alkoxy, alkylthio, hydroxy, carboxy (—COOH), alkyloxycarbonyl (—C(O)R), alkylcarbonyloxy (—OCOR), amino (—NH 2 ), carbamoyl (—NHCOOR— or —OCONHR—), urea (—NHCONHR—) or thiol (—SH).
- alkyl groups are substituted with, for example, amino, heterocycloalkyl, such as morpholine, piperazine, piperidine, azetidine, hydroxyl, methoxy, or heteroaryl groups such as pyrrolidine,
- alkenyl herein alone or as part of another group refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 12 carbon atoms and at least one carbon to carbon double bond. Alkenyl groups may also be substituted at any available point of attachment. Exemplary substituents for alkenyl groups include those listed above for alkyl groups, and especially include C 3 to C 7 cycloalkyl groups such as cyclopropyl, cyclopentyl and cyclohexyl, which may be further substituted with, for example, amino, oxo, hydroxyl, etc.
- alkynyl herein alone or as part of another group refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 12 carbon atoms and at least one carbon to carbon triple bond. Alkynyl groups may also be substituted at any available point of attachment. Exemplary substituents for alkenyl groups include those listed above for alkyl groups such as amino, alkylamino, etc.
- C 1 to C 6 alkyl means a straight or branched saturated carbon chain having from one to six carbon atoms; examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, n-pentyl, sec-pentyl, isopentyl, and n-hexyl.
- C 1 to C 6 alkyl can also refer to C 1 to C 6 alkylene which bridges two groups; examples include propane-1,3-diyl, butane-1,4-diyl, 2-methyl-butane-1,4-diyl, etc.
- C 2 to C 6 alkyenyl means a straight or branched carbon chain having at least one carbon-carbon double bond, and having from two to six carbon atoms; examples include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, and hexenyl.
- C 2 to C 6 alkenyl can also refer to C 2 to C 6 alkenediyl which bridges two groups; examples include ethylene-1,2-diyl (vinylene), 2-methyl-2-butene-1,4-diyl, 2-hexene-1,6-diyl, etc.
- C 2 to C 6 alkynyl means a straight or branched carbon chain having at least one carbon-carbon triple bond, and from two to six carbon atoms; examples include ethynyl, propynyl, butynyl, and hexynyl.
- alkoxy or “alkylthio” herein alone or as part of another group denote an alkyl group as described above bonded through an oxygen linkage (—O—) or a sulfur linkage (—S—), respectively.
- alkoxycarbonyl herein alone or as part of another group denotes an alkoxy group bonded through a carbonyl group.
- An alkoxycarbonyl radical is represented by the formula: —C(O)OR, where the R group is a straight or branched C 1-6 alkyl group, cycloalkyl, aryl, or heteroaryl.
- alkylcarbonyl herein alone or as part of another group refers to an alkyl group bonded through a carbonyl group or —C(O)R.
- alkylcarbonyloxy herein alone or as part of another group denotes an alkylcarbonyl group bonded through an oxygen linkage.
- arylalkyl herein alone or as part of another group denotes an aromatic ring bonded through an alkyl group (such as benzyl) as described above.
- aryl herein alone or as part of another group refers to monocyclic or bicyclic aromatic rings, e.g. phenyl, substituted phenyl and the like, as well as groups which are fused, e.g., napthyl, phenanthrenyl and the like.
- An aryl group thus contains at least one ring having at least 6 atoms, with up to five such rings being present, containing up to 22 atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms or suitable heteroatoms.
- halogen such as Br, F, or Cl
- alkyl such as methyl, ethyl, propyl
- alkoxy such as methoxy or ethoxy
- hydroxy carboxy
- carbamoyl alkyloxycarbonyl
- nitro alkenyloxy
- amino, cycloalkyl, aryl, heteroaryl cyano, alkyl S(O) m (
- amino herein alone or as part of another group refers to —NH 2 .
- An “amino” may optionally be substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, alkenyl, alkynyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, thioalkyl. carbonyl or carboxyl.
- substituents may be further substituted with a carboxylic acid, any of the alkyl or aryl substituents set out herein.
- the amino groups are substituted with carboxyl or carbonyl to form N-acyl or N-carbamoyl derivatives.
- cycloalkyl herein alone or as part of another group refers to fully saturated and partially unsaturated hydrocarbon rings of 3 to 9, preferably 3 to 7 carbon atoms. Further, a cycloalkyl may be substituted.
- a substituted cycloalkyl refers to such rings having one, two, or three substituents, selected from the group consisting of halo, alkyl, substituted alkyl, alkenyl, alkynyl, nitro, cyano, oxo ( ⁇ O), hydroxy, alkoxy, thioalkyl, —CO 2 H, —C( ⁇ O)H, CO 2 -alkyl, —C( ⁇ O)alkyl, keto, ⁇ N—OH, ⁇ N—O-alkyl, aryl, heteroaryl, heterocyclo, a five or six membered ketal (i.e.
- heteroaryl herein alone or as part of another group refers to substituted and unsubstituted aromatic 5 or 6 membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings.
- Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom.
- the fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated.
- the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized.
- Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic.
- the heteroaryl group may be attached at any available nitrogen or carbon atom of any ring.
- the heteroaryl ring system may contain zero, one, two or three substituents selected from the group consisting of halo, alkyl, substituted alkyl, alkenyl, alkynyl, aryl, nitro, cyano, hydroxy, alkoxy, thioalkyl, —CO 2 H, —C( ⁇ O)H, —CO 2 -alkyl, —C( ⁇ O)alkyl, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, cycloalkyl, substituted cycloalkyl, heterocyclo, heteroaryl, —NR′R′′, —C( ⁇ O)NR′R′′, —CO 2 NR′R′′, —C( ⁇ O)NR′R′′, —NR′CO 2 R′′, —NR′C( ⁇ O)R′′, —SO 2 NR′R′′, and —NR′SO 2 R′′, wherein each of R
- Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, diazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and the like.
- Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxaxolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl, dihydroisoindolyl, tetrahydroquinolinyl and the like.
- Exemplary tricyclic heteroaryl groups include carbazolyl, benzidolyl, phenanthrollinyl, acridinyl, phenanthridinyl, xanthenyl and the like.
- heterocycloalkyl herein alone or as part of another group refers to a cycloalkyl group (nonaromatic) in which one of the carbon atoms in the ring is replaced by a heteroatom selected from O, S or N, and in which up to three additional carbon atoms may be replaced by said heteroatoms.
- heterocycloalkyl herein alone or as part of another group refers to a stable, saturated, or partially unsaturated monocyclic ring system containing 5 to 7 ring members of carbon atoms and other atoms selected from nitrogen, sulfur and/or oxygen.
- a heterocyclic ring may be a 5, 6 or 7-membered monocyclic ring and contain one, two, or three heteroatoms selected from nitrogen, oxygen and/or sulfur.
- the heterocyclic ring may be optionally substituted which means that the heterocyclic ring may be substituted at one or more substitutable ring positions by one or more groups independently selected from alkyl (preferably lower alkyl), heterocycloalkyl, heteroaryl, alkoxy (preferably lower alkoxy), nitro, monoalkylamino (preferably a lower alkylamino), dialkylamino (preferably a di[lower]alkylamino), cyano, halo, haloalkyl (preferably trifluoromethyl), alkanoyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkyl amido (preferably lower alkyl amido), alkoxyalkyl (preferably a lower alkoxy[lower]alkyl), alkoxycarbonyl (
- a heteroaryl or heterocycloalkyl group may also be an 8-11 membered bicyclic ring which consists of carbon atoms and contains one, two, or three heteroatoms selected from nitrogen, oxygen and/or sulfur.
- Some preferred bicyclic rings include benzodioxole, quinoxaline, indolyl, and quinolinyl.
- heterocyclyl indicates that the heterocyclyl group may be substituted at one or more substitutable ring positions by one or more groups independently selected from alkyl (preferably lower alkyl), alkoxy (preferably lower alkoxy), nitro, monoalkylamino (preferably a lower alkylamino), dialkylamino (preferably a di[lower]alkylamino), cyano, halo, haloalkyl (preferably trifluoromethyl), alkanoyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkyl amido (preferably lower alkyl amido), alkoxyalkyl (preferably a lower alkoxy[lower]alkyl), alkoxycarbonyl (preferably a lower alkoxycarbonyl), alkylcarbonyloxy (preferably a lower alkylcarbonyloxy) and aryl (preferably phenyl), said
- heteroatom means O, S or N, selected on an independent basis. It should be noted that any heteroatom with unsatisfied valences is assumed to have the hydrogen atom to satisfy the valences.
- halogen refers to chlorine, bromine, fluorine or iodine selected on an independent basis.
- anticancer agent includes any known agent that is useful for the treatment of cancer including 17 ⁇ -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyl-testosterone, Prednisolone, Triamcinolone, chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, Zoladex, matrix metalloproteinase inhibitors, VEGF inhibitors, including as anti-VEGF antibodies such as Avastin, and small molecules such as ZD6474 and SU6668, vatalanib, BAY-43-9006, SU11248, CP-547632, and CEP-7055 are also included.
- Anti-Her2 antibodies from Genentech may also be utilized.
- Suitable EGFR inhibitors include gefitinib, erlotinib, and cetuximab.
- Pan Her inhibitors include canertinib, EKB-569, and GW-572016.
- Src inhibitors dasatinib (BMS-354825) as well as Casodexe (bicalutamide, Astra Zeneca), Tamoxifen, MEK-1 kinase inhibitors, MAPK kinase inhibitors, PI3 inhibitors, and PDGF inhibitors, such as imatinib.
- anti-angiogenic and antivascular agents which, by interrupting blood flow to solid tumors, render cancer cells quiescent by depriving them of nutrition. Castration, which also renders androgen dependent carcinomas non-proliferative, may also be utilized.
- IGF1R inhibitors inhibitors of non-receptor and receptor tyrosine kinases, and inhibitors of integrin signaling.
- Additional anticancer agents include microtubule-stabilizing agents such as paclitaxel (also known as Taxol®), docetaxel (also known as Taxotere®), 7-O-methylthiomethylpaclitaxel (disclosed in U.S. Pat. No.
- CDK inhibitors an antiproliferative cell cycle inhibitor, epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic growth factors.
- cytotoxic agents include, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, topotecan, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons, and interleukins.
- Pyridine-N-oxy refers to a pyridine ring having an oxygen substituted on the N atom of the pyridine ring.
- protecting groups for the compounds of the present invention will be recognized from the present application taking into account the level of skill in the art, and with reference to standard textbooks, such as Greene, T. W. et al., Protective Groups in Organic Synthesis , Wiley, N.Y. (1991).
- patient encompasses all mammalian species.
- phrases “pharmaceutically acceptable salt(s)”, as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be present in the compounds of formulas I and II.
- the compounds of formulas I and II that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
- acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of formulas I and II are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphth
- the compounds of the present invention have the following Formula I or II: including pharmaceutically acceptable salts thereof, wherein:
- the invention also provides a method for treating a proliferative disease, such as cancer, by administering to a patient in need of such treatment an effective amount of a compound of formula I or II, as defined above.
- the invention provides a method for treating a proliferative disease via modulation of Met kinase by administering to a patient in need of such treatment an effective amount of a compound of formula I or II, as defined above, in combination (simultaneously or sequentially) with at least one other anti-cancer agent.
- the proliferative disease is cancer.
- the invention further provides pharmaceutical compositions comprising compounds having formula I or II together with a pharmaceutically acceptable carrier.
- the compounds of Formulas I and II are useful in the treatment of a variety of cancers, including, but not limited to, the following:
- inhibitors could act as reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., benign prostatic hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections.
- benign prostatic hyperplasia familial adenomatosis polyposis
- neuro-fibromatosis e.g., atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery
- hypertrophic scar formation e.g., benign prostatic hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis,
- Compounds of Formulas I and II as modulators of apoptosis will be useful in the treatment of cancer (including but not limited to those types mentioned herein above), viral infections (including but not limited to herpevirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus), prevention of AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus, erythematosus, autoimmune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and autoimmune diabetes mellitus), neurodegenerative disorders (including but not limited to Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion injury, arrhythmi
- Compounds of Formulas I and II may modulate the level of cellular RNA and DNA synthesis. These agents would therefore be useful in the treatment of viral infections (including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus).
- viral infections including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus.
- Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells that have already suffered an insult or inhibiting tumor relapse.
- Compounds of Formulas I and II may also be useful in inhibiting tumor angiogenesis and metastasis.
- Some compounds of the present invention have been found to inhibit protein kinases other than Met, such as those in the Trk family of protein kinases.
- the compounds of this invention may also be useful in combination (administered together or sequentially) with known anti-cancer treatments such as radiation therapy or with cytostatic or cytotoxic agents, such as for example, but not limited to, DNA interactive agents, such as cisplatin or doxorubicin; topoisomerase II inhibitors, such as etoposide; topoisomerase I inhibitors such as CPT-11 or topotecan; tubulin interacting agents, such as paclitaxel, docetaxel or the epothilones (for example ixabepilone), either naturally occurring or synthetic; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors, such as 5-fluorouracil; and anti-metabolites, such as methotrexate, other tyrosine kinase inhibitors such as Iressa and OSI-774; angiogenesis inhibitors; EGF inhibitors; VEGF inhibitors; CDK inhibitors; SRC inhibitors; c
- compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, microcrystalline cellulose, sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to mask the unpleasant taste of the drug or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a water soluble taste masking material such as hydroxypropyl-methylcellulose or hydroxypropyl-cellulose, or a time delay material such as ethyl cellulose, cellulose acetate buryrate may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monoo
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
- preservatives for example ethyl, or n-propyl p-hydroxybenzoate
- coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
- flavoring agents such as sucrose, saccharin or aspartame.
- sweetening agents such as sucrose, saccharin or aspartame.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
- These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisol or alpha-tocopherol.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- the pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening, flavoring agents, preservatives and antioxidants.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
- compositions may be in the form of a sterile injectable aqueous solutions.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- the sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase.
- the active ingredient may be first dissolved in a mixture of soybean oil and lecithin. The oil solution then introduced into a water and glycerol mixture and processed to form a microemulation.
- the injectable solutions or microemulsions may be introduced into a patient's blood-stream by local bolus injection. Alternatively, it may be advantageous to administer the solution or microemulsion in such a way as to maintain a constant circulating concentration of the instant compound.
- a continuous intravenous delivery device may be utilized.
- An example of such a device is the Deltec CADD-PLUS.TM. model 5400 intravenous pump.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension for intramuscular and subcutaneous administration.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- Compounds of Formulas I and II may also be administered in the form of a suppositories for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
- topical use creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
- the compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles and delivery devices, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art.
- the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
- Compounds of the present invention may also be delivered as a suppository employing bases such as cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
- the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, sex and response of the individual patient, as well as the severity of the patient's symptoms.
- Such combination products employ the compounds of this invention within the dosage range described above and the other pharmaceutically active agent or treatment within its approved dosage range.
- Compounds of Formulas I and II may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of Formulas I and II may be administered either prior to or after administration of the known anticancer or cytotoxic agent(s).
- Certain compounds of Formulas I and II may generally be prepared according to the following Schemes 1-16.
- the compounds are synthesized readily using synthetic methods known to one skilled in the art.
- Tautomers and solvates e.g., hydrates
- Methods of solvation are generally known in the art. Accordingly, the compounds of the instant invention may be in the free or hydrate form, and may be obtained by methods exemplified by the following schemes below.
- the desired fused heterocycles can be prepared using the synthetic routes outlined in Schemes 1-3.
- the leaving group (Lg), such as a halogen (or triflate) of a heterocycle (A, whereby open positions may be optionally substituted) 1 can be displaced with a substituted phenol 2 to provide ether 3 (Scheme 1).
- Groups A-Lg can be prepared according to the general procedures outlined in, for example, Hunt, J. T. et al. WO 00/071129; Hunt, J. T. et al. J. Med. Chem. 2004, 47, 4054-4059; Leftheris, K et al. WO 02/040486; Mastalerz, H. et al.
- Reaction of intermediate 8 with a heterocycle (A-Lg) 1 can provide the desired compound 6.
- amide derivatives described in the invention can be prepared using the chemistry outlined in Scheme 3.
- aniline 9 (derived from Scheme 1) can be acylated with compound 10 to provide amide 11.
- Hydrolysis of the ester 11 with, for example sodium hydroxide can afford carboxylic acid 12.
- Desired compound 13 can then be obtained from intermediate 12 using known amide-bond forming conditions.
- aniline 9 can be converted directly to compound 13 using carboxylic acid 14 and a coupling agent, such as benzotriazol-1-yloxytris(trimethylamino)phosphonium hexafluorophosphate, 1-(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, or bromotripyrrolidinophosphonium hexafluorophosphate.
- a coupling agent such as benzotriazol-1-yloxytris(trimethylamino)phosphonium hexafluorophosphate, 1-(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, or bromotripyrrolidinophosphonium hexafluorophosphate.
- a substituted heterocyclic derivative for example pyrrolotriazine compound 26a/b (Scheme 5), can be prepared using the synthetic routes outlined in Schemes 4 and 5.
- Carboxylic esters, wherein R can be an alkyl or an aryl (such as phenyl) 17 can be contacted with no less than 2 equivalents of an alkyl or aryl organometallic agent such as a Grignard reagent, organolithium, organozinc, etc. to produce the tertiary alcohol 18 (Scheme 4).
- the reaction is generally performed in an ether solvent, such as tetrahydrofuran, dibutylether, or diethyl ether, or any other non-reactive solvent such as benzene, toluene, or hexane, for example.
- Tertiary alcohol 18 can be treated with a mixture of acid in the presence of hydrogen peroxide or organic peroxides such as t-butylhydroperoxide, cumenehydroperoxide to affect the rearrangement to hydroxypyrrolotriazine 19. Almost any acid could be used as the catalyst for the oxidative rearrangement, the reaction has been demonstrated with organic acids, mineral acids, and Lewis acids.
- Some acids which have been used for this type of reaction include: p-toluenesulfonic acid, methansulfonic acid, formic acid, sulfuric acid, nitric acid, BF 3 —OEt 2 , trifluoroacetic acid, acidic zeolites, and acidic ion exchange resins.
- the concentration of the acid can be varied, the concentration and strength of the acid is used to control the kinetics of the reaction.
- the concentration of the peroxide can be varied from 30-50%.
- Any reducing agent which reacts to decompose hydrogen peroxide could be used in the quenching of this reaction, including, but not limited to sodium metabisulfite, sodium hydrogen sulfite, sodium thiosulfate, sodium hydrosulfite.
- a variety of bases can be used while quenching the reaction to control the pH.
- Hydroxypyrrolotriazine 19 can be reacted with a variety of acylating reagents, to furnish 20 (where, for example, P can be pivalate ester).
- POCl 3 phosphorous oxychloride
- Other reagents can be used to accomplish this transformation besides POCl 3 , including PCl 5 , mixtures of PCl 5 /POCl 3 , PhP(O)Cl 2 , SOCl 2 .
- an amine is used to catalyze the reaction, including Et 3 N, PhNMe 2 , DABCO, etc.
- formamides such as, for example N,N-dimethylformamide and alkylamides such as N-methylpyrrolidinone can also be used to catalyze the reaction.
- the reaction can be run in any solvent inert to the haloginating agent, including benzene, toluene, THF, etc.
- the appropriately protected imidate 21 (Scheme 5) can be treated with an optionally substituted phenol 2 to provide intermediate 22.
- Amine compounds 30 can be prepared using the chemistry described in Scheme 6. Reduction of ester 27 with for example, diisobutylaluminum hydride (DIBAL-H) can provide alcohol 28. Oxidation of compound 28 with for example Dess-Martin periodinane (1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one) can afford aldehyde 29. Reductive amination of aldehyde 29 with an appropriately substituted amine in the presence of a reducing agent, such as sodium triacetoxyborohydride can furnish the desired amine 30.
- DIBAL-H diisobutylaluminum hydride
- substituents such as optionally substituted aryl, heteroaryl or vinyl groups can be introduced onto the 5-position of the pyrrolo[2,1-f][1,2,4]triazine ring using the chemistry outlined in Scheme 7.
- the aminopyrrole derivative 31 can be cyclized in the presence of formamide to produce 5-chloropyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (32).
- Treatment of intermediate 32 with POCl 3 in the presence of a base, such as Hunig's base at elevated temperatures can afford 4,5-dichloropyrrolo[2,1-f][1,2,4]triazine (33).
- the coupling of an appropriately substituted phenol 2 with compound 33 in the presence of a base, such as potassium carbonate can provide intermediate 34.
- the nitro group of 34 can be reduced using zinc dust and ammonium chloride to generate the aniline 35.
- Palladium-mediated coupling reactions with various boronic acids can provide intermediate 36, which can be converted to the desired compounds 37 or 38 using chemistry described above.
- Substitution at the 5-position of the pyrrolo[2,1-f][1,2,4]triazine ring can also be accomplished by coupling the triethylammonium salt 39 with an appropriately substituted phenol 7 followed by treatment with an amine (HNR′R′′) in the presence of a base, such as Hunig's base to afford the aniline 40 (Scheme 8).
- Aniline 40 can be further processed as described previously to produce the desired compounds 41 or 42.
- 5-methyl-4-(methylthio)pyrrolo[2,1-f][1,2,4]triazine (43) can be brominated with, for example N-bromosuccinimide (NBS) and 2,2-azobisisobutyronitrile (AIBN) in carbontetrachloride at elevated temperatures (Scheme 9).
- N-bromosuccinimide N-bromosuccinimide
- AIBN 2,2-azobisisobutyronitrile
- HNR′R′′ an amine
- Oxidation of the thiomethyl group of 44 can be accomplished with, for example 3-chloroperbenzoic acid (m-CPBA).
- Treatment of the sulfone intermediate with the phenoxide generated from compound 7 and sodium bis(trimethylsilyl)amide (NaHMDS) can provide the aniline intermediate 45.
- the pyrrolo[2,3-b]pyridine intermediate 50 can be prepared using chemistry outlined in Scheme 10.
- 4-Chloro-1H-pyrrolo[2,3-b]pyridine (49) can be obtained from commercially available 1H-pyrrolo[2,3-b]pyridine (46) using the synthetic sequence described by Thibault C. and coworkers ( Org. Lett. 2003, 5, 5023-5025) which is illustrated in Scheme 10.
- Treatment of intermediate 49 with the phenol 2 at elevated temperatures can afford the key intermediate 50, which can be converted to the desired compounds using chemistry described in Schemes 1 and 3.
- intermediate 55 protection of compound 50 with, for example (2-(chloromethoxy)ethyl)trimethylsilane in the presence of a base, such as sodium hydride, followed by bromination with NBS can provide intermediate 55 (Scheme 12).
- the bromide 55 can then be treated with substituted alkynes 56, arylboronates/arylboronic acids 57, or vinylstannanes 58 in the presence of a palladium and/or copper catalyst to afford the intermediates 59-61, respectively.
- Removal of the protecting group of 59-61 with tetrabutylammonium fluoride (TBAF) followed by reduction of the nitro groups can provide the corresponding aniline intermediates, which can be acylated using chemistry previously described in Schemes 1 and 3.
- TBAF tetrabutylammonium fluoride
- compound 62 can be converted to iodide 68 using chemistry described in Scheme 14.
- Intermediate 68 can be coupled with a variety of reagents, such boronic acids, organostannes or substituted olefins in the presence of a transition metal catalyst [i.e., Pd(OAc) 2 —cf. Chi, S. M. et al. Tetrahedron Lett. 2000, 919-922] to give 69.
- Intermediate 69 can be converted to the desired analogues using chemistry previously described.
- the pyridinone intermediate 74 can be obtained by a two step process beginning with commercially available (E)-dimethyl 2-(3-methoxyallylidene)malonate (70) (Scheme 15).
- E E-dimethyl 2-(3-methoxyallylidene)malonate
- reaction of compound 70 with an amine or aniline 71 at room temperature can provide intermediate 72, which can then be cyclized in the presence of a base, such as sodium hydride in dimethylsulfoxide to generate 73.
- Hydrolysis of intermediate 73 under basic conditions can provide the desired pyridinone intermediate 74, which can be coupled to various anilines as described in the aforementioned Schemes.
- the pyridyl N-oxide intermediate 78 (Scheme 16) can be obtained by a two-step process in which the commercially available 6-bromopicolinic acid (75) is coupled with boronic acid or borinate 76 in the presence of a palladium(0) catalyst and sodium carbonate, followed by oxidation of the requisite intermediate 77 at elevated temperature. Intermediate 78 can then be coupled to various anilines as described in the aforementioned Schemes.
- the pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological assays.
- the exemplified pharmacological assays which follow have been carried out with the compounds according to the invention and/or their pharmaceutically acceptable salts.
- Incubation mixtures employed for the Met kinase assay contain the synthetic substrate polyGlu:Tyr, (4:1), ATP, ATP- ⁇ - 33 P and buffer containing Mn ++ and/or Mg ++ , DTT, BSA, and Tris buffer. Reactions are incubated for 60 minutes at 27° C. and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration 4%.
- TCA cold trichloroacetic acid
- TCA precipitates are collected onto GF/C unifilter plates (Packard Instrument Co., Meriden, Conn.) using a Filtermate universal harvester (Packard Instrument Co., Meriden, Conn.) and the filters are quantitated using a TopCount 96-well liquid scintillation counter (Packard Instrument Co., Meriden, Conn.).
- Dose response curves are generated to determine the concentration required to inhibit 50% of kinase activity (IC 50 ).
- Compounds are dissolved at 10 mM in dimethyl sulfoxide (DMSO) and evaluated at six concentrations, each in quadruplicate. The final concentration of DMSO in the assay is 1%.
- the compounds of the invention inhibit the Met kinase enzyme with IC 50 values between 0.01 to 100
- Preferred compounds have IC 50 values less than 1.0 ⁇ M, and more preferably, less than about 0.5 ⁇ M.
- A 90% H 2 O/MeOH+0.2% H 3 PO 4
- Boc or BOC t-butyl carbamate
- Fmoc 9H-fluorenylmethyl carbamate
- NMM N-methylmorpholine
- Ms methanesulfonyl
- DIEA or DIPEA diisopropylethylamine or Hunig's base
- NMP N-methylpyrrolidinone
- BOP reagent benzotriazol-1-yloxytris(trimethylamino)phosphonium hexafluorophosphate
- DCC 1,3-dicyclohexylcarbodiimide
- EDCI 1-(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
- RT room temperature
- t R retention time
- h hour(s); min: minute(s)
- PyBrOP bromotripyrrolidinophosphonium hexafluorophosphate
- a mixture of 1.9 kg of 5-methyl-4-oxo-3,4-dihydro-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester, prepared generally according to the procedures described in, U.S. patent application Ser. No. 09/573,829, and 17.9 kg of THF was prepared under an inert atmosphere and cooled to ⁇ 10° C.
- To this mixture was added 14.2 kg methylmagnesium chloride as a 3 M solution in THF at a rate to maintain the reaction temperature ⁇ 35° C. The reaction mixture was held at 25-45° C. until complete, then cooled to 0° C.
- a solution of 9.9 kg ammonium chloride in 36.7 kg water was prepared and cooled to 5° C.
- the organic reaction mixture was added to the ammonium chloride solution at a rate to maintain the internal temperature ⁇ 15° C.
- the phases were allowed to settle and the lower aqueous phase drained off and re-extracted with 9.5 kg additional THF.
- To the combined organic phases was added 8.6 kg EtOAc and the mixture washed with 7.6 kg of saturated aqueous sodium chloride solution.
- the reaction mixture was filtered, then solvent was removed in vacuo (temperature ⁇ 40° C.) to about 1 ⁇ 3 the original volume. Additional EtOAc was added with continuing distillation until the THF level was ⁇ 7%.
- reaction mixture was quenched, while keeping it at ⁇ 2° C., by adding it portion wise to a cooled solution of 28.5 mL water, 89 g NaHSO 3 and 128 mL 28% aqueous ammonium hydroxide over 40 min, at 15° C. to 25° C.
- the mixture was stirred at room temperature for 20 min; pH was 6.80 and a peroxide test was negative.
- the layers were separated and the aqueous layer was extracted with 100 mL THF. The two organic layers were combined and concentrated, removing 280 mL solvent.
- Example 10 In a similar manner as described for the preparation of Example 10, the title compound was prepared from commercially available 4-chloro-5-methylthieno[2,3-d]pyrimidine and 1-(3-fluoro-4-hydroxyphenyl)-3-(2-(4-fluorophenyl)acetyl)thiourea (24 mg, 0.075 mmol, Compound A of Example 3).
- the above ester was dissolved in 100 mL of ethanol and cooled to 0° C. 1 N aq NaOH solution (100 mL) was added and the reaction was stirred at 0° C. for 1 h. The reaction was concentrated to remove ethanol. The aqueous solution was extracted with EtOAc (50 mL) and was then made acidic with 1 N aq HCl solution. The aqueous solution was extracted with EtOAc (5 ⁇ 100 mL). The combined organic extracts were dried over anhydrous Na 2 SO 4 and concentrated in vacuo to give the crude product (6.31 g, 84%) as a yellow solid which was used without further purification.
- N 1 -(3-Fluoro-4-hydroxyphenyl)-N 3 -(4-fluorophenyl)malonamide 46 mg, 0.15 mmol
- 4-chlorothieno[3,2-d]pyrimidine 17.1 mg, 0.10 mmol
- cesium carbonate 49 mg, 0.15 mmol
- copper(I) chloride 10 mg, 0.10 mmol
- the tube was sealed, flushed with nitrogen, charged with 1-methyl-2-pyrrolidinone (0.3 mL) followed by 2,2,6,6-tetramethyl-3,5-heptanedione (4.0 ⁇ L, 0.02 mmol). The reaction was stirred at 120° C. for 2 h.
- the reaction mixture was purified by preparative HPLC. The appropriate fraction was concentrated to remove methanol and the resulting aqueous solution was made basic with saturated NaHCO 3 solution (5 mL). The aqueous solution was extracted with EtOAc (3 ⁇ 10 mL) and the combined organic extracts were dried over anhydrous Na 2 SO 4 and concentrated in vacuo to give the desired product as a colorless oil. Lyophilization with methanol/water gave the title compound (23 mg, 52%) as a white solid.
- N 1 -(3-Fluoro-4-hydroxyphenyl)-N 3 -(4-fluorophenyl)malonamide 46 mg, 0.15 mmol, Compound B of Example 25
- 4-chlorothieno[2,3-d]pyrimidine 17. mg, 0.10 mmol
- cesium carbonate 49 mg, 0.15 mmol
- copper(I) chloride 10 mg, 0.10 mmol
- the tube was sealed, flushed with nitrogen, charged with 1-methyl-2-pyrrolidinone (0.3 mL) followed by 2,2,6,6-tetramethyl-3,5-heptanedione (4.0 ⁇ L, 0.02 mmol). The reaction was stirred at 120° C.
- triphenylphosphine 3 mmol triphenylphosphine per 1 g of resin, 583 mg, 1.75 mmol
- diethylazodicarboxylate 138 ⁇ L, 0.87 mmol
- 3-dimethyl-aminopropanol 103 ⁇ L, 0.87 mmol
- the solution was directly subject to preparative HPLC purification and the HPLC fraction containing the desired product was passed through a Waters Oasis® MCX 20 cc 500 mg LP Extraction cartridge and washed with MeOH to remove TFA. After that, the cartridge was eluted with 7 N NH 3 in MeOH and the ammonia solution was concentrated under reduced pressure to dryness. The residue was then suspended in a mixture of MeOH and H 2 O and a few drops of 1 N HCl was added. The suspension became a clear solution and it was frozen in dry ice-acetone bath. The frozen solution was then lyophilized to afford the title compound (20 mg, 80%).
- Examples 54 to 85 illustrated in Table 1 below were synthesized from 3-fluoro-4-(5-methylpyrrolo[2,1-][1,2,4]triazin-4-yloxy)benzenamine (Compound B of Example 28) using one equivalent of the corresponding carboxylic acid, (1 eq) PyBrOP (1 eq), DIEA (1 eq) in DMF.
- the reaction mixture was heated to 70° C. and the crude products were purified by preparative HPLC (H 2 O/MeOH/0.1% TFA, gradient 35-90% MeOH over 10 min, 20 ⁇ 100 mm 5 ⁇ m YMC ODS-A column) utilizing mass-directed fractionation.
- the purified sample was reconstituted in 1:1/MeOH:DCE, transferred to a tared 2.5 mL plastic microtube, dried via centrifugal evaporation, weighed and analyzed by LCMS (H 2 O/MeOH/0.1% TFA).
- the crude product in DCE was diluted to a volume of 1 mL with methanol, then purified by standard preparative HPLC (H 2 O/MeOH/0.1% TFA, gradient 35-90% MeOH over 10 min, 20 ⁇ 100 mm 5 ⁇ m YMC ODS-A column) utilizing mass-directed fractionation.
- the purified sample was reconstituted in 1:1/MeOH:DCE, transferred to a tared 2.5 mL plastic microtube, dried via centrifugal evaporation, weighed and analyzed by LCMS (H 2 O/MeOH/0.1% TFA).
- Example 134 In a similar manner as described for the preparation of Example 134, the title compound was isolated as a TFA salt and was prepared using commercially available nicotinyl chloride and 4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-3-fluorobenzenamine (Compound B, Example 132). Yield: 55%.
- a flask was charged with palladium acetate (4.5 mg, 0.02 mmol), X-Phos ligand (24 mg, 0.05 mmol, Strem), 4-(5-chloropyrrolo[2,1-f][1,2,4]triazin-4-yloxy)-3-fluorobenzenamine (56 mg, 0.20 mmol), 3-acetamidobenzene boronic acid (72 mg, 0.40 mmol, Lancaster), and potassium phosphate (127 mg, 0.60 mmol) in that order.
- the flask was flushed with nitrogen and then t-BuOH was added (0.40 mL). The mixture was heated at 80° C. for 8 h.
- Examples 139-144 were prepared in a manner similar to Example 138.
- N 1 -(3-fluoro-4-(5-((4-oxocyclohexylidene)methyl)pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)phenyl)-N-3-(4-fluorophenyl)malonamide 80 mg, 0.15 mmol, Example 149) in methanol (2 mL) at 0° C. was added a spatula tip of sodium borohydride. The reaction was stirred at 0° C. for 30 min and was then quenched with saturated aqueous ammonium chloride solution (10 mL) and stirred at 0° C. for 5 min.
- N 1 -(3-fluoro-4-(5-((4-oxocyclohexylidene)methyl)pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)phenyl)-N-3-(4-fluorophenyl)malonamide (20 mg, 0.038 mmol, Example 149) in dichloroethane (1 mL) was added methylamine (23 ⁇ L, 0.045 mmol, 2 M THF), acetic acid (2.6 ⁇ L, 0.045 mmol), followed by sodium triacetoxyborohydride (13 mg, 0.056 mmol).
- Boc protected material 33 mg, 59%) as a colorless oil.
- the Boc protected material was suspended in ether (2 mL) at 0° C. and charged with 4 N HCl in dioxane (5 mL). After stirring at 0° C. for 1.5 h, the reaction was concentrated in vacuo.
- the crude product was purified by reverse phase prep HPLC and the appropriate fractions were concentrated in vacuo. Toluene was added (2 ⁇ 2 mL) and concentrated to give the TFA salt of the title compound (3 mg, 8%) as a white solid.
- the acylurea was prepared in a similar manner as Example 155 to give the corresponding azide (48%). MS(ESI + ) m/z 578.16 (M+H) + .
- the azide 35 mg, 0.06 mmol was then dissolved in ethyl acetate (1 mL) at 0° C. and charged with trimethylphosphine (0.11 mL, 0.11 mmol) followed by water (1 drop). After stirring at rt for 3 h, the reaction was concentrated in vacuo and purified by reverse phase prep HPLC. The appropriate fractions were concentrated in vacuo and toluene was added (2 ⁇ 2 mL) and concentrated to give the TFA salt of the title compound (8 mg, 17%) as a white solid.
- the examples 174-236 illustrated in Table 3 were prepared from 3-(4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-3-fluorophenylamino)-3-oxopropanoic acid (Compound A of Example 173) and the corresponding amines, in the presence of HATU, DIPEA, and DMAP in DMF.
- the crude products were purified by prep-HPLC (H 2 O/MeOH/0.1% TFA, gradient 35-90% MeOH over 10 min, 20 ⁇ 100 mm 5 ⁇ m YMC ODS-A column).
- the desired fraction(s) was/were centrifugally evaporated, weighed and analyzed by LCMS (H 2 O/MeOH/0.1% TFA).
- Argon was bubbled through a mixture of 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-2-ylboronic acid (5.55 g, 17 mmol), 3-iodopyridine (6.97 g, 34 mmol), Pd(OAc) 2 , 2-dicyclohexylphosphino-2′,4′,6′-tri-1-propyl-1,1′-biphenyl (405 mg, 0.85 mmol), and K 3 PO 4 (2 M in H 2 O, 34 mmol) in DME (50 mL) for 10 min and then heated at reflux overnight.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/167,043 US20050288290A1 (en) | 2004-06-28 | 2005-06-24 | Fused heterocyclic kinase inhibitors |
US11/292,358 US7439246B2 (en) | 2004-06-28 | 2005-12-01 | Fused heterocyclic kinase inhibitors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58345904P | 2004-06-28 | 2004-06-28 | |
US61256304P | 2004-09-23 | 2004-09-23 | |
US11/167,043 US20050288290A1 (en) | 2004-06-28 | 2005-06-24 | Fused heterocyclic kinase inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/292,358 Continuation-In-Part US7439246B2 (en) | 2004-06-28 | 2005-12-01 | Fused heterocyclic kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050288290A1 true US20050288290A1 (en) | 2005-12-29 |
Family
ID=35457856
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/167,049 Active US7173031B2 (en) | 2004-06-28 | 2005-06-24 | Pyrrolotriazine kinase inhibitors |
US11/167,043 Abandoned US20050288290A1 (en) | 2004-06-28 | 2005-06-24 | Fused heterocyclic kinase inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/167,049 Active US7173031B2 (en) | 2004-06-28 | 2005-06-24 | Pyrrolotriazine kinase inhibitors |
Country Status (14)
Country | Link |
---|---|
US (2) | US7173031B2 (de) |
EP (3) | EP1768983A2 (de) |
JP (3) | JP4860609B2 (de) |
KR (3) | KR20070028458A (de) |
AR (2) | AR050254A1 (de) |
AU (2) | AU2005260056B2 (de) |
BR (1) | BRPI0512722A (de) |
CA (1) | CA2571680A1 (de) |
IL (1) | IL180325A0 (de) |
MX (2) | MXPA06015032A (de) |
NO (3) | NO20070453L (de) |
PE (2) | PE20060374A1 (de) |
TW (2) | TW200604184A (de) |
WO (3) | WO2006004884A2 (de) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050239820A1 (en) * | 2004-04-26 | 2005-10-27 | Borzilleri Robert M | Bicyclic heterocycles as kinase inhibitors |
US20050245530A1 (en) * | 2004-04-23 | 2005-11-03 | Borzilleri Robert M | Monocyclic heterocycles as kinase inhibitors |
US20050288289A1 (en) * | 2004-06-28 | 2005-12-29 | Gerard Crispino | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US20060004006A1 (en) * | 2004-06-28 | 2006-01-05 | Borzilleri Robert M | Pyrrolotriazine kinase inhibitors |
US20060074056A1 (en) * | 2004-07-30 | 2006-04-06 | Methylgene, Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
US20060241104A1 (en) * | 2005-04-21 | 2006-10-26 | Borzilleri Robert M | Oxalamide derivatives as kinase inhibitors |
US20060287343A1 (en) * | 2005-05-20 | 2006-12-21 | Methylgene, Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
US20070004675A1 (en) * | 2005-05-20 | 2007-01-04 | Methylgene, Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
US20070060613A1 (en) * | 2005-09-14 | 2007-03-15 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007081690A2 (en) * | 2006-01-04 | 2007-07-19 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US20070244116A1 (en) * | 2003-09-26 | 2007-10-18 | Exelixis, Inc. | c-MET MODULATORS AND METHOD OF USE |
US20080064718A1 (en) * | 2006-03-22 | 2008-03-13 | Saavedra Oscar M | Inhibitors of protein tyrosine kinase activity |
US20080114033A1 (en) * | 2006-11-08 | 2008-05-15 | Bristol-Myers Squibb Company | Pyridinone compounds |
US20090209555A1 (en) * | 2006-05-08 | 2009-08-20 | Peter Hansen | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial |
US20090270391A1 (en) * | 2005-03-28 | 2009-10-29 | Kirin Pharma Kabushiki Kaisha | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY |
JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
US20100022529A1 (en) * | 2008-07-24 | 2010-01-28 | Tiechao Li | Amidophenoxyindazoles useful as inhibitors of c-met |
US7723330B2 (en) | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
US20100144730A1 (en) * | 2006-06-30 | 2010-06-10 | Sunesis Phamaceuticals | Pyridinonyl pdk1 inhibitors |
US20100216843A1 (en) * | 2009-02-20 | 2010-08-26 | Astrazeneca R&D | Novel salt 628 |
US20110034416A1 (en) * | 2008-01-23 | 2011-02-10 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
WO2011022028A2 (en) * | 2009-05-18 | 2011-02-24 | Tufts University | Small molecule antagonists of phosphatidylinositol-3, 4, 5-triphosphate (pip3) and uses thereof |
US20110077240A1 (en) * | 2008-03-05 | 2011-03-31 | Michael Mannion | Inhibitors of protein tyrosine kinase activity |
US20110224197A1 (en) * | 2008-03-10 | 2011-09-15 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
US8471005B2 (en) | 2008-12-19 | 2013-06-25 | Cephalon, Inc. | Pyrrolotriazines as ALK and JAK2 inhibitors |
US8569319B2 (en) | 2010-04-29 | 2013-10-29 | Deciphera Pharmaceuticals, LLS | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
US8648086B2 (en) | 2009-08-24 | 2014-02-11 | Ascepion Pharmaceuticals, Inc. | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors |
US8722889B2 (en) * | 2004-03-30 | 2014-05-13 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
US8829007B2 (en) | 2009-06-17 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US8877776B2 (en) | 2009-01-16 | 2014-11-04 | Exelixis, Inc. | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
US9051319B2 (en) | 2011-08-01 | 2015-06-09 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US9580416B2 (en) | 2014-07-02 | 2017-02-28 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
US9771361B2 (en) | 2013-11-13 | 2017-09-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US10023569B2 (en) | 2013-11-13 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
WO2019016071A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES |
US10273233B2 (en) | 2015-05-13 | 2019-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US10533004B2 (en) | 2015-05-13 | 2020-01-14 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
US10736886B2 (en) | 2009-08-07 | 2020-08-11 | Exelixis, Inc. | Methods of using c-Met modulators |
WO2021020362A1 (ja) | 2019-07-29 | 2021-02-04 | 武田薬品工業株式会社 | 複素環化合物 |
CN114716440A (zh) * | 2021-10-13 | 2022-07-08 | 广州六顺生物科技股份有限公司 | 吡咯并三嗪衍生物及其制备方法和应用 |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030112B2 (en) * | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
US9169406B2 (en) * | 2003-08-25 | 2015-10-27 | Dow Global Technologies Llc | Coating compositions |
DE10357510A1 (de) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
TW200538097A (en) | 2004-02-27 | 2005-12-01 | Eisai Co Ltd | Novel pyridine derivative and pyrimidine derivative |
DE102004017438A1 (de) * | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
AU2005270068B2 (en) * | 2004-07-02 | 2012-04-19 | Exelixis, Inc. | C-Met modulators and method of use |
US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
US7148348B2 (en) | 2004-08-12 | 2006-12-12 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
US7569725B2 (en) * | 2004-10-21 | 2009-08-04 | Britsol-Myers Squibb Company | Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
US8875040B2 (en) * | 2005-06-07 | 2014-10-28 | Rockwell Automation Technologies, Inc. | Universal web-based reprogramming method and system |
TW200635927A (en) * | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US7619083B2 (en) * | 2005-07-01 | 2009-11-17 | Bristol-Myers Squibb Company | Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates |
US7405213B2 (en) * | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
US7402582B2 (en) * | 2005-07-01 | 2008-07-22 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
US8299252B2 (en) | 2005-08-05 | 2012-10-30 | Chugai Seiyaku Kabushiki Kaisha | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors |
WO2007023768A1 (ja) | 2005-08-24 | 2007-03-01 | Eisai R & D Management Co., Ltd. | 新規ピリジン誘導体およびピリミジン誘導体(3) |
US7348325B2 (en) * | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
JP5203353B2 (ja) * | 2006-04-21 | 2013-06-05 | ブリストル−マイヤーズ スクイブ カンパニー | [(1R),2S]−アミノプロピオン酸2−[4−(4−フルオロ−2−メチル−1H−インドール−5−イルオキシ)−5−メチルピロロ[2,1−f][1,2,4]トリアジン−6−イルオキシ]−1−メチルエチルエステルの製造方法 |
TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
US20090306103A1 (en) * | 2006-05-19 | 2009-12-10 | Stephen Boyer | Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders |
EP2062886B1 (de) * | 2006-08-23 | 2011-11-30 | Eisai R&D Management Co., Ltd. | Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung |
US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
WO2008046216A1 (en) * | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
WO2008049855A2 (en) * | 2006-10-27 | 2008-05-02 | Glaxo Group Limited | 7-azaindole derivatives as c-met kinase inhibitors |
CN101730699A (zh) * | 2007-03-21 | 2010-06-09 | 百时美施贵宝公司 | 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物 |
US8907091B2 (en) | 2007-08-29 | 2014-12-09 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
CN101932586A (zh) * | 2007-08-29 | 2010-12-29 | 梅赛尔基因股份有限公司 | 蛋白酪氨酸激酶活性的抑制 |
DE102007051762A1 (de) | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
AU2008325288B2 (en) | 2007-11-06 | 2011-12-22 | Astrazeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
US8183225B2 (en) | 2007-11-08 | 2012-05-22 | New York University | Inhibition of bone resorption using medical implants containing adenosine receptor antagonists |
JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
US8558000B2 (en) | 2008-01-23 | 2013-10-15 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
UY31984A (es) * | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
UY31982A (es) * | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
KR100961410B1 (ko) * | 2008-10-14 | 2010-06-09 | (주)네오팜 | 단백질 키나제 억제제로서 헤테로사이클릭 화합물 |
AU2011254242B2 (en) | 2010-05-17 | 2015-10-29 | Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3H-imidazo[4,5-b]pyridine and 3,5- disubstitued -3H-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
EP2586443B1 (de) | 2010-06-25 | 2016-03-16 | Eisai R&D Management Co., Ltd. | Antitumorwirkstoff mit verbindungen mit kinasehemmungswirkung in kombination |
EP2423208A1 (de) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmazeutisch aktive Zusammensetzungen als Axl-Hemmer |
US9283225B2 (en) * | 2011-08-10 | 2016-03-15 | Merck Patent Gmbh | Pyrido-pyrimidine derivatives |
EP2831073B1 (de) | 2012-03-30 | 2020-12-09 | Rhizen Pharmaceuticals S.A. | Neue 3,5-disubstituierte 3h-imidazo [4,5-b]pyridin- und 3,5- disubstituierte 3h- [1,2,3]triazolo [4,5-b] pyridinverbindungen als modulatoren von c-met protein kinase. |
TWI520962B (zh) * | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
US9447105B2 (en) | 2013-01-24 | 2016-09-20 | Council Of Scientific & Industrial Research | Triazine compounds and a process for preparation thereof |
RU2658601C2 (ru) | 2013-05-14 | 2018-06-21 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба |
ES2923888T3 (es) | 2013-10-17 | 2022-10-03 | Blueprint Medicines Corp | Procedimiento para preparar composiciones útiles para tratar trastornos relacionados con la KIT |
ES2654931T3 (es) * | 2013-12-26 | 2018-02-15 | Ignyta, Inc. | Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos |
MX2017001980A (es) | 2014-08-28 | 2017-05-04 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y metodo para su produccion. |
KR20170122734A (ko) | 2015-02-25 | 2017-11-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 고미 억제 방법 |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
US10654808B2 (en) | 2015-04-07 | 2020-05-19 | Guangdong Raynovent Biotech Co., Ltd. | Tyrosine kinase inhibitor and pharmaceutical composition comprising same |
WO2016204193A1 (ja) | 2015-06-16 | 2016-12-22 | 株式会社PRISM Pharma | 抗がん剤 |
EP3521276B1 (de) * | 2016-09-30 | 2021-03-10 | Guangdong Raynovent Biotech Co., Ltd. | Kristallform und salzform von und herstellungsverfahren für tyrosin-kinase-inhibitor |
JP7164203B2 (ja) | 2017-02-08 | 2022-11-01 | 中国医▲薬▼研究▲開▼▲発▼中心有限公司 | ピロロ芳香族複素環化合物及びその製造方法並びに医薬用途 |
US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
EP3638670B1 (de) * | 2017-06-13 | 2021-07-21 | Bayer Pharma Aktiengesellschaft | Substituierte pyrrolopyridinderivate als map4k1-modulatoren zur behandlung von krebserkrankungen |
TWI721483B (zh) * | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
CN113874015B (zh) | 2018-12-21 | 2024-05-24 | 细胞基因公司 | Ripk2的噻吩并吡啶抑制剂 |
EP3953357B1 (de) | 2019-04-12 | 2024-04-17 | Blueprint Medicines Corporation | Pyrrolotriazinederivate zur behandlung von kit- und pdgfra-verbundenen krankheiten |
HRP20231533T1 (hr) | 2019-04-12 | 2024-03-01 | Blueprint Medicines Corporation | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave |
CN110407839B (zh) * | 2019-07-01 | 2022-01-04 | 江西科技师范大学 | 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用 |
TW202140426A (zh) * | 2020-02-14 | 2021-11-01 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
WO2023111996A1 (en) * | 2021-12-17 | 2023-06-22 | Reglagene Holding, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753940A (en) * | 1985-02-15 | 1988-06-28 | Ciba-Geigy Corporation | Barbituric acid derivatives |
US5132315A (en) * | 1989-05-19 | 1992-07-21 | The United States Of America As Represented By The Department Of Health And Human Services | Therapeutic application of an anti-invasive compound |
US6143764A (en) * | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US20030082631A1 (en) * | 2001-07-03 | 2003-05-01 | Anna-Lena Gustavsson | Compounds modulating PPAR-gamma |
US20030232765A1 (en) * | 2001-12-03 | 2003-12-18 | Bayer Corporation | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
US20030232831A1 (en) * | 2002-04-23 | 2003-12-18 | Alaric Dyckman | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
US20040048891A1 (en) * | 2000-12-22 | 2004-03-11 | Fuminori Kato | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
US20040053908A1 (en) * | 2000-10-20 | 2004-03-18 | Yasuhiro Funahashi | Nitrogen-containing aromatic derivatives |
US20040209886A1 (en) * | 2003-03-25 | 2004-10-21 | Salvati Mark E. | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
US20040242603A1 (en) * | 2001-06-22 | 2004-12-02 | Yasunari Fujiwara | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same |
US20050038035A1 (en) * | 2001-11-28 | 2005-02-17 | Hisashi Takasugi | Heterocyclic amide compounds as apolipoprotein b inhibitors |
US20050043306A1 (en) * | 2002-04-23 | 2005-02-24 | Katerina Leftheris | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
US20050143398A1 (en) * | 2003-10-22 | 2005-06-30 | Jagabandhu Das | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
US20050288289A1 (en) * | 2004-06-28 | 2005-12-29 | Gerard Crispino | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US6982265B1 (en) * | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
US20060004006A1 (en) * | 2004-06-28 | 2006-01-05 | Borzilleri Robert M | Pyrrolotriazine kinase inhibitors |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3646202A (en) | 1967-11-22 | 1972-02-29 | Merck & Co Inc | Liver fluke compositions containing salicylic acid derivatives |
JPS54115384A (en) | 1978-02-28 | 1979-09-07 | Hokko Chem Ind Co Ltd | Ryrazolyl pyrimidine derivative, and agricultural and horticultural fungicides |
CH648611A5 (de) | 1980-08-18 | 1985-03-29 | Staeubli Ag | Verfahren und schaftmaschine zur gleichstellung aller schaefte einer webmaschine. |
GB2106500B (en) | 1981-09-18 | 1986-01-02 | Dow Chemical Co | Method for making benzoylphenylureas |
DE3139457A1 (de) | 1981-10-03 | 1983-04-21 | Bayer Ag, 5090 Leverkusen | Neue substituierte benzanilidether, verfahren zu ihrer herstellung, ihre verwendung als fungizide und zwischenprodukte hierfuer |
DE3464368D1 (de) | 1983-03-09 | 1987-07-30 | Beecham Group Plc | Anti-inflammatory pyrazolo pyridines |
EP0151962A3 (de) | 1984-01-25 | 1985-10-02 | Beecham Group Plc | Pyrazolopyridin-Derivate |
US4663341A (en) | 1984-02-16 | 1987-05-05 | Rohm And Haas Company | Insecticidal n-aryl-3-aryl-4,5-dihydro-1h-pyrazole-1-carboxamides |
GB8404584D0 (en) | 1984-02-22 | 1984-03-28 | Beecham Group Plc | Compounds |
CH657015A5 (de) | 1984-06-27 | 1986-08-15 | Ciba Geigy Ag | Motten- und kaeferschutzmittel. |
JPS6133176A (ja) | 1984-07-24 | 1986-02-17 | Ishihara Sangyo Kaisha Ltd | N−ニトロベンゾイル−n’−ピリダジニルオキシフエニルウレア系化合物、それらの製造方法及びそれらを含有する抗癌剤 |
JPS62135463A (ja) | 1985-12-09 | 1987-06-18 | Ishihara Sangyo Kaisha Ltd | N−ベンゾイルウレア系化合物、それらを含有する抗癌剤並びにそれらの製造方法 |
JPS625959A (ja) | 1986-03-05 | 1987-01-12 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物 |
JPS6262A (ja) | 1986-03-05 | 1987-01-06 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物の製造方法 |
JPS625960A (ja) | 1986-03-05 | 1987-01-12 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物の製造方法 |
US4908056A (en) | 1986-04-25 | 1990-03-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
DE3830054A1 (de) | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
EP0420804A3 (en) | 1989-09-26 | 1991-11-27 | Ciba-Geigy Ag | Anthelmintic compounds |
SU1761753A1 (ru) | 1990-07-16 | 1992-09-15 | Ф. С. Михайлицын и Н. С. Уварова | 5-(2-Хлор-4-нитро(амино)фенокси) бензо-2,1,3-тиадиазол в качестве промежуточного соединени в синтезе 5- @ 2-хлор-4-[(2-окси-3,5-дибромбензоил)амино]фенокси @ бензо-2,1,3-тиадиазола, про вл ющего активность при гименолепидозе белых мышей |
US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
EP0874846B1 (de) * | 1995-11-01 | 2003-04-02 | Novartis AG | Purinderivate und verfahren zu ihrer herstellung |
DE19710609A1 (de) | 1997-03-14 | 1998-09-17 | Bayer Ag | Substituierte Aminosalicylsäureamide |
TW589309B (en) | 1997-07-03 | 2004-06-01 | Bristol Myers Squibb Pharma Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
WO1999024440A1 (en) * | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
TW515786B (en) | 1997-11-25 | 2003-01-01 | Nihon Nohyaku Co Ltd | Phthalic acid diamide derivatives, agricultural and horticultural insecticides, and a method for application of the insecticides |
US6362369B2 (en) | 1997-11-25 | 2002-03-26 | Nihon Nohyaku Co., Ltd. | Phthalic acid diamide derivatives fluorine-containing aniline compounds as starting material, agricultural and horticultural insecticides, and a method for application of the insecticides |
ATE413386T1 (de) | 1998-01-29 | 2008-11-15 | Amgen Inc | Ppar-gamma modulatoren |
CZ299375B6 (cs) | 1998-11-30 | 2008-07-09 | Nihon Nohyaku Co., Ltd. | Ftalamidové deriváty nebo jejich soli, zemedelsko-zahradnický insekticid je obsahující a jeho použití |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
US6797823B1 (en) | 1999-01-22 | 2004-09-28 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives |
CZ301498B6 (cs) | 1999-02-22 | 2010-03-24 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) | C-21 modifikované epothilony |
GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
CN1351498B (zh) | 1999-05-21 | 2012-08-15 | 布里斯托尔-迈尔斯斯奎布公司 | 激酶的吡咯并三嗪抑制剂 |
EP1181296A1 (de) | 1999-06-03 | 2002-02-27 | Abbott Laboratories | Zelladhäsionshemmende entzündungshemmende verbindungen |
US6355660B1 (en) | 1999-07-20 | 2002-03-12 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
JP2003528806A (ja) | 1999-07-20 | 2003-09-30 | ダウ・アグロサイエンス・エル・エル・シー | 殺菌・殺カビ性複素環式芳香族アミドおよびそれらの組成物、使用および製造方法 |
GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
ES2334879T3 (es) | 1999-09-21 | 2010-03-17 | Astrazeneca Ab | Derivados de quinazolina y su uso como productos farmaceuticos. |
KR100531990B1 (ko) | 1999-09-24 | 2005-12-02 | 니혼노야쿠가부시키가이샤 | 방향족 디아미드 유도체 또는 그의 염, 농/원예용 약제 및그의 사용 방법 |
AU2576501A (en) | 1999-12-08 | 2001-06-18 | Advanced Medicine, Inc. | Protein kinase inhibitors |
TWI281915B (en) | 1999-12-24 | 2007-06-01 | Kirin Brewery | Quinoline and quinazoline derivatives and drugs containing the same |
US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
EP1149583A3 (de) * | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Kombinationen bestehend aus Antagonisten des Corticotropin freisetzenden Faktors und Stoffen, die die Wachstumshormonsekretion fördern |
JP2003535867A (ja) | 2000-06-06 | 2003-12-02 | ファイザー プロダクツ インコーポレイテッド | 抗癌剤として有用なチオフェン誘導体 |
FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
PL366376A1 (en) | 2000-11-17 | 2005-01-24 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
EP1341771A2 (de) | 2000-11-29 | 2003-09-10 | Glaxo Group Limited | Benzimidazolderivate und ihre verwendung als tie-2 und/oder vegfr-2 hemmer |
AU2002254152A1 (en) * | 2001-03-08 | 2002-09-24 | Millennium Pharmaceuticals | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
AU2002323743A1 (en) | 2001-08-01 | 2003-02-17 | Nissan Chemical Industries, Ltd. | Substituted amides and pest controllers |
EP1447405A4 (de) | 2001-10-17 | 2005-01-12 | Kirin Brewery | Chinolin- oder chinazolinderivate, die die autophosphorylierung von rezeptoren für den fibroblastenwachstumsfaktor hemmen |
TW200300350A (en) | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
JP2003321472A (ja) | 2002-02-26 | 2003-11-11 | Takeda Chem Ind Ltd | Grk阻害剤 |
US6900208B2 (en) | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
SI1497019T1 (sl) * | 2002-04-23 | 2015-08-31 | Bristol-Myers Squibb Company | Pirolo-triazin anilin spojine uporabne kot inhibitorji kinaze |
TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
US6933386B2 (en) * | 2002-07-19 | 2005-08-23 | Bristol Myers Squibb Company | Process for preparing certain pyrrolotriazine compounds |
TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
EP1543009A4 (de) | 2002-08-02 | 2007-08-08 | Bristol Myers Squibb Co | Pyrrolotriazin-kinaseinhibitoren |
CA2515218A1 (en) * | 2003-02-05 | 2004-08-26 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine kinase inhibitors |
DE10357510A1 (de) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
US7102002B2 (en) * | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
TW200600513A (en) * | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
-
2005
- 2005-06-24 US US11/167,049 patent/US7173031B2/en active Active
- 2005-06-24 US US11/167,043 patent/US20050288290A1/en not_active Abandoned
- 2005-06-27 TW TW094121497A patent/TW200604184A/zh unknown
- 2005-06-27 TW TW094121488A patent/TW200607505A/zh unknown
- 2005-06-28 AR ARP050102669A patent/AR050254A1/es not_active Application Discontinuation
- 2005-06-28 PE PE2005000752A patent/PE20060374A1/es not_active Application Discontinuation
- 2005-06-28 KR KR1020067027376A patent/KR20070028458A/ko not_active Application Discontinuation
- 2005-06-28 AU AU2005260056A patent/AU2005260056B2/en not_active Ceased
- 2005-06-28 KR KR1020067027370A patent/KR20070037448A/ko not_active Application Discontinuation
- 2005-06-28 KR KR1020067026897A patent/KR20070026621A/ko not_active Application Discontinuation
- 2005-06-28 MX MXPA06015032A patent/MXPA06015032A/es not_active Application Discontinuation
- 2005-06-28 WO PCT/US2005/023198 patent/WO2006004884A2/en active Application Filing
- 2005-06-28 CA CA002571680A patent/CA2571680A1/en not_active Abandoned
- 2005-06-28 EP EP05764291A patent/EP1768983A2/de not_active Withdrawn
- 2005-06-28 AU AU2005259894A patent/AU2005259894C1/en not_active Ceased
- 2005-06-28 JP JP2007519322A patent/JP4860609B2/ja not_active Expired - Fee Related
- 2005-06-28 PE PE2005000754A patent/PE20060524A1/es not_active Application Discontinuation
- 2005-06-28 WO PCT/US2005/022682 patent/WO2006004636A2/en active Application Filing
- 2005-06-28 JP JP2007519416A patent/JP2008504368A/ja not_active Withdrawn
- 2005-06-28 EP EP05790229A patent/EP1771177A4/de not_active Withdrawn
- 2005-06-28 AR ARP050102668A patent/AR049536A1/es not_active Application Discontinuation
- 2005-06-28 EP EP05791275A patent/EP1761268A4/de not_active Withdrawn
- 2005-06-28 JP JP2007519390A patent/JP4782117B2/ja not_active Expired - Fee Related
- 2005-06-28 WO PCT/US2005/023099 patent/WO2006004833A2/en active Application Filing
- 2005-06-28 MX MXPA06015192A patent/MXPA06015192A/es active IP Right Grant
- 2005-06-28 BR BRPI0512722-0A patent/BRPI0512722A/pt not_active Application Discontinuation
-
2006
- 2006-12-25 IL IL180325A patent/IL180325A0/en unknown
-
2007
- 2007-01-24 NO NO20070453A patent/NO20070453L/no not_active Application Discontinuation
- 2007-01-26 NO NO20070514A patent/NO20070514L/no not_active Application Discontinuation
- 2007-01-26 NO NO20070506A patent/NO20070506L/no not_active Application Discontinuation
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753940A (en) * | 1985-02-15 | 1988-06-28 | Ciba-Geigy Corporation | Barbituric acid derivatives |
US5132315A (en) * | 1989-05-19 | 1992-07-21 | The United States Of America As Represented By The Department Of Health And Human Services | Therapeutic application of an anti-invasive compound |
US6143764A (en) * | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US6982265B1 (en) * | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
US20040053908A1 (en) * | 2000-10-20 | 2004-03-18 | Yasuhiro Funahashi | Nitrogen-containing aromatic derivatives |
US20040048891A1 (en) * | 2000-12-22 | 2004-03-11 | Fuminori Kato | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
US20040242603A1 (en) * | 2001-06-22 | 2004-12-02 | Yasunari Fujiwara | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same |
US20030082631A1 (en) * | 2001-07-03 | 2003-05-01 | Anna-Lena Gustavsson | Compounds modulating PPAR-gamma |
US20050038035A1 (en) * | 2001-11-28 | 2005-02-17 | Hisashi Takasugi | Heterocyclic amide compounds as apolipoprotein b inhibitors |
US20030232765A1 (en) * | 2001-12-03 | 2003-12-18 | Bayer Corporation | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
US20030232831A1 (en) * | 2002-04-23 | 2003-12-18 | Alaric Dyckman | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
US20050043306A1 (en) * | 2002-04-23 | 2005-02-24 | Katerina Leftheris | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
US20040209886A1 (en) * | 2003-03-25 | 2004-10-21 | Salvati Mark E. | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
US20050143398A1 (en) * | 2003-10-22 | 2005-06-30 | Jagabandhu Das | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
US20050288289A1 (en) * | 2004-06-28 | 2005-12-29 | Gerard Crispino | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US20060004006A1 (en) * | 2004-06-28 | 2006-01-05 | Borzilleri Robert M | Pyrrolotriazine kinase inhibitors |
Cited By (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11124482B2 (en) | 2003-09-26 | 2021-09-21 | Exelixis, Inc. | C-met modulators and methods of use |
US8497284B2 (en) | 2003-09-26 | 2013-07-30 | Exelixis, Inc. | C-met modulators and method of use |
US8476298B2 (en) | 2003-09-26 | 2013-07-02 | Exelixis, Inc. | c-Met modulators and method of use |
EP2409704A3 (de) * | 2003-09-26 | 2013-02-13 | Exelixis Inc. | c-Met-Modulatoren und Verwendungsverfahren |
US20070244116A1 (en) * | 2003-09-26 | 2007-10-18 | Exelixis, Inc. | c-MET MODULATORS AND METHOD OF USE |
US8987454B2 (en) | 2004-03-30 | 2015-03-24 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
US8722889B2 (en) * | 2004-03-30 | 2014-05-13 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
US20050245530A1 (en) * | 2004-04-23 | 2005-11-03 | Borzilleri Robert M | Monocyclic heterocycles as kinase inhibitors |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
US20050239820A1 (en) * | 2004-04-26 | 2005-10-27 | Borzilleri Robert M | Bicyclic heterocycles as kinase inhibitors |
US7566784B2 (en) | 2004-04-26 | 2009-07-28 | Bristol-Myers Squibb Company | Bicyclic heterocycles as kinase inhibitors |
US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US20060004006A1 (en) * | 2004-06-28 | 2006-01-05 | Borzilleri Robert M | Pyrrolotriazine kinase inhibitors |
US20050288289A1 (en) * | 2004-06-28 | 2005-12-29 | Gerard Crispino | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US20100216766A1 (en) * | 2004-07-30 | 2010-08-26 | Arkadii Vaisburg | Inhibitors of VEGF Receptor and HGF Receptor Signalling |
US7772247B2 (en) | 2004-07-30 | 2010-08-10 | Methylgene Inc. | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor |
US8470850B2 (en) | 2004-07-30 | 2013-06-25 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signalling |
US20060074056A1 (en) * | 2004-07-30 | 2006-04-06 | Methylgene, Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
US20090270391A1 (en) * | 2005-03-28 | 2009-10-29 | Kirin Pharma Kabushiki Kaisha | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY |
US7470693B2 (en) | 2005-04-21 | 2008-12-30 | Bristol-Myers Squibb Company | Oxalamide derivatives as kinase inhibitors |
US20060241104A1 (en) * | 2005-04-21 | 2006-10-26 | Borzilleri Robert M | Oxalamide derivatives as kinase inhibitors |
US7790729B2 (en) | 2005-05-20 | 2010-09-07 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
US8329726B2 (en) | 2005-05-20 | 2012-12-11 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
US20060287343A1 (en) * | 2005-05-20 | 2006-12-21 | Methylgene, Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
US20070004675A1 (en) * | 2005-05-20 | 2007-01-04 | Methylgene, Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
US8093264B2 (en) | 2005-05-20 | 2012-01-10 | Methylgene Inc. | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling |
US20100249145A1 (en) * | 2005-05-20 | 2010-09-30 | Methylgene, Inc. | Inhibitors of VEGF Receptor and HGF Receptor Signaling |
US7732613B2 (en) | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007033196A1 (en) * | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US20070060613A1 (en) * | 2005-09-14 | 2007-03-15 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007081690A2 (en) * | 2006-01-04 | 2007-07-19 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2007081690A3 (en) * | 2006-01-04 | 2007-12-13 | Locus Pharmaceuticals Inc | Inhibitors of protein kinases |
US20100256356A1 (en) * | 2006-03-07 | 2010-10-07 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
US7723330B2 (en) | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
US20080064718A1 (en) * | 2006-03-22 | 2008-03-13 | Saavedra Oscar M | Inhibitors of protein tyrosine kinase activity |
US8114881B2 (en) | 2006-05-08 | 2012-02-14 | Astrazeneca Ab | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial |
US20090209555A1 (en) * | 2006-05-08 | 2009-08-20 | Peter Hansen | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial |
JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
US20110053931A1 (en) * | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
US8778977B2 (en) * | 2006-06-30 | 2014-07-15 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl PDK1 inhibitors |
US9873693B2 (en) | 2006-06-30 | 2018-01-23 | Sunesis Pharmaceuticals, Inc. | Methods of treatment using pyridinonyl PDK1 inhibitors |
US20100144730A1 (en) * | 2006-06-30 | 2010-06-10 | Sunesis Phamaceuticals | Pyridinonyl pdk1 inhibitors |
US8536200B2 (en) | 2006-11-08 | 2013-09-17 | Bristol-Myers Squibb Company | Pyridinone compounds |
US20110052583A1 (en) * | 2006-11-08 | 2011-03-03 | Bristol-Myers Squibb Company | Pyridinone compounds |
US7851489B2 (en) | 2006-11-08 | 2010-12-14 | Bristol-Myers Squibb Company | Pyridinone compounds |
US20080114033A1 (en) * | 2006-11-08 | 2008-05-15 | Bristol-Myers Squibb Company | Pyridinone compounds |
US8258118B2 (en) | 2008-01-23 | 2012-09-04 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
US20110034416A1 (en) * | 2008-01-23 | 2011-02-10 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
US8124768B2 (en) | 2008-01-23 | 2012-02-28 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
US20110098293A1 (en) * | 2008-03-05 | 2011-04-28 | Michael Mannion | Inhibitors of Protein Tyrosine Kinase Activity |
US8759522B2 (en) | 2008-03-05 | 2014-06-24 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
US8729268B2 (en) | 2008-03-05 | 2014-05-20 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
US20110077240A1 (en) * | 2008-03-05 | 2011-03-31 | Michael Mannion | Inhibitors of protein tyrosine kinase activity |
US20110224197A1 (en) * | 2008-03-10 | 2011-09-15 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
US20100022529A1 (en) * | 2008-07-24 | 2010-01-28 | Tiechao Li | Amidophenoxyindazoles useful as inhibitors of c-met |
US8030302B2 (en) | 2008-07-24 | 2011-10-04 | Eli Lilly And Company | Amidophenoxyindazoles useful as inhibitors of c-Met |
USRE43878E1 (en) | 2008-07-24 | 2012-12-25 | Eli Lilly And Company | Amidophenoxyindazoles useful as inhibitors of c-Met |
US8471005B2 (en) | 2008-12-19 | 2013-06-25 | Cephalon, Inc. | Pyrrolotriazines as ALK and JAK2 inhibitors |
US11091439B2 (en) | 2009-01-16 | 2021-08-17 | Exelixis, Inc. | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
US11098015B2 (en) | 2009-01-16 | 2021-08-24 | Exelixis, Inc. | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
US9809549B2 (en) | 2009-01-16 | 2017-11-07 | Exelixis, Inc. | Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
US8877776B2 (en) | 2009-01-16 | 2014-11-04 | Exelixis, Inc. | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
US11091440B2 (en) | 2009-01-16 | 2021-08-17 | Exelixis, Inc. | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
US20100216843A1 (en) * | 2009-02-20 | 2010-08-26 | Astrazeneca R&D | Novel salt 628 |
US8232296B2 (en) | 2009-02-20 | 2012-07-31 | Astrazeneca Ab | Salt 628 |
WO2011022028A3 (en) * | 2009-05-18 | 2011-06-23 | Tufts University | Small molecule antagonists of phosphatidylinositol-3, 4, 5-triphosphate (pip3) and uses thereof |
WO2011022028A2 (en) * | 2009-05-18 | 2011-02-24 | Tufts University | Small molecule antagonists of phosphatidylinositol-3, 4, 5-triphosphate (pip3) and uses thereof |
US9345708B2 (en) | 2009-06-17 | 2016-05-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US9518056B2 (en) | 2009-06-17 | 2016-12-13 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US10874673B2 (en) | 2009-06-17 | 2020-12-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US8829007B2 (en) | 2009-06-17 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US9808459B2 (en) | 2009-06-17 | 2017-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US10039762B2 (en) | 2009-06-17 | 2018-08-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US10736886B2 (en) | 2009-08-07 | 2020-08-11 | Exelixis, Inc. | Methods of using c-Met modulators |
US11433064B2 (en) | 2009-08-07 | 2022-09-06 | Exelixis, Inc. | Methods of using c-Met modulators |
US8648086B2 (en) | 2009-08-24 | 2014-02-11 | Ascepion Pharmaceuticals, Inc. | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors |
US8569319B2 (en) | 2010-04-29 | 2013-10-29 | Deciphera Pharmaceuticals, LLS | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
US9051319B2 (en) | 2011-08-01 | 2015-06-09 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US9908878B2 (en) | 2011-08-01 | 2018-03-06 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US10875855B2 (en) | 2011-08-01 | 2020-12-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US9394302B2 (en) | 2011-08-01 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US11345700B2 (en) | 2013-11-13 | 2022-05-31 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
US10640501B2 (en) | 2013-11-13 | 2020-05-05 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
US9771361B2 (en) | 2013-11-13 | 2017-09-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
US10023569B2 (en) | 2013-11-13 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
US9580416B2 (en) | 2014-07-02 | 2017-02-28 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
US10533004B2 (en) | 2015-05-13 | 2020-01-14 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
US10273233B2 (en) | 2015-05-13 | 2019-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
WO2019016071A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES |
WO2021020362A1 (ja) | 2019-07-29 | 2021-02-04 | 武田薬品工業株式会社 | 複素環化合物 |
CN114716440A (zh) * | 2021-10-13 | 2022-07-08 | 广州六顺生物科技股份有限公司 | 吡咯并三嗪衍生物及其制备方法和应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7439246B2 (en) | Fused heterocyclic kinase inhibitors | |
US7173031B2 (en) | Pyrrolotriazine kinase inhibitors | |
US7547782B2 (en) | Met kinase inhibitors | |
US7566784B2 (en) | Bicyclic heterocycles as kinase inhibitors | |
US7348325B2 (en) | Pyrrolotriazine kinase inhibitors | |
JP6959250B2 (ja) | 癌治療用の2−シアノイソインドリン誘導体 | |
US7989477B2 (en) | Monocyclic heterocycles as kinase inhibitors | |
US7470693B2 (en) | Oxalamide derivatives as kinase inhibitors | |
KR20110039383A (ko) | cMET 억제제 | |
US9475817B2 (en) | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BORZILLERI, ROBERT M.;CHEN, ZHONG;HUYNH, TRAM N.;AND OTHERS;REEL/FRAME:016417/0638;SIGNING DATES FROM 20050720 TO 20050816 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |